Publication - Gustave Roussy

Transcription

www.gustaveroussy.fr
Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Tél. : 01 42 11 42 11
Fax : 01 42 11 53 00
Follow us :
ANNUAL REPORT 2014 - Living the futuretoday
Photo credits: Stéphanie Têtu, DHSimon, SADEV94, ASCO / Rodney White, Gustave Roussy - Communications Department Gustave Roussy - Design and Production:
Living
the future
ANNUAL REPORT
2014
today
- Printed by Grillet Impressions
GUSTAVE ROUSSY TODAY
Compassion, commitment, creativity, dynamism and
the sharing of expertise are the values that define
Gustave Roussy and lead it to place innovation at the
heart of its humanitarian, scientific, technological
and service activities. Its advances in these areas
are of direct benefit to the patient. Gustave Roussy
represents a beacon of advanced medicine and
personalised care. It is recognised internationally as a
model of innovation and a place where major progress
in the fight against cancer is being made.
3,000 300 2,800 47,600 369
SALARIED STAFF
RESEARCHERS
STUDENTS
AND TRAINED
PROFESSIONALS
PATIENTS TREATED
CLINICAL
STUDIES
Figures up to 1st January 2015
Refer to our annual report for 2014
and its appendices online:
• Publications with an Impact Factor between 5 and 10
• Details of the research teams at
gustaveroussy.fr
heading: annual reports
Gustave Roussy is a member of UNICANCER.
UNICANCER is a group of Comprehensive Cancer Centres and is
devoted exclusively to the fight against cancer. It promotes a treatment
model based on a multidisciplinary approach, personalisation of
treatment and support for the research / patient-care continuum.
www.unicancer.fr
3
ANNUAL REPORT 2014 | GUSTAVE ROUSSY
Living
the future
today
SCIENTIFIC, TECHNOLOGICAL AND HUMANITARIAN INNOVATION
NOURISHES THE HOPE TO BRING THE CARE OF CANCER PATIENTS
TO A COMPLETELY DIFFERENT LEVEL IN THE 21ST CENTURY.
GUSTAVE ROUSSY IS AN INTERNATIONAL REFERRAL CENTRE
DEDICATED TO ONCOLOGY AND AN INTEGRATED CENTRE FOR PATIENT
CARE, RESEARCH AND TEACHING. ITS RESEARCHERS, ITS DOCTORS,
ITS NURSING AND SUPPORT STAFF AND ALL ITS PERSONNEL
ARE COMMITTED TO THE PROCESS OF INNOVATION.
Every day at Gustave Roussy, cutting-edge research is mobilised to produce major
advances in therapy. Our key mission is to innovate and increase access to innovative
therapies for our patients. Our doctors and researchers are establishing more
personalised and less invasive medicine. We provide high quality treatment under
stringent safety conditions. We are investing in the technologies of the future. We pass
on the latest knowledge by educating students on an international scale. We are
creating services which are tailored to needs of our patients, in order to provide both
patients and their families at difficult moments in their lives with practical solutions
and a sense of well-being, of communication and of trust.
Gustave Roussy employs the most advanced techniques to mobilise all its forces in
the fight against cancer. Armed by its entrepreneurial spirit, it is an engine of rapid
advance in making discoveries directly benefitting patients’ lives.
Gustave Roussy. Living the future today.
Gustave Roussy is
living the future today
4
inventing
Revolutionising knowledge
of the disease and its treatment,
by developing tomorrow’s therapies.
06
07
08
12
Mission International ambitions
Interview with the Board of Directors
Development project 2015-2020
15INVENTING
16
17
18
20
21
Portrait: Professor Fabien Calvo
Report: Cancer Core Europe
Review of the year’s research
Pioneer in immunotherapy
Personalised medicine
23CARING
24
25
26
27
28
29
30
Portrait: Doctor Diane Goéré
Report: Surgery
Review of the year in care
New premises / Theatre suite
Tomotherapy / Radiosurgery
The patient environment / Information
Cancer Campus – Grand Paris / Local roots
31EDUCATING
32
Portrait: Claudio Nicotra
33
Report: PhD in oncology
34
Review of the year in teaching
Highlights 2014
36
38The Gustave Roussy model in Kazakhstan
39
Two important anniversaries
40
Summary of international publications
Liv
the fu
toda
41SUPPORTING
42
Portrait: Thierry Bruhat
43
Report: Fondation Gustave Roussy
44
Fundraising 2014
46
Bequests and other donations
47
Account of use of funds in 2014
48Gustave Roussy Foundation in 2014
49APPENDICES
50
Social responsibility
52
Governance
54
Work activity and financial results
55
Report on the annual accounts
56
Balance sheet
58
Accounts 2014
60Report on the annual expenditure accounts
of funds raised from the public
61
Overall annual use of resources
62
International publications
supporting
Giving researchers, doctors and care
providers the resources to innovate more
and implement these advances in the
comprehensive treatment of patients.
5
ving
uture
day
caring
Tackling cancer by means of patient tailored
innovative treatments which are less invasive
and more effective, thus ensuring a better
quality of life.
educating
Training tomorrow’s researchers and care
teams in the oncological skills of the future,
both in France and on an international scale.
6
MISSION
PERSON-CENTRED COMPREHENSIVE
MEDICINE
AS A EUROPEAN LEADER IN CANCER, GUSTAVE ROUSSY TREATS
PATIENTS WITH ANY TYPE OF CANCER, AT ANY STAGE, AT ANYTIME.
EXPERT IN RARE CANCERS AND COMPLEX TREATMENTS,
GUSTAVE ROUSSY IS ONE OF THE WORLD LEADERS IN THE FIGHT
AGAINST CANCER.
I
ts 3,000 staff, researchers, teachers,
doctors and care providers place
innovation at the heart of its
humanitarian, scientific and technological revolution.
INTEGRATION OF CARE, RESEARCH
AND TEACHING
Fo u n d e d i n 1 9 2 6 b y P ro fe ss o r
Gustave Roussy, the Institute has
been developing since then an
approach to oncology which is faithful to its founder’s values: innovation,
commitment, sharing of knowledge
and compassion.
The approach is one that integrates
fully the three founding principles of
Gustave Roussy: research, care and
teaching. It is the source of innovative
therapies and advances in diagnosis.
The high level research carried out
at the Institute now combines basic
research with translational and clinical approaches, to bring the results of
research to the bedside to benefit the
patient as rapidly as possible.
COMBINING INNOVATION AND
HUMANITY
Gustave Roussy offers its patients
personalised treatment combining
cutting-edge medicine, innovation
and compassion. This approach takes
into account the patient’s physical,
psychological and social quality of
life. The Institute is aiming to practise medicine which is increasingly
personalised and less invasive, so as
to offer treatment of high quality and
safety, thereby improving all aspects
of patient management at all stages
of the disease.
ANTICIPATING TOMORROW’S
ONCOLOGY
The educational programs of Gustave
Roussy for students, researchers and
medical practitioners is constantly
TREATING ALL PATIENTS,
WHATEVER THE CANCER TYPE,
WHATEVER THE AGE.
evolving and adapting skills to develop
ments in oncology and ensuring the
continuity of innovation.
FORGING PARTNERSHIPS TO
PREPARE FOR THE FUTURE
As a major scientific centre in the
south of the Île-de-France, the
Institute plays a central role locoregionally, in particular through
Cancer Campus Grand Paris. Thanks
to local partnerships, it contributes
to the organisation of oncology in its
locale by improving care programmes.
Gustave Roussy as a key actor on the
European and international oncological
stage is forging strategic partnerships
with the leading research and treatment
centres in the world focusing on major
projects to keep ahead in the battle
against cancer. The e-hospital of tomorrow is being prepared today.
7
SIGNATURE OF A CONTRACT WITH THE KINGDOM
OF SAUDI ARABIA FOR TRAINING OF SAUDI
ONCOLOGISTS, 23RD OCTOBER 2014, IN THE
PRESENCE OF THE FRENCH MINISTER FOR THE
DHSimon
ECONOMY AND FINANCES, EMMANUEL MACRON.
INTERNATIONAL AMBITIONS
SPREADING THE GUSTAVE ROUSSY MODEL,
BEYOND BORDERS
GUSTAVE ROUSSY IS LAUNCHING AN INTERNATIONAL DEVELOPMENT STRATEGY.
WHILE CONCENTRATING ON THE LONG TERM AND CREATING THE MEANS FOR
EXPANSION, THE INSTITUTE IS SPREADING AND EXPORTING ITS MODEL.
DESIGNING TOMORROW’S
INTERNATIONAL RESEARCH
In 2014, historic academic partnerships with leading institutions were
reinforced, in order to speed up
research.
Gustave Roussy, together with DKFZNCT Heidelberg*, took the initiative to
found Cancer Core Europe. Cancer
Core Europe was created by signing
a far reaching consortium agreement
between 6 leading comprehensive
cancer centers in Europe: Gustave
Roussy, NKI-Amsterdam, Cambridge
Cancer Center, VHIO-Barcelona,
Karolinska Cancer Institute and
DKFZ-NCT Heidelberg. Cancer Core
Europe is a unique initiative to create
a virtual cancer institute that welcomes 60.000 new patients per year
and treats more than 250.000 patients
per year. It will share databases and
conduct research programs focused
on personalized cancer medicine,
biomarker discovary, and outcome
research (see page 17).
In June 2014, the WIN symposium
brought together, as it does every
year, the leading specialists in the
field. The WINTHER trial is being
conducted within the WIN framework
to assess the contribution of mole
cular testing to choice of therapy.
Professor Jean-Charles Soria, director of DITEP** at Gustave Roussy, is
the principal investigator and world
coordinator of this trial.
The partnership developed with
DKFZ-NCT in Heidelberg has moved
b e y o n d e s t a b l i s h e d co m b i n e d
research projects in paediatrics,
immunotherapy, personalised medi
cine and cell death.
WELCOMING FOREIGN PATIENTS
In 2014, Gustave Roussy continued
to expand its care of patients from
abroad, seeing 1,400 international
patients in 2014 compared with 900 in
2013. The number of foreign patients
managed as outpatients increased by
40% compared with 2013, while the
number admitted for conventional
hospitalisation rose by 22%. The
departments to which these patients
present are mainly those for diseases
of the breast and the digestive tract
and the haematology department.
Gustave Roussy is continuing to seek
to attract international patients and
is looking to provide suitable areas in
which they can be treated.
DEVELOPING KNOWLEDGE
ABROAD
Gustave Roussy is developing projects
which aim to create the infrastructure
for training of health professionals
and for sharing our treatment models. Following the creation in 2013 of
a breast cancer unit in the Sharjah
University Hospital (UAE), a longterm partnership was forged with
the Ministry of Health in Kazakhstan.
This will help train doctors from the
cancer centers and academic institutions in Kazakhstan and will establish
a centralised chemotherapy preparation facility in the town of Astana as
well as in other centres across the
country (see page 38).
In addition to these agreements, there
are plans for new projects in Saudi
Arabia and Kuwait. In February 2014,
the first studies were initiated to look
into opening a hospital under Gustave
Roussy management in Kuwait. This
would be the first French hospital
outside France devoted solely to the
management of cancer. This project
enjoys support from the public sector.
* Deutsche Krebs Forschungs Zentrum – National
Centrum für Tumoren.
** Drug Development Department.
8
FROM LEFT TO RIGHT:
CHARLES GUEPRATTE,
DEPUTY GENERAL DIRECTOR,
PROFESSOR ALEXANDER EGGERMONT,
GENERAL DIRECTOR,
PROFESSOR ERIC SOLARY,
RESEARCH DIRECTOR.
9
Let's live
the future
today
INTERVIEW WITH
THE BOARD OF DIRECTORS
INNOVATION, TRANSLATIONAL RESEARCH, STRENGTHENING OUR PROGRAMMES
AND PROJECTS, EXTENDING OUR EXPERTISE, QUALITY PARTNERSHIPS… IN 2014,
GUSTAVE ROUSSY REINFORCED ITS ROLE AS A PIONEER IN THE FIGHT AGAINST
CANCER IN FRANCE AND ON THE INTERNATIONAL STAGE.
HOW DO YOU LOOK BACK ON YOUR
WORK IN 2014?
PROFESSOR ALEXANDER
EGGERMONT:
The year was marked by significant
innovation and advances in every
field. Of these, we might single out
the merger without job losses with
the Chevilly-Larue Hospital centre,
progress in the immunotherapy programme, the joint creation with five
other European centres of excellence
of Cancer Core Europe and the acquisition of da Vinci Xi, a latest generation
surgical robot – the first robot dedicated to surgical oncology in France.
And again, reflecting our recognition
abroad, publication of the results of
our research in major journals.
The scale of these successes is testimony to the decisions on its direction
of travel taken by the Institute over a
number of years.
CHARLES GUÉPRATTE:
This progress has been made with
financial results that are better than
expected. Instead of the forecast
5 M€ budget deficit, the amount
was only slightly over 1 M€. Our
investments bore fruit, especially
in radiotherapy, with improvements
in treatment options, and also in
the numbers of foreign patients
seen. We also managed to control
our expenses. We manage to keep
recruitment of new personnel under
control with 70 new positions. The
increase in staff costs was contained
within predefined limits.
WHICH ACHIEVEMENTS IN
RESEARCH STAND OUT?
PROFESSOR ÉRIC SOLARY:
These involve the three principal areas
of research at Gustave Roussy. One of
the Institute’s teams has obtained
an ERC Starting Grant, a prestigious
award from the European Research
Council, for its work on DNA repair.
Immunotherapy continues to be a
very promising field, in which our
innovative therapies are confirming
our leading role in Europe. Finally, the
deployment of personalised medicine
with its patient benefits has resulted
in the first publications from clinical
trials and the launch of studies on
resistance to targeted therapies.
YOU REFERRED TO THE MERGER
WITH CHEVILLY-LARUE. WHAT
WAS THE RATIONALE FOR THIS?
PROFESSOR ALEXANDER
EGGERMONT:
Here again, the main beneficiaries
are the patients. We were facing very
heavy demand, which was exceeding
10
+3%
INCREASE IN ACTIVITY IN 2014
18M€
GUSTAVE ROUSSY’S
AUTOFINANCING CAPACITY
We provide every type of oncological
treatment and we treat every condition.
We have a dedicated team in each field
and a critical mass of information. That
is what distinguishes us and defines
the position of Gustave Roussy.
Professor Alexander Eggermont
our capacity to handle it; in particular, our Emergency Department was
overloaded. As a result of this merger
we have increased our capacity by a
third, i.e. 110 extra beds.
CHARLES GUÉPRATTE:
In addition to responding to that need,
Chevilly-Larue will have its own medical
projects, notably in personalised cancer
prevention strategies in at-risk individuals, the development of cardiology
services and the reception of patients
from abroad and their families.
YOU HAVE DEVELOPED A NEW
DEVELOPMENT PROJECT.
WHAT ARE ITS PRINCIPAL GOALS?
CHARLES GUÉPRATTE:
Firstly, we should emphasise that it is
the result of a collaborative approach
involving patients and our staff. Some
400 individuals contributed directly to
the project. We are very proud of this.
PROFESSOR ALEXANDER
EGGERMONT:
This is a project which will engage us
over five years in five areas. The first of
these is in the field of treatment, our
primary mission. We shall continue
to develop our infrastructure so that
our patients have access to the best,
most modern and effective techno
logy in radiotherapy, robotic surgery,
imaging, etc. The second area is that
of research where we aim to deliver
innovation to our patients in every
field. We have the ambitious strategy
of ensuring translational effectiveness
by developing the continuum between
basic research, clinical trials and the
delivery of care.
example, by optimising our information systems we should be able to
improve the integration of all the shared
research data from trials and from
patient care carried out within Cancer
Core Europe, together with that from
the patients’ electronic records.
To flush out this approach still further, the hospital plan foresees the
creation of one physician/researcher
position each year up to 2020. We
have also programmed an investment of 50 M€ to establish a unit
of 5,000 m² devoted to pre-clinical
studies. This is scheduled to open
in 2019.
PROFESSOR ALEXANDER
EGGERMONT:
The fourth area is that of Human
Resources, a field in which we intend
to set standards. The fifth is that of our
international role, both to improve our
attractiveness to patients from abroad
and to export our model. We are
already doing the latter in Kazakhstan,
within the framework of a long-term
partnership, and we are preparing to
expand into other countries.
PROFESSOR ALEXANDER
EGGERMONT:
The third area will be that of transformation, or rather acceleration in improvements, of our IT-infrastructures. For
CHARLES GUÉPRATTE:
In 2015, Gustave Roussy’s investment
in information systems will be nearly
6 M€. Our internet site has been completely recast and it will later have a
portal designed especially for patients.
11
Our translational approach establishes
a pathway from basic research through
clinical trials to patient care. This means
that our patients benefit from the latest
advances without delay.
Professor Éric Solary
Our financial results, much better
than forecast, show that we are
on the right way and that our
investments over several years
has been appropriate.
Charles Guépratte
WHAT ROLE DOES FUNDRAISING
PLAY, AND PARTICULARLY THE
GUSTAVE ROUSSY FOUNDATION,
IN THIS STRATEGY?
CHARLES GUÉPRATTE:
A key role. Citizens contribute almost 10%
of our funds through donations and legacies. In this way, the Foundation supports
research and we shall be launching a new
major fundraising campaign to run over
several years. This ought to raise some tens
of millions of euros.
TO CONCLUDE, WHAT IS IT THAT
DISTINGUISHES GUSTAVE ROUSSY
IN THE CANCER FIELD?
PROFESSOR ALEXANDER
EGGERMONT:
Cancer Core Europe and beyond that our
partnerships on a global scale mean that
we can function in every area of oncology
and treat every condition. In each field
we have a dedicated team and a critical
mass of information. That is what distinguishes us and gives us our position
of strength.
Thus, our agreement with IntraGen
has resulted in the first large scale
high-throughput sequencing unit to
facilitate targeted therapy of patients. In
2014, 750 patients participated in early
trials in a dedicated department which
is the largest in Europe. Another figure:
more than 3,300 patients were entered in
clinical trials, a reflection of the scale of
this work.
PROFESSOR ALEXANDER
EGGERMONT:
Gustave Roussy organises its research
work, trials and patient care. It integrates all this for the benefit of today’s
patients and those of tomorrow. At the
same time, in collaboration with ParisSud University, it is training new teams
and contributing to local developments
through the Cancer Campus. Today the
Institute does indeed embody the future.
Living
the future
today
12
TOMORROW’S TREATMENTS ARE BEING
DETERMINED BY THE GREAT CHANGES
WHICH ARE UNDERWAY. GUSTAVE ROUSSY
IS INVESTING TO INNOVATE.
DEVELOPMENT PROJECT 2015-2020
DEFINING THE MODEL OF TOMORROW’S
CANCER CENTRE
THE DEVELOPMENT PROJECT 2015-2020 IS A PRODUCT OF THE IDEAS OF
ALL OF THE GUSTAVE ROUSSY TEAMS PROPOSED DURING 2014. IT INCORPORATES
THE INSTITUTE’S AMBITIONS FOR THE NEXT FIVE YEARS: TO BE AN ENGINE
OF INNOVATION IN ORDER TO ACHIEVE DIRECT BENEFITS FOR PATIENTS.
G
ustave Roussy’s goal is to
develop a scientific, technological and organisational
programme of the highest quality in
order to offer all its cancer patients
the latest generation, highly specific,
novel treatments.
The Institute is preparing to be a
leader by 2020 in innovative organisation of the patient pathway, implementing a coordinated programme
for the patient and for the hospital,
which can adjust to new conditions
arising from advances in treatment.
THE MEDICAL CARE PROJECT
This depends on a purposeful investment in high technology equipment. It
will mean that over five years we shall
renew the model of surgical oncology,
integrate interventional radiology
with it, increase the range of our radio
therapy equipment and develop
molecular medicine (as a routine service) and immunotherapy, so that all
our patients can have access to perso
nalised medicine. We shall double our
capacity for bone marrow transplantation by establishing a haematology
department.
RESEARCH AND TEACHING
These will evolve in close collaboration
with the future Paris-Saclay University.
In 2020, Gustave Roussy will be a major
university hospital centre with a
research centre completely integrated
with patient care. It will also, by virtue of
its partnership with the Institut Curie,
be the leading department in Europe
conducting pre-clinical studies. This
pre-clinical centre will attract commercial partners specialising in biotechno
logy and bio-informatics and will underlie
the growth of the Cancer Campus. The
development of early trials through the
Drug Development Department (DITEP)
and the routine provision of molecular
biology will respond to the requirements
of personalised medicine and immunotherapy, fields in which Gustave Roussy
is keen to become the European leader.
The very close integration of research
with patient care will, moreover, be
encouraged by the creation of doctorresearcher posts with guaranteed time
dedicated to research activity.
QUALITY POLICY
Conforming to the most demanding
international standards will underpin
new therapies.
By 2020, Gustave Roussy will have
developed new quality models to
ensure that all its patients have
access to the highest levels of care
for their conditions from the moment
of admission to follow-up after discharge. Priority is to be accorded to
13
coordination of care, communication
with patients, the medication circuit
and risk management.
THE PATIENT-HOSPITAL
RELATIONSHIP
By proposing a renewed vision of the
patient-hospital relationship, Gustave
Roussy seeks to become a reference
standard in the field of services for
patients and to develop a structured
programme ranging from cure to
care. The objective is to reassure the
patient and to help him/her to understand the treatment and to be independent. Work is already underway to
improve the patient’s experience, the
admission process and communications. This work is very dependent on
new technologies which give access
to personalised communication processes and help to maintain continuity of the relationship both within the
hospital and outside it.
THE DIGITAL REVOLUTION
This will constitute a new base underlying all the activities of Gustave
Roussy. It will facilitate access to
information and transform the organisation. It will encourage the formation
of internal and external relationships,
notably with patients, whose auto
nomy will thus be strengthened. The
substantial increase in data storage
facilities and the capacity to handle data is redrawing the future in
research, patient care and hospital
organisation.
Through an e-hospital, the creation
of “Health Big Data” at international
level will respond to the need to master ever larger data sets.
MANAGERIAL INNOVATION
This will take shape through a
dynamic human resources policy
fully orientated to the acquisition of
skills. Internal contracting will help
units at Gustave Roussy to benefit from more delegation of mana
gement functions, thus fostering
autonomy and flexibility.
Economic balance and financial
independence are key to the growth
of Gustave Roussy: routine health
economics studies will inform
day-to-day running and additional
financing will be sought by continuing communication, especially with
established donors.
INTERNATIONAL AMBITIONS
On the international stage, Gustave
Roussy will continue to develop
academic partnerships based on
research and a policy of exploitation
of its expertise and offer to patients.
Its international ambitions are also
reflected by the Cancer Core Europe
network directed by Gustave Roussy
and bringing together six centres of
excellence in the fight against cancer.
Established in 2014, this consortium
has set up five working groups: data
sharing, early trials, molecular diagnosis, imaging and training.
Gustave Roussy as an inspiration
for progress and a bearer of hope
is using its hospital plan for 20152020 to define the future of the fight
against cancer.
PARTNERSHIP POLICY
Gustave Roussy’s strategy is ultimately based on a policy of partnership rooted in the local area. It
is situated in the heart of the Bievre
scientific valley and on the threshold of
Grand Paris. It will play a major role
in the development of a “biopark”,
which will maximise the potential of
its research and encourage interactions between its clinical functions
and industry.
PROPOSING A RENEWED
VISION OF THE PATIENT-HOSPITAL
RELATIONSHIP.
Living
the future
today
INCORPORATING
INNOVATION IN EVERY
SECTOR OF THE INSTITUTE’S
WORK IN ORDER TO DEFINE
THE FUTURE OF ONCOLOGY.
14
DEVELOPMENT PROJECT: FIRST STEPS IMPLEMENTED
GUSTAVE ROUSSY 2015-2020:
A PROGRAMME ALREADY UNDERWAY
DRAWN-UP IN 2014, PUBLISHED RIGHT AT THE BEGINNING OF 2015, THE GUSTAVE ROUSSY DEVELOPMENT
PROJECT CONTAINS A NUMBER OF INTENTIONS WHICH HAVE BEEN SWIFTLY IMPLEMENTED. ADHERING
TO A YEAR-BY-YEAR PROGRAMME UP TO 2020, THE INSTITUTE WILL ROLL OUT A SERIES OF INNOVATIVE
INITIATIVES TO HELP PATIENTS.
Cancer Core Europe, the European consortium
A pilot unit for personalised prevention
initiated by Gustave Roussy is organising its first
joint work and research projects within its five
designated fields: IT and data sharing, early trials,
molecular diagnosis, imaging, and training and
exchange of expertise between the six major
centres.
will be established in January 2016, to improve
individuals’ knowledge about their own health,
their perception of the risk of cancer and their
involvement in putting suitable preventive measures
into practice.
The latest generation surgical robot,
the da Vinci Xi, was acquired by Gustave Roussy
late in 2014; this is the first step in the institute’s
ambitious surgical programme. With the intention
of making surgery an important arm of clinical
research, the Institute will explore new indications
and prospects for robotic surgery.
The digital revolution
being a major
component of its strategic project, Gustave Roussy
will invest massively in 2015 in its information
systems to improve access to medical data
which are always on the increase. Initial steps:
installation of an integrated management system
and the launch in spring 2015 of the new Gustave
Roussy website. Portals intended for patients and
professionals will follow.
Doctor-researcher positions are being
created and recruitment will be launched in 2015
with the intention of contributing to excellence in
oncology research. Five positions are to be created
for doctors in this programme and guaranteed
designated research time is provided.
The merger between Gustave Roussy and
Chevilly-Larue Hospital centre represents a
decisive initiative to improve care pathways, a major
focus in the medical care plan. In a few months,
the care pathways will be reviewed, the teams will
be trained and a medical plan created for the new
Gustave Roussy site.
BUILDING THE FUTURE
OF GUSTAVE ROUSSY
TOGETHER
In 2014, the Gustave Roussy teams joined
forces to work together on their hospital plan.
400 individuals contributed and there were
200 interviews: a proliferation of ideas,
a prioritisation seminar and an opportunity
for free expression for all.
A programme providing a wide range
of services to patients is to start in 2015,
ranging “from care to taking care”. This reinvents
the relationship with the patient and is divided
into five areas with substantive projects already
defined. The first is communication with a role
for the new website and the other four initiatives
in patient services will soon be introduced. These
are: welcoming patients with touch tablet devices
in reception areas; personalised arrangements
for hotel facilities; opportunities to participate in
specific cultural activities; and finally, the possibility
of being involved in assessment of services through
the future Patients Observatory.
This participatory approach to
the process was led exclusively from
within departments. Its encouragement
of sharing and creativity tapped
in to all the energy of the institution.
15
RESEARCHERS
REVOLUTIONISING THE UNDERSTANDING
OF CANCER AND ITS MANAGEMENT
BY DEVELOPING TOMORROW’S TREATMENTS.
From basic research to technological innovation; from epidemiology to clinical
trials; and from sociology to psycho-oncology: Gustave Roussy marshals all the
skills which are essential to speed up discoveries in the field of oncology. This
broad range is reflected in the implementation of an integrated research policy
which brings together basic research, translational research, clinical research,
and clinical practice. The results of research are rapidly mobilised to help patients and this process is widely recognised on the world stage. 300 research
workers, of whom 100 are doctoral students and 50 post-doctoral, work within
13 research units, forming 36 teams. There is close collaboration on a global
scale with many specialised partner organisations. In particular, there is the
consortium, Cancer Core Europe, founded in 2014 by the efforts of Gustave
Roussy. Living the future today involves participating in this strategy of integration and synergy and maintaining the continuum from basic research to the
bedside. In this way the Institute can fulfil its objective to become a world referral centre in oncology and the leading European centre for innovative treatment.
inventing
Gustave Roussy
research on video
16
I am living
the future today
PROFESSOR FABIEN CALVO, SCIENTIFIC
DIRECTOR OF CANCER CORE EUROPE.
Laboratory medical doctor, researcher with expertise in
molecular medicine, former Deputy General Director of
INCa and instigator of the international consortium on
cancer genomics, Professor Fabien Calvo became scientific
director of Cancer Core Europe in December 2014.
His mission is to organise and coordinate the consortium’s
scientific projects so as to implement its strategy.
“Cancer Core Europe is a virtual institute structure which
brings together 6 of the leading major forces in cancer
research in Europe.”
17
CANCER CORE EUROPE
A VIRTUAL CANCER INSTITUTE FOR
A CRITICAL MASS OF INFORMATION
60,000 NEW CASES,
300,000 COURSES OF TREATMENT,
1.2 MILLION CONSULTATIONS, MORE
THAN 1,500 CLINICAL TRIALS: WITH THIS
ANNUAL WORKLOAD, CANCER CORE
EUROPE REPRESENTS A STRIKE FORCE
THAT CAN LEAD THE FIGHT AGAINST
CANCER AT THE HIGHEST LEVEL.
Established in 2014, Cancer Core Europe brings
together six European centres: Gustave Roussy,
the Cambridge Cancer Centre (United Kingdom),
the Karolinska Institutet (Sweden), the Netherlands
Cancer Institute (Holland), the Vall d’Hebron Institute
of Oncology (Spain) and the German Cancer Research
Centre - National Centre for Tumor Diseases
(Germany). Objective: improving their work in every
field involved with cancer by ensuring that a continuum
exists from basic research through clinical trials to
patient care.
EXCELLENCE AND COLLABORATION
To give this approach full force, Professor Fabien
Calvo was appointed Scientific Director of the consortium (see opposite). His role is to organise and
coordinate the projects carried out in common by the
six partners. This is a mission that he fulfils in close
cooperation with the committees which direct and
lead these projects, as well as with all the scientists
who are taking part.
By treating the data on all the patients from the six
centres in common a “virtual hospital” is created.
Establishing such a comprehensive data base in
oncology responds to an urgent need. Firstly, the
sharing of experience, knowledge and skills as flexibly and effectively as possible should be encouraged,
because current cancer research is characterised by
very wide inter-disciplinary collaboration. Secondly,
the consolidation of an enormous volume of information is indispensable in order to recognise the emergence of phenomena which frequently only concern
a small number of patients. This latter aspect takes
on particular importance in the current context of
developments in personalised medicine where very
varied tumour genetic profiles are taken into account.
A COMMON OVERALL VISION
This spirit of sharing of knowledge and the desire to
improve performance is present in the other objectives of Cancer Core Europe: training, enrichment of
doctors’ career pathways by means of international
exchanges between the partner centres, the use of
apparatus endowed with the latest technology or
the optimisation of methodology. But, beyond these
major directions, its commitment is even more ambitious: to develop a comprehensive vision through
common research strategies in order to accelerate
genuine advances and bring them as quickly as possible to the aid of patients.
1.2
MILLION
THE TOTAL NUMBER OF
CONSULTATIONS EACH YEAR
FOR THE SIX CANCER CORE
EUROPE PARTNERS
18
REVIEW OF THE YEAR’S RESEARCH
G
ustave Roussy confirms its place each year
as an agent of progress. The dynamic of its
innovative research contributes strongly to
this. Gustave Roussy’s organisation, integrating the
continuum between basic research, translational
research and clinical medicine, enables the Institute
to create care models and to renew them. Oncology
research being international in nature, Gustave
Roussy is well-endowed with the means to benefit
from this situation.
RESEARCH AT
GUSTAVE ROUSSY
AS OF 31/12/2014
36
TEAMS
13
UNITS
369
CLINICAL STUDIES
MOVING TOWARDS A GUSTAVE ROUSSY
ONCOLOGY RESEARCH CENTRE BY 2020.
Pursuing the logic of the integration of various types
of research with clinical care, Gustave Roussy is
undertaking the creation of an oncology research
centre under the aegis of Gustave Roussy, the
University of Paris-Saclay, Inserm and the CNRS to
be fully installed by 2020. During the next three years
the Research Directorate will shape a Gustave Roussy
oncology research centre, uniting all the on-campus
teams. This will facilitate the implementation of an
integrated scientific strategy with the most efficient
use of human and financial resources and should
promote interactions between departments and collaboration across disciplines. At present, research at
Gustave Roussy is conducted in 13 Inserm or CNRS
Units divided into 34 teams subject to evaluation by
the AERES.
ARRIVAL OF NEW TEAMS
For a number of years Gustave Roussy has pursued a
strategy of recruitment of young researchers accredited by Inserm or the CNRS, in order to develop its
research potential and new scientific areas connected to modern medicine. Three new teams came
to the Gustave Roussy campus in 2014 as part of the
Inserm/CNRS Atip-Avenir programme:
RESEARCH IMPLEMENTING
NEW
EQUIPMENT
• a spinning disc microscope for the
imaging and cytometry unit (PFIC);
• new irradiation equipment
(department for pre-clinical
evaluation) and a laser
microdissection station (laboratory
for translational research
in partnership with Biopath);
will be installed in 2015;
• a patent has been obtained by
the PFIC for a new dorsal chamber
plate device to allow multimodality
imaging in animals.
• 1st February: Endocytosis, cytoskeleton and cell
migration team led by Guillaume Montagnac.
• 1st April: Repair of double-strand breaks and integrity
of the genome team led by Gerard Mazon.
• 1st June: Normal and cancerous haematopoietic
stem cells: genetic and epigenetic control mechanisms team led by Camille Lobry.
This year Doctor Mehdi Khaled (Atip-Avenir 2013)
obtained the status of Inserm chargé de recherche 1
[research leader-CR1 Inserm).
The Atip-Avenir programme helps young researchers
to establish a team and lead it. It disposes of a budget
of 600,000 euros over five years.
In addition, Valéria Naïm, CNRS research leader in
the Disorders of DNA Repair team (UMR 8200), led
by Professor Filippo Rosselli, was a prizewinner in
the highly competitive ERC Starting Grant (European
Research Council) programme and was awarded funding to support her team.
THERAPEUTIC INNOVATION
UMS AMMICA
The Mixed Unit consisting
of the Department of
Molecular Testing and
Modelling together with the
Department of Imaging of
Oncological Disease was
formed on 1st January 2014.
This coordinates the
technology services at
Gustave Roussy, harmonises
their running and facilitates
their certification and/
or accreditation. Another
objective is to help certain
departments (morphological
methods, molecular testing)
to respond better to the needs
of academic and commercial
research.
19
c
FOR...
CONGRESSES
WIN 2014
Professor Alexander Eggermont, General Director
of Gustave Roussy and Vice-chairman of the
WIN consortium, chaired the 2014 WIN symposium.
Four Gustave Roussy doctor researchers including
Professor Eggermont himself participated
at this prestigious international symposium
on precision medicine.
ASCO 2014
Gustave Roussy was very prominent at the
50th ASCO Congress with 18 oral communications,
10 of them presented by doctor researchers
from the Institute, and 37 posters.
CLINICAL TRIALS: ENSURING THE CONTINUUM
BETWEEN RESEARCH AND CARE
Gustave Roussy brings together the necessary skills for
the conduct of high quality research in oncology. The
Institute’s clinical research interests comprise diagnosis, therapy, psycho-oncology, sociology and health
economics.
The continuum between research and clinical care is
instrumental in the development of new therapies and
advances in diagnostic techniques. Making trials accessible to the greatest number of patients is a thread running through the thinking of the Institute. In 2014, 26%
of patients, i.e. 3,308 individuals were enrolled in clinical research. Since the formation in 2013 of the Drug
Development Department (DITEP), Gustave Roussy has
been an essential partner in phase I trials in adults and
children. In 2014, almost 450 patients took part in early
trials and more than 300 patients in molecular portrait
driven treatment decisions.
ASCO / Rodney White
ESMO 2014
The discovery of six key genes in lung cancer
was a high light. This research conducted
in collaboration with the Institut HyperCube
has been submitted for a patent.
BIOMEDE, A LARGE SCALE PAEDIATRIC CLINICAL TRIAL
Biomede, a project emanating from Gustave Roussy research, is
the largest randomised trial ever conducted in invasive glioma
of the brain stem, a rare and serious condition. This is the first
European trial where treatment is based on biopsy findings with
laboratory testing in real time and sequencing of the tumour
at diagnosis. It is planned to include 250 patients on 25 sites in
France together with international participation. Recruitment
is to take place over a period of four years. This has been made
possible by collaboration within European paediatric oncology
organisations (ITCC, SIOPE…) as well as with parent associations
and three commercial companies.
20
COORDINATING TEAMWORK AROUND
A MAJOR PROGRAMME DEVOTED
TO IMMUNOTHERAPY.
i
FOR...
IMMUNOTHERAPY
STIMULATINGTHE PATIENTS
IMMUNE SYSTEM
Immunotherapy introduces a paradigm
shift: whereas up to recently, the
tumour cell killing has been the
objective by chemotherapy and
targeted agents to eradicate the
tumour immunotherapy targets the
immune system and the tumour as
a whole to eradicate the tumour or
prevent progression. In particular
a new class of antibodies, immunecheck point inhibitors are now
succeeding in arresting progression
of a wide range of tumour types, that
were up till now virtually resistant to
most treatments. Immunotherapy
can now be considered as a leading
therapeutic approach against cancer.
Professor Alexander Eggermont,
General Director of Gustave Roussy,
talks about immunotherapy: the video
GUSTAVE ROUSSY,
PIONEER IN IMMUNOTHERAPY
I
mmunotherapy or anti-tumour immunology is
one of the major areas of research at Gustave
Roussy. It carries great hope for new therapies.
Several teams are collaborating in this research.
A programme led by individuals dedicated to it
was established to offer access to immunotherapy
to the greatest number of patients with a variety
of types of cancers. The involvement of Institute
teams in the first clinical trials of monoclonal
antibodies (anti-CTLA4, anti-PD1 and anti-PDL1)
means that Gustave Roussy is a European leader in
demonstrating the efficacy of these agents.
CREATION OF AN IMMUNOTHERAPY
PROGRAMME
An Immunotherapy Programme was recently established by Professor Alexander Eggermont General
Director of Gustave Roussy, to strengthen the teams
working on immunotherapy.
Doctor Aurelien Marabelle was recruited to take
charge of clinical trial development program, while
Professor Laurence Zitvogel directs the scientific
work. The objective of this programme is to develop
novel therapeutic strategies and bring them to clinical trials and clinical practice, as well as to provide a
support function for various Gustave Roussy departments. A programme of this type, with this structure
and on this scale, is something very new in Europe.
It ought to enable Gustave Roussy to take a leading
role in cancer immunotherapy.
AN IMMUNOLOGICAL PROFILING LABORATORY
The Research Directorate has appointed Nathalie
Chaput to lead the new immuno-monitoring platform, set up in 2014. This laboratory specialises in
immunological profiling and in functional analysis of
immunological cell populations. This platform, incorporated in the hospital structure, will develop and
validate biomarkers for selecting patients for appropriate treatments. The study of immunodynamic
effects will result in better recognition of potential
therapeutic combinations and lead to new developments in immuno-oncology and transfer of this into
clinical practice. The Immuno-monitoring Laboratory
is attached to UMS AMMICa, CNRS 3655 & Inserm
US23 coordinated by Professor Jean-Yves Scoazec.
PUBLICATIONS: PRODUCTIVITY
OF THE DOCTOR RESEARCHERS
Thanks to the efforts of Gustave Roussy’s medical
researchers, major advances in immunotherapy
have been made in recent years in the use of mono
clonal antibodies and the development of promising
therapeutic options. Two studies published in the
same issue of the journal Nature reported the
beneficial effects of the antibody anti PD-L1.
21
TOWARDS ROUTINE
DEPLOYMENT OF
PERSONALISED MEDICINE
T
he position of Gustave Roussy in the field of
personalised medicine is now firmly established. Armed with this success, the Institute
intends to organise and expand its use of perso
nalised medicine, facilitate access to early trials
and develop molecular medicine as a routine. The
diagnostic approach in personalised medicine is
based on analysis of the tumour genome, referred
to as molecular diagnosis. The goal is to be able to
recommend a patient-tailored treatment, including
identification and use of predictive biomarkers.
VERY HIGH THROUGHPUT SEQUENCING,
BIG-DATA AND DIRECTING THERAPY
Gustave Roussy is at present one of the few
European centres capable of producing a mole
cular portrait within a two week time-frame. This
facilitates rapid therapeutic decision making. The
first very high-throughput sequencing apparatus,
marketed by IntegraGen was installed in 2014
at the Institute. This has been employed in some
150 patients included in personalised medicine trials.
The technique generates a substantial volume of
data. It is necessary to extract relevant information
from this big-data, so as to optimise the diagnosis
and direct the patient towards the best treatment.
In order to achieve this, in June 2014 the Institute, in
partnership with IntegraGen and Sogeti High Tech,
launched the ICE (Interpretation of Clinical Exome)
project with the intention of developing software
to help interpret data from genomic sequencing.
This project was adopted by the 17th Fonds Unique
Interministériel (Single Interministry Fund).
Doctor Yohann Loriot’s phase I trial demonstrated
the efficacy of antibody MPDL3280A in patients
with urothelial bladder cancer. The other study, by
Professor Jean-Charles Soria, showed that using
the same antibody to block an immunological control point produced lasting responses in patients
with cancer in lung, skin and kidney, amongst
others. This study also found biomarkers which
predicted response to treatment. We should also
draw attention to a remarkable study published by
Doctor Caroline Robert in the New England Journal
of Medicine reporting major progress in immunotherapy of metastatic melanoma. This phase III trial
was terminated prematurely when interim analysis
showed remarkable efficacy of the immune checkpoint inhibitor.
RESEARCH, CARRYING HOPE
OF NEW THERAPIES.
1,330
PATIENTS HAVE HAD A MOLECULAR
PORTRAIT OVER FOUR YEARS
JAK2, 10 YEARS
AFTER ITS DISCOVERY
Ten years ago, Professor William
Vainchenker discovered the JAK2V617F
mutation in myeloproliferative syndromes.
This discovery has had several major
consequences for management of
these conditions, in particular the
development of a test for this mutation
which facilitates diagnosis. This is now
the most commonly employed test in
haematology. This research has also led
to the identification of other mutations
and to an understanding of the cytokine/
JAK/STAT pathway which is involved in
the pathogenesis of these disorders.
In addition, therapies targeted against
JAK2 have been developed.
22
LARGE SCALE CLINICAL TRIALS
In the context of its precision medicine project initiated
in 2011, Gustave Roussy launched a research programme comprising a series of large scale clinical trials:
SAFIR01, MOSCATO, WINTHER and SAFIR02 lung and
breast. Ultimately this collection of trials will generate a
unique data base of clinical and laboratory information
on more than 3,000 patients. Tumour biopsies will be
stored in tissue banks in readiness for future ancillary
studies.
MATCH-R is a new trial commenced in 2014. This is
intended to elucidate the mechanisms of resistance to
targeted therapy. Patients being treated for metastatic
disease who initially were responsive to targeted therapy
will have biopsies taken at the time when resistance has
supervened. A variety of tests will be performed. It is
planned to recruit about 600 patients over five years.
TO MAKE TARGETED THERAPY AVAILABLE TO
THE LARGEST NUMBER OF PATIENTS
The AcSé programme – secure access to drugs – was
launched by INCa in 2013. It comprises two clinical
trials: AcSé crizotinib and AcSé vemurafenib.
The AcSé crizotinib trial is sponsored by UNICANCER,
co-financed by the ARC Foundation and coordinated
by Professor Gilles Vassal, paediatrician and clinical research director at Gustave Roussy. The initial
results are encouraging and were presented at the
51st ASCO meeting. This trial is still recruiting. It is
the first trial in the world where the treatment given
is directed at a genetic abnormality and not at an
organ. Crizotinib, initially used in lung cancer, targets
tumours with gene abnormalities found in more than
20 different cancer types.
t
FOR...
TRANSFER
The non-hierarchical nature of the organisation
of research at Gustave Roussy means that
patients can benefit from recent advances
in basic research, as has happened with
Doctor Stephane de Botton’s collaborative work
on IDH inhibitors in acute myeloid leukaemia.
This research led on to a DITEP phase I trial
of the drug AG 221. 56% of patients showed a
response. This promising drug will now be tested
in a trial on solid tumours with IDH2 mutations.
A BETTER
UNDERSTANDING
OF RESISTANCE
New mechanisms of resistance to
targeted therapies in melanoma have
been brought to light by Doctor Caroline
Robert and Doctor Stephane Vagner.
The results of their research were
published in the journal Nature*.
These results open up new prospects for
predicting the efficacy of certain targeted
therapies in melanoma and might also
lead to the development of new drugs to
treat other cancers more effectively.
* Nature. 2014 Jul 27. doi: 10.1038/nature13572.
23
PATIENTS AND CARE
PROVIDERS BEATING THE DISEASE WITH
LESS INVASIVE, MORE EFFECTIVE, NOVEL AGENTS
RESULTING IN A BETTER QUALITY OF LIFE.
The patient is at the heart of the Institute’s vision and its day-to-day work.
Its raison d’être, its main objective, is to help the patient with the most
conscientious care, the most effective treatment strategies and the most
modern technologies and therapeutic agents tailored to the patient and to
the disease. Overall management combines compassion with clinical innovation. That is why advances in understanding are reflected so quickly in
clinical trials and then in treatment for the largest number of patients. In the
spirit of Cancer Plan 3, Gustave Roussy is also committed to optimisation of
the care pathway, in particular through progress in outpatient care, an
approach which is combined with that of the use of less invasive treatment.
In addition, a number of services other than medical care are designed for
the patient to reinforce trust and to offer support. Living the future today
means responding to all expectations.
Caring
for patients
Our patients’
testimony on video
24
I am living
the future today
DOCTOR DIANE GOERE, ONCOLOGICAL
SURGERY OF THE DIGESTIVE TRACT.
Doctor Diane Goere has been practising as a specialist in digestive tract cancer surgery at
the Institute for ten years. “At Gustave Roussy, we combine skill and innovative approaches
to bring advances in the field of surgery. A multidisciplinary approach by integrating
medicine and research makes it possible to innovate on a daily basis in the development of
new treatments, particularly surgical ones. This collaborative work between highly skilled
teams helps us to envisage comprehensive cancer treatment. This approach has always
the best outcome for the patient in mind.”
25
SURGERY
CUTTING-EDGE TECHNIQUES REINFORCED
BY A NEW ROBOT
WITH EXPERTISE IN A NUMBER OF
SPECIALTIES, THE DEPARTMENT
OF SURGERY IS THE FIRST IN
FRANCE EQUIPED WITH THE LATEST
GENERATION DA VINCI XI ROBOT.
AN ACQUISITION THAT IMPROVES
PATIENT TREATMENT.
Each year some 14,000 cancer operations are performed at Gustave Roussy. The Department of Surgery
is totally committed to innovation and uses the most
modern techniques such as image-guided radiotherapy, searching for sentinel nodes, complex hepatectomy, intra-hepatic radio-frequency ablation, surgery
in irradiated fields and treatment of peritoneal carcino
matosis by debulking surgery and hyperthermic
intraperitoneal chemotherapy. Its expertise in this
latter field makes it a world leader in peritoneal
surgery.
DEVELOPMENT OF OUTPATIENT CARE AND FLAP
RECONSTRUCTIONS.
Breast surgery represents another area of excellence.
Outpatient surgery is progressing and is advised when
possible for those patients who desire it. As for breast
reconstruction, this has been totally integrated into
the treatment plan. After mastectomy the use of the
patient’s own tissue is preferred. Almost 500 reconstructions are performed annually, making Gustave
Roussy the leading centre in France in this field.
A further illustration of progress comes from the field
of Head and Neck surgery, where in a single operation
tumour resection and reconstruction with patients
own tissue by means of transfer of free flaps is routinely performed. The Head and Neck / Reconstructive
Surgery Group of Gustave Roussy has acquired an
international reputation for its most innovative and
complex approaches in this field.
DA VINCI XI, THE ROBOT WHICH TRANSFORMS
THE SITUATION FOR PATIENTS
These skills are accentuated by advances in the
use of surgical robotics. A strategic investment of
2.785 M€ in the latest generation da Vinci Xi device,
made possible by support from the Fondation
Philanthropia, should help to treat patients with the
maximum of comfort. “The robot helps us to widen
the therapeutic window in order to advise less invasive and less traumatic surgery for the greatest
number,” states Professor Dominique Elias, head
of the Department of Surgery,
“While reducing complications both during and after
surgery, the use of the robot results in fewer functional and cosmetic consequences.” To give one example among others, tumours of the face and neck
can be accessed via natural orifices.
In total, some 450 operations per year will be suitable for this robotic surgery. A cutting-edge technique with which Gustave Roussy will turn a new
page in surgical treatment.
27 MAY 2015
FIRST SURGICAL ENT
PROCEDURE WITH
THE DA VINCI XI ROBOT
26
RAPPORT ANNUEL 2014 | GUSTAVE ROUSSY
11,300
NEW PATIENTS
IN 2014
228, 000
355
BEDS AND 94 PLACES
MEDICAL OUTPATIENT
CONSULTATIONS
PATIENT CARE: REVIEW OF THE YEAR
47,600
PATIENTS IN 2014, I.E. + 1.2%
COMPARED WITH 2013
100, 730
AMBULATORY SESSIONS
i
FOR...
CLINICAL NURSE
IN ONCOLOGY
The Care Management at Gustave
Roussy has been supporting
the creation of clinical nurses
in oncology for several months.
The Cancer Plan 3 initiative promises
to improve multi-disciplinary
patient care.
PATIENT CARE TEAMS
AT FULL STRETCH
G
ustave Roussy experienced a further increase
in its patient care workload in 2014, both for
adults and children with cancer.
The hospital staff has been extremely busy to implement multiple developments in terms of major
projects and structural changes: investment in latest
generation equipment, opening of new hospital
premises, preparations for the merger with ChevillyLarue Hospital centre, elaboration of the hospital
plan, deployment of computerised patient files, etc.
All this under the with ever increasing patient numbers while responding to increased quality requirements has stretched expectations and demands to
which the staff has responded magnificently. Helping
patients remained the prime concern and kept all
motivated to go the extra mile.
SUSTAINED OVERALL WORKLOAD
228,000 medical consultations took place in 2014,
with a particularly marked increase in workload in
cervico-facial cancer (+ 7.9%) and ambulatory care
(+ 11.5%). While nurse consultations fell by 3.7%,
consultations for communication of diagnosis and
treatment strategy increased by 41.4% in 2014. More
than 13,800 patients were admitted to hospital, an
increase of 3.5% over 2013. The bed occupancy rate
was unchanged at 89%. Ambulatory care increased
both in terms of numbers of patients (+ 4.6%) and
the number of stays (+ 2.7%). There were increases
in sessions of therapy of all types: radiotherapy (+
4.2%), chemotherapy (+ 1.1%), transfusion (+ 12.2%)
and brachytherapy (+ 42.5%). In addition, day-case
surgical activity grew, with 716 patients being treated
in 2014, an increase of 36.6%.
In 2014, 11,300 new patients (+ 0.6%) were seen as
outpatients at Gustave Roussy. The numbers of new
patients primarily resident abroad rose by 22%.
The number of new patients admitted grew by 3.1%, new
patients representing 51.1% of hospitalised patients. The
number and proportion of new patients admitted with
malignancy both rose: 5,077 patients, i.e. 88% of the new
patients admitted to hospital.
LABORATORY MEDICINE AND HEAD AND NECK
ONCOLOGY: TWO GROWTH AREAS
Laboratory medicine and medical pathology is a
key department with a support role in the work of
the medical and surgical specialties. The department splits into a patient section for the laboratory
tests and a tumour section for the morphological
and molecular diagnosis activities. The workload
increased in 2014 with almost 2.2 million laboratory
medical tests (B and BHN codes) while there were
5,600 gene tests for solid tumours. Professor JeanYves Scoazec was appointed head of this department
in December 2014.
The department of cervicofacial oncology at Gustave
Roussy specialises in the management of complex
cases and is one of the world leaders in the field.
It deploys innovative techniques; robotic surgery,
advanced reconstruction procedures, endoscopic
laser therapy, endonasal endoscopy and also
endoscopic cranial base surgery. In addition, novel
chemotherapeutic regimens and targeted molecular
therapy are also employed. In 2014, work in medical
oncology and referrals as well as basal cranial surgery increased by nearly 12% in patient numbers and
by 17% in the number of hospital stays.
PATIENTS TREATED IN THE DEPARTMENT OF ONCOLOGICAL MEDICINE LISTED ACCORDING TO THE
SITE OF THE MALIGNANT TUMOUR
The Department of Oncological Medicine is directed by Professor Karim Fizazi. It is responsible
for management and treatment of patients with cancer whatever the primary site. The range of
disciplines covered by the specialists in this team is such as to make this department one of the
most important of its type nationally and internationally.
BREAST
29.40%
HAEMATOLOGY
14.60%
DIGESTIVE TRACT
13.64%
RESPIRATORY TRACT
12.9%
3.77%
ENT
TUMOUR, PRIMARY
SITE UNKNOWN
SARCOMAS AND
MESENCHYMAL TUMOURS
MESOTHELIOMA
3.26%
ENDOCRINE TUMOURS
NEUROLOGY
PREVIOUS MALIGNANT
TUMOURS
3.19%
2.53 %
DERMATOLOGY
1.88%
4.52 %
0.82 %
MALE GENITAL TRACT
FEMALE GENITAL TRACT
7.87%
1.66%
UROLOGY
0.40%
0.36%
OTHERS
0.01%
27
RAPPORT ANNUEL 2014 | GUSTAVE ROUSSY
NEW PREMISES
CHILD AND ADOLESCENT
ONCOLOGY DEPARTMENT
T
oday 80% of children with cancer recover; doctors and researchers are working to improve
these figures still further. Looking beyond their
treatment and their care, it is essential that these
young patients continue to lead their lives as children
and prepare to become adults.
An area of more than 1,600 m2 was replanned and laid out
to provide children, adolescents and also their families
with an environment comprising not only the facilities
for care but also suitable provision for shared time
and the preservation of family ties, which are so vital
for young patients. This was conceived by the patient
management team and the project was carried through
with the support of management and major contributions from the medical, patient care, logistics and
technical teams. The new department is designed to
deliver patient care and be welcoming for children, their
families and care providers. The refurbishment work
was carried out in three phases over two years without
interrupting the care of children and adolescents:
• installation of a new day-hospital with nine beds and
three cubicles situated right within the department.
This enables children to receive their treatment on
an ambulatory basis rather than having to be hospitalised in a conventional fashion. Trials of new drugs
are also performed in this provision;
• reorganisation of the central section of the outpatient
provision in order to increase ambulatory care activity;
• organisation of facilities around a central common area to aid social activity and establishment of
relationships: school, plastic arts studio, an area for
psychological and physiotherapy activity, information
technology and areas for patient associations;
• creation of a « parents’ hotel » with five emergency
bedrooms.
THANKS TO…
ASSOCIATION LISA, ALBERT DE MUN SCHOOL, ÉTOILE DE MARTIN,
FONDATION GUSTAVE ROUSSY, AMAR & MERTENT FAMILIES,
FONDATION HÔPITAUX DE PARIS – OPÉRATION PIÈCES JAUNES,
FONDS INKERMAN, FONDS DOTATION HAGURO - MR. VIANDIER,
IMAGINE FOR MARGO – CHILDREN WITHOUT CANCER, LA PETITE
CHAISE, LE GÂTEAU CLUB DE L’OUEST PARISIEN, LES MAINS
D’ARGENT, LIONS CLUBS OF SULLY – GIEN, POISSY, AND LE PECQ,
OSIRIS, ROTARY CLUB PALAISEAU, INCA (CASA), TOUS AVEC CLÉMENT.
THE COST OF WORKS IN CHILD AND
ADOLESCENT ONCOLOGY DEPARTMENT:
3.4 M€
1.6 M€
CAME AS CHARITABLE DONATIONS
There were multiple sources of finance:
individuals, charitable associations, appeals,
foundations… The fundraising campaign
«Poussons les murs pour les enfants»
(Let’s push the walls for the children) helped to
stimulate the generosity of the public for this
project. In total more than 1,000 individuals
participated in financing these new premises.
NEW SPACES TO IMPROVE
CHILDREN’S LIVES.
OPERATING THEATRE SUITE
A NEW TREATMENT METHOD
C
FOR...
DITEP
The Drug Development Department
(DITEP) carries out phase I clinical
trials. Its patient capacity increased in
2014: 13 day-case places (4 of which
opened in 2014) and 11 weekday
hospital beds (one of which opened in
2014). In 2014, 791 DITEP patients were
admitted to hospital, thus obtaining
access to new therapies deriving from
pharmaceutical or basic research.
7,088 outpatient consultations were
carried out by DITEP doctors, mainly
for patients on Early trials (27.7%)
or from Lung disease (18.3%) and
Haematology (16.2%) departments.
DITEP ROUND TABLE 2014
On 3rd November, DITEP, headed by
Professor Jean-Charles Soria, organised
a round table at Gustave Roussy bringing
together the leading French specialists
in early trials. Participants included
Professor Jean-Luc Harousseau,
President of the French National
Health Authority and Professor Agnès
Buzyn, President of the National
Cancer Institute.
OF WHICH
oming to the theatres for cancer surgery gives
rise to anxiety and makes the patient feel vulne
rable. In November 2014, Gustave Roussy introduced a care pathway whereby a patient who wished
to do so could come to the theatre suite not lying down
but on foot, accompanied by a theatre porter. With this
d
arrangement now in place for several months, 60% of
the patients are choosing to arrive in this way.
A first patient survey shows that this new facility is
much appreciated. The patients say that they feel
less passive and less disturbed and that the process
is more compassionate.
28
120,000
HOSPITAL STAYS OF WHICH16%
WERE FOR ONE NIGHT ONLY
AND MORE THAN 54% DID NOT
REQUIRE ANY NIGHTS IN HOSPITAL
(INCLUDING RADIOTHERAPY AND
CHEMOTHERAPY SESSIONS)
MORE THAN
6,000
TOMO-RADIOTHERAPY SESSIONS
IN 250 PATIENTS
TOMO-RADIOTHERAPY, FOR STILL
MORE INNOVATION
A
lways keen to provide the most effective treatment for its patients and motivated by its
reputation for innovation, in 2014 Gustave Roussy
acquired apparatus of very high added technological
value to offer its patients new, less invasive, more
precise treatment methods. In this vein, the acquisition
of the da Vinci Xi surgical robot was a major event of the
year (see page 25). After acquiring Novalis Tx in 2013,
two tomo-radiotherapy machines were purchased
to add to the Radiotherapy Department’s range, now
consisting of eight machines. This represents an investment of six million euros, 80% of which came from
contributions by the public.
A MORE PRECISE SYSTEM
Tomo-radiotherapy is a method of delivering intensitymodulated radiotherapy. It is guided by 3D imaging
and delivers personalised irradiation treatment very
precisely for multiple tumours, those of complex
shape and those close to sensitive organs. The technique limits the radiation dose to healthy tissue,
thus reducing immediate and long term complications. At Gustave Roussy, we are principally using this
technique for patients with large sarcomas, pelvic
tumours which are hard to reach (prostate, uterine
cervix, etc.) and head and neck cancers.
Development of the Gustave Roussy radiotherapy service is part of the overall strategy of investment in
high technology equipment with the aim of providing
more precise and effective treatment in a context of
innovation and safety for all.
RADIOSURGERY: GUSTAVE ROUSSY’S
WELL-ESTABLISHED EXPERTISE
Living
the future
today
THE LATEST EQUIPMENT,
INNOVATIVE TECHNIQUES,
MORE COMPASSIONATE CARE:
GUSTAVE ROUSSY ASSERTS ITS
COMMITMENT TO THE DIRECT
BENEFIT OF THE PATIENT.
W
ith radiosurgery – or very high precision
targeted radiotherapy – patients receive
comprehensive and multidisciplinary treatment, a provision which best underpins the procedures and maximises the chances of cure.
After two years of follow-up in more than 600 patients, Gustave Roussy’s outcomes of radiosurgery
are in the first rank. Of the cerebral tumours treated,
almost 90% have not progressed one year after treatment. These excellent figures result from techniques
developed in continuous collaboration with our medical physicists with the aim of tailoring irradiation
very precisely to tumour size and calculating almost
to the millimeter the correct dose of radiation to be
delivered in full safety. For each patient, the choice
THE NOVALIS Tx TREATS
TUMOURS WHICH ARE
NOT ACCESSIBLE TO
CONVENTIONAL SURGERY.
of therapy depends on shared expertise and involves
oncological surgeons and physicians and radiotherapists, so that the best technology available in the
radiotherapy department can be selected.
The Novalis Tx apparatus provides non-invasive
treatment delivered over one or more sessions. It
can treat or re-treat in a radical manner tumours
which are not accessible to conventional surgery or
are situated too close to sensitive organs. The first
patients treated in this way at Gustave Roussy had
primary cerebral tumours (benign or malignant) or
cerebral metastases. Today a wider spectrum of
tumours is being treated including those located in
lung, liver, spinal cord and prostate.
29
THE PATIENT ENVIRONMENT
CARE PATHWAYS,
LIFE PATHWAYS
G
ustave Roussy keeps one step ahead in the compassionate, comprehensive and personalised
treatment of patients combining cutting-edge
medicine and concern for the quality of life. The
Institute focuses on the patients and those close to
them throughout the difficult periods of their journey.
This desire to deliver “patient tailored” treatment is
deeply embedded in our strategic vision – formalised
in the 2015-2020 hospital plan.
At Gustave Roussy, this different approach to patient
care, combining care and cure, is underpinned by the
Multidisciplinary Department of Patient Support Care
i
FOR...
(DISSPO), which works across specialties. It strengthens
and coordinates care designed to improve patient
quality of life during treatment and in the « after cancer » phase. It covers pain relief, diet and nutrition,
psychological support, social support, palliative care,
etc. The « Mieux Vivre le Cancer » (Living Better with
Cancer) initiative coordinates support activities and
follows the patient. It complements medical and allied
specialised support functions by measures focusing on
well-being and physical and psychological fulfilment.
Three years after it was implemented « Mieux Vivre le
Cancer » has demonstrated its value and its efficacy.
INNOVATIVE
SUPPORT CARE
In 2014, Gustave Roussy DISSPO
developed some new initiatives to
help patients benefit from better care.
Two examples:
THE « PAIN » TEAM
now offers management of complex
secondary neuropathic pain by invasive
analgesic techniques: injections
of botulinum toxin and application
of capsaicin patches under cover of
local and regional anaesthesia.
DISSPO
is developing and improving psychooncological management, and has
established cognitive remediation
groups and social rehabilitation
groups for children treated for
cerebral tumours, as well as cognitive
remediation workshops for adults with
cognitive problems.
BETTER INFORMATION,
FOR BETTER CARE.
INFORMATION
ONE OF THE KEYS TO PATIENT
REASSURANCE
H
elping preparation for admission, providing
the right information at the right time and
encouraging patient independence; all of this
enables the patient to start treatment more calmly.
Over recent months, Gustave Roussy has developed
a number of innovative methods of communicating with patients. This is now easier because of the
Institute’s new website, which is designed to respond
to patients’ information needs and is fully accessible to mobile phone technology. In addition, we have
continued to put video material on line on the website
giving patients simple, targeted information on care
pathways, treatments, etc. We have also instituted
the sending of SMS reminders 48 hours prior to an
appointment which was arranged several months
earlier.
Finally, Gustave Roussy suggests that patients form
connections with each other through the “My Hospi
Friend” social network, set up to tackle the isolation
felt by hospitalised patients.
CANCER - CARE
PATHWAYS - ILE-DEFRANCE REGION
CAPRI is a clinical trial sponsored by Gustave
Roussy. An Internet portal is available
to patients after an admission to enter
information on their state of health and
to locate information and advice. A facility
intended for health care professionals links
care staff at the Institute with family doctors
and care networks. At the Institute, two nurse
coordinators regularly contact patients
to review their state of health. In 2015,
500 patients will use this facility in the context
of the CAPRI trial.
30
CANCER CAMPUS-GRAND PARIS
BRINGING TALENT TOGETHER TO INNOVATE
C
SADEV94
ancer Campus was established by Gustave
Roussy and its partners in Val-de-Marne and
the Ile-de-France. It is developing a “bio
cluster” on a global scale, which is committed to
innovation in oncology by bringing together research
groups and training programmes of the highest
quality. This biocluster is set in an 82 hectares development site which will have a connecting station
on the Grand Paris Express railway line in 2022. It
comprises an extension of research capacity, the
installation of Paris Sud University, a bioparc for
innovative companies, patient facilities, companies,
student life and, finally, housing and public utilities.
Late in 2011, Cancer Campus established Villejuif
Bio Park, an “enterprise zone-enterprise hotel” to
house new enterprises specialised in biotechnology.
The building is now 90% occupied. The lay section of
Cancer Campus and its Cancer Contribution component represent a novel tool of health democracy.
Gustave Roussy is also one of the landmark sites in
the Vallée Scientifique de la Bièvre (Bièvre Scientific
Valley) and is contributing to the development of a
“pilot health territory” by helping to form connections
to the health needs of the local population.
Because of the high quality of its research and the
very large number of patients it receives, Gustave
Roussy acts as a magnet in terms of attracting
scientific development in the Ile-de-France and as
an engine of growth in relation to Grand Paris.
www.cancer-campus.com
www.cancercontribution.fr
PROSPECTS FOR THE FUTURE
CAMPUS GRAND PARC COMMERCIAL
DEVELOPMENT SITE.
LOCAL ROOTS
CHEVILLY-LARUE
HOSPITAL CENTRE
(AS OF 1ST JUNE 2015)
47
32
SHORT STAY BEDS
CONVALESCENT AND
REHABILITATION BEDS
8
DAY-HOSPITAL BEDS
ORGANISING THE CARE LOCALITY
LOCAL AND REGIONAL PARTNERSHIPS
Gustave Roussy is building partnerships with other
establishments such as the Institute of Thoracic
Oncology, established for thoracic cancer in 2012 by
collaboration with the Marie-Lannelongue Medicosurgical Centre, and the Sainte-Anne Hospital Centre
for nervous system disorders in 2015.
CHEVILLY-LARUE HOSPITAL CENTRE, SECOND
GUSTAVE ROUSSY SITE
In late 2013 it was decided to merge Gustave Roussy
with the Chevilly-Larue Hospital centre, which specialised in respiratory diseases. Preparatory work
proceeded throughout 2014 and the merger took
place on 1 st January 2015. Because of this short
time-scale, preparatory work had to be carried
out swiftly. This included bringing separate teams
together, training, administrative convergence,
harmonising equipment, merging information systems, works management, cost control and legal
aspects. The efforts made by everybody concerned
meant that even before the merger agreement was
officially signed, services in every area were already
harmonised. The medical plan for the ChevillyLarue site was set in train in 2014 by Professor
Michel Ducreux, medical coordinator, thanks to the
cooperation of the care and medical teams and of all
the operational directorates. The transformation of
the Chevilly-Larue site has already started and the
5.3 M€ investment programme is projected to run
over five years.
The merger agreement signed by the parties on 11th
July 2014 included a commitment by the Institute to
re-employ all staff. An interim consultative body was
set up in January 2014 and the integration of CHSP
personnel was effected on 1st January 2015.
31
STUDENTS AND PARTNERS
PREPARING TOMORROW’S RESEARCHERS
AND CARE TEAMS IN FRANCE AND ABROAD.
The transmission of knowledge cannot be dissociated from research but it
is also part of the Institute’s clinical mission and its provision of care. This
important activity acquired a new dimension in 2012 with the creation,
in partnership with Paris University-Sud, of the École des Sciences du
Cancer, an institution which is unique in France, because it is the only one
to assemble a high quality teaching body to provide training covering the
whole field of oncology ranging from basic research to clinical practice. The
courses are usually multidisciplinary and are attuned to the emergence of
new posts in the world of oncology. More widely, the transmission of skills
and experience goes beyond the teaching setting and even crosses national
borders: Gustave Roussy is involved in the creation or improvement of departments and care facilities around the world. Living the future today also
means sharing knowledge to advance understanding.
teaching
Teaching at
Gustave Roussy
on video
32
I am living
the future today
CLAUDIO NICOTRA, CLINICAL RESEARCH ASSOCIATE
AT DITEP.
In 2012, Claudio Nicotra studied for his University Diploma in Clinical Research
in Oncology (DURCO) at Gustave Roussy. This one year course, provided by the
École des Sciences du Cancer and the Paris-Sud Medical Faculty, specifically
offers a combination of theoretical instruction, given by leading specialists from all
departments of the Institute, and a six month practical attachment. It is also the
only oncologically specialised University Diploma which trains clinical research
associates. Once he had obtained his diploma, Claudio came to work at DITEP where
he coordinates phase I clinical trials. “This very comprehensive course enabled me to
function from the moment I completed the training”.
33
PHD IN ONCOLOGY
EXCELLENCE IN ONCOLOGY
ESTABLISHED WITHIN THE ÉCOLE DES
SCIENCES DU CANCER, THE COURSE
OF EXCELLENCE IN ONCOLOGY –
FONDATION PHILANTHROPIA HAS THE
GOAL OF TRAINING TEN INDIVIDUALS
TO A HIGH LEVEL, WITH AN EMPHASIS
ON AMBITIOUS AND ADVANCED
TRANSLATIONAL RESEARCH.
Recent advances such as targeted therapies and
immunotherapy represent a revolution in the fight
against cancer, which now finds itself at a crossroads. Embarking on new paths, extending them and
opening them up for every patient necessitate training to a high level in a combination of complex disciplines. This is the goal of the Course of excellence
in Oncology – Fondation Philanthropia which takes
on its third intake on 1st October 2015. Established
within the École des Sciences du Cancer (Paris-Sud
University – Gustave Roussy) and supported by the
umbrella Fondation Philanthropia to the extent of
2 ME over four years, this programme involves training of ten individuals.
DOCTORAL STUDENTS WITH HIGH POTENTIAL
Doctors, pharmacists and engineers, half of the chosen
candidates come from outside France.
Their dual course over three years is completed by a
thesis in science, oriented towards research and innovation. DNA repair, molecular medicine, radiobiology,
onco-haematology, immunotherapy and molecular
epidemiology are among the fields covered. The candidates are selected not only for their research potential but also for their ability to teach and train others.
Thus, the future transmission of skills and knowledge
is taken into account. These students are remunerated.
They receive personalised training within the Paris-Sud
University’s École Doctorale de Cancérologie. They
carry out their research on the Gustave Roussy site
where they are supervised by a clinician or researcher
and possibly may enter into collaboration with other
international centres of excellence.
DOCTORAL STUDENTS SPEAK
One of these PhD students, Dorine De Jong, is a biomedical engineer with a thesis in oncology. “When
you are excited by something and a perfectionist,”
she points out, “you want the best. I applied because
the course could give me everything I was looking
for. It is an excellent programme and the remuneration means that I can manage without any worries.”
Anna Gueiderikh is halfway through a dual course in
medicine and science. “I am very impressed by the
numbers of high-quality doctors and researchers,”
she says, “The proximity to the hospital means that
we have to face the reality of patients.” Bertrand Routy
is a Canadian doctor and he too has found what he
wanted. “There were three reasons for applying: the
excellence of this oncology research centre, one of the
best in the world; the completely bilingual environment, a real plus when one is an English speaker; and
finally the emphasis on research with personalised
medicine and courses in immuno-oncology.”
Living
the future
today
2 M€
OVER FOUR YEARS FINANCED
BY THE FONDATION PHILANTHROPIA
TO TRAIN 10 INTERNATIONAL
HIGH QUALITY SPECIALISTS
34
TEACHING: REVIEW OF THE YEAR
PREPARING FOR TOMORROW’S ONCOLOGY
T
26
UNIVERSITY DIPLOMAS
2,300
raining for tomorrow’s oncology is one of Gustave
Roussy’s principal missions. Education and the
sharing of knowledge are deeply rooted in the
Gustave Roussy culture and vocation. The Institute has
an unrivalled experience of nearly 90 years of onco
logy. In order to improve the essential connections
which should link training, research and patient care,
Gustave Roussy founded the École des Sciences du
Cancer within the Faculty of Medicine at Paris-Sud
University. The Institute has forged strong links with
Paris-Sud University – future Paris-Saclay University–
and its four research and training units in Medicine,
Pharmacy, Sciences and Economics-Management.
The strength of the collaboration between Gustave
STUDENTS AND
500 STAFF TRAINED
90 %
OF THE TEACHERS COME
FROM PARIS-SUD UNIVERSITY
AND/OR FROM GUSTAVE ROUSSY
TRANSMIT EXPERIENCE
AND EXPERTISE, SO KNOWLEDGE
MAKES PROGRESS.
Roussy and the Medical Faculty derives from the
École des Sciences du Cancer, and enables us to
establish a real continuum between innovation and
knowledge, each institution benefitting from the
expertise of the other.
CONTRIBUTING TO THE DEVELOPMENT
OF HIGH QUALITY TRAINING PROGRAMMES
Since its establishment in 2012, the École des
Sciences du Cancer has offered teaching in oncology,
incorporated in the university networks of Paris-Sud
University. High quality training is provided there by
recognised experts and those at the cutting edge in
oncology. Oncology teaching at Gustave Roussy is
provided by a faculty of 26 university teachers and
214 medical practitioners with teaching responsi
bilities. Each year they devote 40,000 hours – of which
5,000 are at university level – to teaching 2,300 students and 500 doctors, nurses, professionals allied to
medicine, research workers and engineers.
These courses comprise: oncology modules of undergraduate medical studies, DES and DESC, 26 university diplomas in oncology, some forty scientific
seminars and master’s degrees (M1 and M2). As for
the Ecole Doctorale de Cancérologie, this is the only
doctoral school in France devoted solely to oncology.
35
It has 85 units which can accept doctoral students
and each year 55 of the latter are trained.
CONFIRMING ITS PLACE AS AN AGENT
OF PROGRESS
In the context of the 2015-2020 hospital plan, the
high quality training offered by the École Doctorale
de Cancérologie will continue to be provided and
will expand, with a particular debt to its sponsor,
Fondation Philanthropia.
During the year 2014, four new doctoral students
were recruited as the second intake of “Course of
excellence in Oncology – Fondation Philanthropia”
(see page 33) and have also joined the École
Doctorale de Cancérologie.
CONNECTED LEARNING
In response to the issues raised by
innovative therapies, the École des
Sciences du Cancer developed a new
teaching model consisting of e-sessions
with student feedback, and on-line
seminars. In 2014, the medical and
scientific library became accessible on
line and 200 hours of classes were made
available on a digital facility. In 2015,
this teaching facility will expand and will
provide novel training based, for example,
on digital simulation. This will facilitate
regular assessments of participants and
teachers. It will also link in to the PACRI
(Parisian Alliance of Oncology Research
Institutes) commitment to put modules
of e-learning in oncology on line.
240
TEACHERS, PRACTITIONERS AND
NON-PRACTITIONERS
40
SCIENTIFIC SEMINARS
40 ,000
HOURS DEVOTED TO TRAINING,
OF WHICH 5,000 ARE AT
UNIVERSITY LEVEL
Theory
Real
and virtual
classes
MENTORED TRAINING
The École des Sciences du Cancer also
organises training on an international basis
by offering tailor-made teaching incorporating
immersion apprentiships accompanied by
individual mentors at Gustave Roussy, distance
learning and teaching in English. In 2014,
a hundred Kazakh oncological surgeons and
physicians received such mentored training
at Gustave Roussy (see page 38).
Practice
Support
THE TRANSMISSION OF
Dialogue
KNOWLEDGE, INNOVATIVE
TEACHING BASED ON
DIALOGUE, VISUAL AIDS,
TRAVEL, DIGITAL SUPPORT.
2014
FROM THE VIEWPOINT OF INNOVATION
High
lights
January
March
1ST HIGH-THROUGHPUT
SEQUENCING FACILITY
WORK ON THE
DEVELOPMENT
PROJECT 2015-2020
Gustave Roussy, in collaboration with IntegraGen,
established the first large-scale high-throughput
sequencing facility which, allowing for some delay
and determination of strict quality criteria, would go
on to perform molecular testing and diagnosis. This
thorough and novel analysis of tumours facilitates
the correct choice of treatment in patients on the
personalised medicine programme.
After carrying through the 2009- 2013 development
project, the keynote of which was the implementation
of personalised medicine, Gustave Roussy moved on
to determine its strategic goals for 2015-2020. During
2014, all of the Institute’s teams involved themselves
in thinking this through in working groups, interviews
or written contributions. The major lines of thought
were shared with the greatest number, to work out
Gustave Roussy’s pathway for the next five years.
Innovation was to be the keystone of our vision for
the future.
> AND TOMORROW?
High-throughput sequencing
will enable
us to assess the value of NGS (next-generation
sequencing) in clinical practice.
> AND TOMORROW?
Engine of scientific, technological and
organisational innovations, the Institute
sees patient care as the end-point of research in
the service of patients. The development of clinical
trials, discoveries in immunotherapy, molecular
medicine for the largest number of patients;
all of these make Gustave Roussy a catalyst of
progress in oncology.
February
GUSTAVE ROUSSY
INVESTS IN
TOMO-RADIOTHERAPY
Gustave Roussy has two tomo-radiotherapy
machines: the first started work in February, the
second in October. Progress in radiotherapy depends
on a global strategy focusing on the use of high techno
logy apparatus to develop more precise and effective
treatment while limiting side effects. This double
acquisition, at a cost of six million euros, was made
possible by the generosity of the Institute’s donors
and sponsors.
> AND TOMORROW?
Gustave Roussy launches a programme
of hypofractionated radiotherapy
By giving a higher dose at each session,
hypofractionation reduces the duration of treatment
and improves the quality of care. This programme
is key to strategy over the next decade and will
reinforce the Institute’s standing.
May
GUSTAVE ROUSSY’S
HIGH PROFILE AT
ASCO AND THE MAJOR
INTERNATIONAL
SCIENTIFIC
CONFERENCES
At the 50th ASCO Meeting in Chicago (2014), Gustave
Roussy teams presented their clinical and translational
research studies. These were the subject of 18 oral
communications, 10 of which were delivered by Gustave
Roussy doctor researchers, and 37 poster presentations.
The 6th WIN symposium, instigated by Gustave Roussy
and accredited by ASCO, reviewed the state of know
ledge in the field of precision medical treatment of
cancer. This was attended by 400 individuals from
more than 35 countries.
April
2ND INTAKE IN
THE “COURSE OF
EXCELLENCE IN
ONCOLOGY”
Four students were selected to form the second
intake of this PhD programme in Oncology at
Gustave Roussy. This dual course combines madeto-measure classes and production of a scientific
thesis. The “Course of excellence in Oncology –
Fondation Philanthropia” is based in the École des
Sciences du Cancer with support from Fondation
Philanthropia. It is intended to train 10 individuals
(three intakes) in innovative aspects of the posts of
the future in clinical oncology.
> AND TOMORROW?
Philanthropia, leading sponsor
of Gustave Roussy, is committed
to renewing this course beyond the
three intakes initially envisaged.
> AND TOMORROW?
TAT, ASCO, WIN, ECCO, Paris Breast
Rendez-vous… Gustave Roussy medical
researchers participate through their presentations
and publications in the most significant
international scientific advances.
June
REVIEW OF CANCER
REVOLUTION
The campaign “Cancer Revolution” finished in 2013
with the 10 M€ target exceeded. The Gustave Roussy
Foundation, engine of this fundraising campaign, organi
sed an evening at the Molitor swimming pool to round off
the campaign and thank major donors for their contributions. An auction of street-art conducted by Emmanuelle
Beart and Maitre Arnaud Oliveux realised a total of
319,000 €, with special thanks to the Philanthropia
Foundation for doubling the auction receipts, and to the
sponsors of the evening: Colony Capital, Molitor, Accor,
the Dassault Group, Artcurial and the agnès b Donation
Fund. Thanks also to Central-Dupont, JogSwimwear,
Patyba, PRPA, Pure Bonheur and Taittinger.
> AND TOMORROW?
Gustave Roussy is developing a specific
strategy which seeks to attract donations
from leading donors and sponsors in France and
from abroad. A new campaign committee faces
the challenge of increasing donations and gifts
between now and 2020 substantially, in order to
finance innovation directly benefitting patients.
July
September
MERGER AGREEMENT
WITH THE CHEVILLYLARUE HOSPITAL
CENTRE
CREATION OF CANCER
CORE EUROPE
Gustave Roussy and five European centres of excellence formed the consortium Cancer Core Europe.
This research organisation will share data and seek
to develop the continuum between clinical research
and treatment of patients. Cancer Core Europe will
represent a real strike-force against disease with its
critical volume of work enabling it to contribute in
all fields of basic, translational and clinical research.
Gustave Roussy and the Chevilly-Larue Hospital
centre signed a cooperation agreement with a view
to a merger. On 1st January 2015, the Chevilly-Larue
Hospital centre became a Gustave Roussy site. The
objective was to respond to the growing numbers of
new patients and to improve care pathways. Over a
period of a few months, teams were trained, building
work carried out and a medical plan drawn up.
> AND TOMORROW?
To respond to the research demands of
the future, which depend on the handling of
> AND TOMORROW?
Gustave Roussy – Chevilly-Larue
Hospital centre will implement its own medical
plan comprising new methods of dispensing care:
personalised cancer prevention measures in atrisk individuals, improved cardiology services and
admission of patients from abroad together with
their families.
August
A MAJOR PUBLICATION
ON RESISTANCE TO
TARGETED THERAPIES
Researchers from Gustave Roussy/Inserm/Paris-Sud
published the results of a study on mechanisms of
resistance to targeted therapy in melanoma in the
prestigious scientific journal Nature. This throws
new light on the loss of efficacy of drugs and opens
up new lines of research and management of these
aggressive skin tumours with application also to
some cancers of thyroid, colon, lung and brain.
> AND TOMORROW?
The establishment of a major research
centre on an international scale fostering the
integration of all types of research: basic, clinical,
epidemiological, human and social sciences,
bio-statistics, bio-informatics, systems biology,
biophysics and technology.
ever increasing quantities of data, six European
cancer centres of excellence will share their
progress in research through an e-hospital –
the Cancer Core Europe network. The consortium
treats 60,000 new cases annually, manages
300,000 courses of treatment and around one
million outpatient visits, and conducts more
than 1,500 clinical trials.
November
THE GAME-CHANGING
ROBOT
Gustave Roussy is the first hospital in Europe to
acquire da Vinci Xi, the latest generation surgical robot.
This robot is designed to aid patient care, research
and training and is used for innovative procedures in
abdominal, gynaecological, ENT and breast surgery as
well as reconstructive plastic surgery.
This strategic investment costing 2.8 M€, was
made possible by a donation from the Fondation
Philanthropia, Gustave Roussy’s leading sponsor.
> AND TOMORROW?
The Institute is launching its programme
of innovation in oncological surgery with
the intention of developing new procedures by
combining three advanced therapeutic techniques:
euronavigation, endoscopy and robotic surgery.
October
ACTION FOR
“PINK OCTOBER”
Gustave Roussy prepared itself for the month devoted
to the fight against breast cancer. A week of lectures
and functions within the Institute were arranged with
the goal of informing the public about the disease
and the latest advances in treatment. 38,000 people
participated, as part of “Pink October” 2014, in the
walking race, Odysséa Paris, which raised more than
470,000 euros for clinical research and development
of personalised treatment at Gustave Roussy.
> AND TOMORROW?
Throughout the year, the Institute organises
events intended for patients and their families to
coincide with world or national days: “Pink October”
for breast cancer; “Blue March” for colon cancer;
the national day for screening and prevention of skin
cancer through the #connaistapeau campaign; the
tobacco-free day; the patient safety week; etc.
December
OPENING OF THE NEW
PAEDIATRIC UNIT BY
MARISOL TOURAINE
After 18 months of building work, the Department of
Childhood and Adolescent Oncology opened its new
premises. Colour, light play and transparency are the
themes of the building, designed with the collaboration of care staff and patients’ families. The 1,600 m2
replanned area is intended to foster communication
and to preserve family ties. This represents a new
vision of patient management. The work, which cost
3.2 M€, was partly financed by donations. The unit
was formally opened by Marisol Touraine, Minister
of Health.
> AND TOMORROW?
A European leader in clinical trials in
paediatric oncology with 40% of its young
patients included in some twenty trials, Gustave
Roussy is contributing to progress in research.
Thus, researchers at Gustave Roussy have reported
significant progress in the treatment of invasive
glioma of the brain stem. This work was published
in the journal Nature Medicine in May 2015.
The study was supported by donations from patient
associations including L’Étoile de Martin, la Famille
et les amis de Noé Lemos and le Défi de Fortunée.
38
PROFESSOR EGGERMONT AND
MR. TASMAGAMBETOV, MAYOR OF
ASTANA, AT THE TIME OF SIGNATURE
OF THE COOPERATION AGREEMENT,
13TH FEBRUARY 2014.
THE GUSTAVE ROUSSY MODEL
ESTABLISHED IN KAZAKHSTAN
THE MAYOR OF ASTANA PARTNERS WITH GUSTAVE ROUSSY
TO MODERNISE AND IMPROVE ONCOLOGY CARE IN ASTANA,
WITH AN AMBITIOUS PROJECT.
I
Russia
France
Kazakhstan
n the context of the modernisation of its health system, the Republic of Kazakhstan selected Gustave
Roussy to support the development of its cancer
care service. This long-term collaboration began in
2011 and is intended to raise oncology standards in
this rapidly developing country to the highest international levels. “We have established a programme
with the intention of steadily bringing the work in
Kazakhstan up to European standards, starting by
making the chemotherapeutic medication circuit
safe,” explains Professor Alexander Eggermont,
General Director at Gustave Roussy.
In 2014, under the guidance of the Gustave Roussy
Department of Clinical Pharmacy, doctors, pharmacists and health managers went every three months to
the Astana (capital of the country) oncological centre
to help train their Kazakh counterparts, establish new
practices and lead working and study groups.
OPENING OF A CHEMOTHERAPY
PREPARATION UNIT
As a result of this transfer of skills, a centralised
chemotherapy preparation unit, the first in the country,
was opened late in the year. Similarly, Kazakh teams
are coming regularly to Gustave Roussy to improve
their skills in the whole field of the chemotherapy circuit: developing a drug purchasing policy appropriate to
patient needs, bringing protocols up to date, ensuring
that the preparation of chemotherapy is safe, improving
methods of administration of medication with a view
to nurse and patient safety, etc. The model which has
been put in place in this way in Astana is susceptible
to gradual application in other centres in the country.
The creation of a referral centre for bone marrow
transplantation is one of the other projects currently
being conducted by Gustave Roussy in Kazakhstan. A
dedicated laboratory and clinical unit will be opened
in a few months’ time at the Astana National Medical
Research Centre.
A LONG-TERM VISION
Looking beyond patient care, close collaboration
between the Republic of Kazakhstan and the Institute
extends naturally into other areas of expertise. This
includes an agreement with the Kazakh Ministry of
Health for a hundred oncological physicians and surgeons to be trained at Villejuif; a plan to establish
a new research centre in Astana; and a contribution
to public health by helping the Kazakh government
to establish a pain programme on a national scale.
“Our added-value is more than a technical one; it is
an overarching vision which places patients at the
heart of their treatment, while striving to preserve
their health and well-being for the long-term,” adds
Professor Eggermont.
39
TWO KEY TEACHING ANNIVERSARIES
AT GUSTAVE ROUSSY
THIS YEAR GUSTAVE ROUSSY CELEBRATES HOLDING ITS 30TH RENOWNED ANNUAL
COURSE ON ANTI-TUMOUR CHEMOTHERAPY AND 15 YEARS OF THE ECOLE
DOCTORALE DE CANCÉROLOGIE, FOUNDED BY THE PARIS-SUD MEDICAL FACULTY
AND THE ÉCOLE NORMALE SUPÉRIEURE DE CACHAN.
30 YEARS OF THE HIGHEST QUALITY
TEACHING OF ONCOLOGY
The “anti-tumour chemotherapy and medical treatment of cancer” course was established at Gustave
Roussy in 1985 and has been delivered there since. It
has become the benchmark in oncology teaching. It
attracts participants not only from all over France, but
also from abroad: “It is the only two week course conducted in French which reviews the basic information
and the most recent developments in routine cancer
treatment for an international audience,” underlines
Professor Jean-Charles Soria, who has directed the
course since 2007.
200 doctors, pharmacists, laboratory scientists and
other research scientists attend this high quality
teaching course annually. It is, moreover, recom
mended by the National Board of the Order of
Physicians to doctors who have obtained their
qualifications abroad and want to practise oncology
in France.
15TH ANNIVERSARY OF THE ÉCOLE DOCTORALE DE
CANCÉROLOGIE (ED 418)
This was initiated in 2000 by Professors Thomas Tursz
and Christian Auclair. It is responsible for training
run by the Paris-Sud Medical Faculty in association
with the École Normale Supérieure de Cachan and is
based on the Gustave Roussy site. It provides doctoral
students with oncology research experience through
their thesis work and a training component delivered
by the École des Sciences du Cancer. The students
are, therefore, able to conduct the research for their
theses in a setting dedicated to this where they are in
constant contact with leading oncologists. The course
consists of research work linked to the production of
a doctoral thesis and additional relevant teaching. In
fifteen years, 651 students have completed their theses while working in one of 85 research teams. The
École Doctorale de Cancérologie is currently directed
by Professor Martin Schlumberger, who is also head of
the Nuclear Medicine Department at Gustave Roussy.
The teaching is provided by leading specialists and
researchers from Gustave Roussy and other hospitals. Their aim is to transmit the knowledge acquired
in their day-to-day use of systemic cancer therapies.
The main subjects covered are fundamental mechanisms of action of anti-cancer agents, conventional
and novel therapeutic strategies in the common cancers and complications of treatment. The course also
deals with new approaches currently being assessed
in clinical trials in patients. In the thirty years since
it commenced, the Gustave Roussy chemotherapy
course has taught almost 3,000 health professionals.
THE «ANTI-TUMOUR CHEMOTHERAPY AND
MEDICAL TREATMENT OF CANCER» COURSE
AT GUSTAVE ROUSSY.
Living
the future
today
GUSTAVE ROUSSY FOSTERS THE
SPREAD OF KNOWLEDGE AND
OF ADVANCES IN ONCOLOGY
BY PURSUING ITS MISSION
TO DISSEMINATE KNOWLEDGE
AND TO TRAIN HEALTH
PROFESSIONALS IN ONCOLOGY
IN FRANCE AND ABROAD.
40
16
PUBLICATIONS WITH
AN IMPACT FACTOR
GREATER THAN 30
947
994
919
888
757
722
656
618
541
481
471
431
447
471
431
507
434
489
422
335
OF THE INTERNATIONAL
PUBLICATIONS HAVE AN IMPACT FACTOR
GREATER THAN 10.
336
14,5%
330
NUMBER OF PUBLICATIONS
1 149
JOURNALS
Publication in French journals, which have a lower
impact factor or do not even have one at all, remains
above 11% of the total annual production. This figure
illustrates the fact that Gustave Roussy is fulfilling its
role to spread knowledge within the French medical
and scientific community by writing articles for educational journals.
1 172
380
A
fter a marked increase in 2012 in the number
of publications emanating from Gustave Roussy
research scientists and doctor researchers, the
figures have remained stable for two years. Their
international recognition is shown by the fact that the
proportion of publications with a high impact factor
(IF above 10) has remained around 14% for several
years (147 of the 1,149 articles appearing).
1 219
IN 2014, THE GUSTAVE ROUSSY
SCIENTIFIC COMMUNITY
PUBLISHED IN
SUMMARY OF INTERNATIONAL
PULICATIONS
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
p
DISTRIBUTION OF PUBLICATIONS
2009
2010
2011
2012
2013
2014
FOR...
International publications IF < 10
696
740
702
930
868
867
French publications IF < 10
128
142
114
165
162
135
PUBLICATIONS
Publications with IF from 10 to 20
73
87
92
79
100
129
THE TOP 8 JOURNALS IN WHICH
GUSTAVE ROUSSY PUBLISHES
MOST FREQUENTLY:
• Annals of Oncology
• European Journal of Cancer
• Journal of Clinical Oncology
• Bulletin du Cancer
• OncoImmunology
• International Journal of Cancer
• PloS one
• Lancet Oncology
450
MEDICAL LIBRARY SUBSCRIPTIONS
TO ON-LINE REVIEWS
170,000
DOWNLOADS OF ARTICLES
BY GUSTAVE ROUSSY TEAMS
Publications with IF from 20 to 30
5
8
9
27
22
35
Publications with IF over 30
17
17
30
18
20
16
Total publications
919
994
947
1,219
1,172
1,149
INTERNATIONAL PUBLICATIONS IN JOURNALS WITH A HIGH IMPACT FACTOR:
Cancer Cell
2
Cell
1
Lancet
7
Lancet Oncology
18
Nature
5
Nature Cell Biology
1
Nature Genetics
7
Nature Medicine
1
Nature Reviews Cancer
1
Nature Reviews Molecular
Cell Biology
1
New England journal of Medicine
5
Science
1
Total
50
41
CIVIL SOCIETY
TO GIVE RESEARCHERS, DOCTORS AND NURSING
STAFF THE MEANS TO INNOVATE MORE,
SPEED UP PROGRESS IN FIGHTING DISEASE AND PROVIDE
COMPREHENSIVE PATIENT CARE.
Gustave Roussy is a non-profit making Private Health Establishment of Public
Benefit: its innovations, in research and patient care, depend in large part
on the generosity of civil society. Financial transparency, good management
of donations and bequests and respect for donors’ wishes are longstanding
principles of the Institute: its vigilance in this area is shown in the “Trust
in Fundraising” approval by the National Charter Committee. Anyone may
donate – individual, company or patient association – by payments, by sponsorship activities, by patronage of a specific research team and by support of
a hospital or the Gustave Roussy Foundation.
Supporting Gustave Roussy is to become committed to innovation in the fight
against cancer. Your donation is transformed into a weapon against the condition and is helping patients every day. You are alongside patients, researchers,
doctors and nurses today and tomorrow. It is living the future today.
supporting
42
I am imagining
the future today
THIERRY BRUHAT, PATIENT EXCITED BY INNOVATION.
Thierry Bruhat devoted his working life to innovation in business and related areas.
An entrepreneur to his fingertips, he has no equal when it comes to getting people to
work together, encouraging open and collaborative approaches and getting things done.
From Silicon Valley to competitive areas in French business, he has been at the heart
of the French innovation ecosystem. As a patient at Gustave Roussy for more than two
years, he works with DITEP very frequently. With these visits to the various parts of
Gustave Roussy, he has created his own goal: to use his years of experience of innovation
in the service of other patients, particularly in the cancer field. With the encouragement
of Professor Jean-Charles Soria, director of DITEP, he works with unflagging
enthusiasm. With support from Sebastien Bazin, Chief Executive of Accor and VicePresident of the Gustave Roussy Foundation, and with the help of many of the Institute
doctors, Thierry Bruhat devotes his energy to a concrete achievement of the goals of
the « Molitor Évasion » programme. “This is the first stage of a well-structured concept
of provision of support which is complementary to treatment. One day this will come to
fruition as a fine well-being centre for every Institute patient. The beginning of a story.”
43
THE GUSTAVE ROUSSY FOUNDATION
MISSION CANCER RESEARCH:
A FOUNDATION BACKED BY GUSTAVE ROUSSY
THE GUSTAVE ROUSSY FOUNDATION
WAS ESTABLISHED IN 2005.
ITS PRIMARY AIM IS TO FUND
RESEARCH DIRECTED AGAINST
CANCER. THUS, AT THE HEART OF ITS
WORK IS THE DESIRE TO IMPROVE
PATIENT TREATMENT AND QUALITY
OF LIFE. THE CREATION OF THE
GUSTAVE ROUSSY FOUNDATION WAS
A RESULT OF THE INSTITUTE’S DESIRE
TO DISTINGUISH BETWEEN SUPPORT
OF AND INVESTMENT PROPER IN
THE HOSPITAL AND SUPPORT OF
THE RESEARCH POLICY.
CANCER REVOLUTION: THE FIRST WAGER
In 2010, the Gustave Roussy Foundation launched its
first fundraising campaign: Cancer Revolution.
The wager: to collect 10 million euros in three years
to devote to a better understanding of cell mutations
in each patient. Three years later, the outcome was
strongly positive with more than 11 M€ collected
by late 2014. The Cancer Revolution campaign
funded personalised medicine: identification of each
tumour’s genes, production of a molecular portrait of
the patient in less than one month, the more effective characterisation of rare tumours, modelling of
personalised treatment options and better analysis of
treatment resistance associated with certain genomic
profiles.
The collected monies financed very high technology
apparatus, a substantial part of the construction of
the Molecular Medicine building in 2013, and also salaries of new research teams and laboratory personnel responsible for performing the molecular portrait
tests… As for the patients, several hundreds of them
have benefited from these innovations.
THE NEXT BIG FUNDRAISING CAMPAIGN
The programme for a new fundraising campaign is
being put together and is orientated even more towards
patient quality of life. Gustave Roussy research scientists and doctor researchers are already very involved
in discussing what research programmes should be
funded. Some major possibilities have already come
to the fore:
• high-throughput sequencing to help understand each
patient’s tumour better. In 2015, it is already making it
possible to analyse more than 25,000 genes;
• integration and analysis of all the laboratory and
medical information of patients enrolled in persona
lised medicine trials;
• immunotherapy, thought of up to the present as a
supplementary treatment, has now become a very
promising avenue of research.
Research workers at Gustave Roussy are faithful to
their commitments and fully conscious of the role of
involvement of civil society in these very important
research projects. Thus, the researchers participate
actively in development meetings with donors who
are sympathetic to the cause, so as to establish close
relationships with them, explain things simply, report
back, crystallise concepts and help to project.
44
FUNDRAISING 2014
Generosity translated into events
CLOSURE OF “CANCER REVOLUTION”
Two prestigious functions were arranged in 2014 to raise funds for the
Gustave Roussy Foundation. A unique auction of street art took place
on 17th June at the Molitor swimming pool and raised 319,000 €.
The 2nd Cancer Revolution Open at the Saint-Cloud Golf Club in October
generated 40,000 €, thanks to the hard-working organising committee
and to Nelson Monfort.
MARS BLEU (BLUE MARCH):
2ND YEAR OF “ROULONS POUR
LE CÔLON”
During Blue March, the month devoted to publicity for colo-rectal
cancer, Gustave Roussy repeated its “Roulons pour le côlon” event,
with the support of its loyal partners, including Dell and Natixis.
From 10th to 16th March a Gustave Roussy lorry drove around Paris
to promote screening and raise funds for research. The operation
finished off with the Val-de-Marne half-marathon, the funds raised
being assigned to Gustave Roussy. 70,000 € were collected and were
used to recruit an engineer to Doctor Fanny Jaulin’s team.
TOGETHER
AGAINST
MELANOMA
The group “Ensemble contre le
mélanome” (Together against
melanoma), which works regularly with
Gustave Roussy, collects donations for
prevention, education about screening
and funding of research on skin cancer.
Gustave Roussy is embedded in the
work of the group in the person of
Doctor Caroline Robert, head of the
Gustave Roussy Onco-dermatology
Department. In 2014, the group’s
efforts raised 583 K€.
On 2nd April, Thomas Dutronc had a
free hand at the Casino de Paris for
a fundraising concert for “Together
against melanoma”. This gipsy jazz event raised more than 73 K€. For the
music festival on 21st June, Gustave Roussy, Radio France, Olympia and the
Crédit Mutuel combined to deliver a message on prevention and education
about the development of melanomas.
ODYSSÉA, SHOPPING SOLIDAIRE:
A GREAT SUCCESS FOR PINK OCTOBER
In 2014 the Odysséa walking race, which raises funds for the fight against
breast cancer, was again very successful with 38,000 participants. Also in 2014,
Gustave Roussy attracted 200 people to its first “charity zumba”. For the sixth
year, Odysséa chose to fund research on personalised medicine in breast cancer
at Gustave Roussy. 370,000 € was donated by Odysséa to which was added
100,000 € raised by the regular “Shopping Solidaire” (charitable shopping) event
arranged by Printemps Nation (Paris). In six years Odysséa has raised almost
2 M€ for Gustave Roussy, devoted to research on breast cancer, especially in
the area of personalised medicine and immunology, and for improvements in
patient quality of life.
45
Our ambassadors in action
ÉTOILE DE MARTIN, A
LONGSTANDING COMMITMENT
IN THE FIGHT AGAINST
CHILDHOOD CANCER
The Étoile de Martin association exhibits boundless energy
and creativity in its activities related to childhood cancer: a
cake for research, a petanque competition, swimming and
marathon events, etc. It funds research and quality of life
initiatives at Gustave Roussy. Over nine years the Étoile de
Martin has handed over 1.636 M€. Its support and its trust
are a source of strength for doctors and researchers at
Gustave Roussy.
DANS LA PEAU
D’UN CHERCHEUR
1ST EVENT
On 29th November Gustave Roussy
mounted “Dans la peau d’un chercheur”
(In a researcher’s shoes), a new venture
in molecular medicine. Doctors and
research scientists invited nearly
200 donors to share their passion and
their knowledge during an educational
visit to the laboratories: films;
literature searching; drawing up a
research budget and forming a team;
and laboratory experiments.
During the day the annual “Sponsor
a researcher meeting” took place: a
hundred individual patrons listened
to the directors of sponsored projects
presenting the findings of their current
research and prospects for the future.
Patronage is a strong and generous longterm commitment: the patron undertakes
to support an individual team with
automatic donations over a three year
period, thus securing a part of its budget.
IMAGINE FOR MARGO
RACE – CHILDREN
WITHOUT CANCER
This recently formed charitable group has already
established its name by its commitment, energy,
professionalism and initiatives. “Imagine for Margo
- Children without cancer” conducts ambitious
fundraising projects for the fight against childhood
cancer at Gustave Roussy. It contributes to the development
of innovative European research programmes and to the
introduction of quality of life projects in the Department of Childhood and Adolescent Oncology. Imagine for
Margo works with the ITCC consortium to lobby for the development of drugs specifically for children and for
accelerated access to novel treatments.
LES AMIS DE MIKHY, ASSOCIATION WITH A BIG HEART
In April 2014, Les Amis de Mikhy organised the
1st “Les chefs au grand cœur” (Big-hearted
chefs) event. Over a week, 52 Parisian starred
chefs contributed by providing a special menu
or by donating a proportion of their takings. This
event raised 50,000 € to fund specialist paediatric
psychiatry care for children in hospital with
cerebral tumours or in remission from them.
Early in 2015, the Amis de Mikhy handed over
140,000 € for support care for young patients at
Gustave Roussy.
ERIC SCHNEIDER, A REMARKABLE CHALLENGE
TO COUNTER CHILDHOOD CANCER
Eric Schneider is a former patient at Gustave Roussy and father of a child followed at the Institute. By covering
the equivalent of a marathon each day for 18 days, between Marseille and Villejuif, he managed to run 757 km to
support the fight against childhood cancer. During the run he raised 19,050 €.
46
4.4 M€
OF BEQUESTS AND OTHER
GIFTS IN 2014
BEQUESTS AND OTHER DONATIONS,
A POTENTIAL TO BE DEPLOYED
EACH YEAR, SEVERAL MILLION EUROS COME TO GUSTAVE ROUSSY IN THE FORM
OF DONATIONS, BEQUESTS AND LIFE INSURANCE. THESE PRECIOUS FUNDS
ALLOW US TO ACQUIRE THE LATEST EQUIPMENT, TO IMPROVE OUR PATIENT
FACILITIES AND TO CONTINUE TO PUSH BACK THE DISEASE.
I
n 2014, bequests and donations collected by Gustave
Roussy came to 4.4 M€. The economic situation in
France explains why the total amount has fallen
in comparison with 2013. Life-insurance, a favourite
saving vehicle of the French, and temporary donation
of income from assets, less well-known by the public,
are promising areas for philanthropy.
NEW PUBLICITY
CAMPAIGN
“No need to own a chateau to make a
bequest to a cancer charity”. In Gustave
Roussy’s last publicity campaign, the
famous Chambord chateau served
as the visual background to the key
message: there is no small contribution.
Shares, furniture, property… All goods,
whatever they may be worth, contribute
to innovative research at Gustave Roussy.
PUBLICISING THIS TYPE OF DONATION
In 2014, a significant effort was made to inform the
public about bequests and life-insurance. In addition
to its publication in the donor magazine “Gustave
Roussy & You” (70,000 copies), the press release “No
need to own a chateau…” achieved wide distribution
through 15 publications in the popular written press.
This was supplemented by two weeks of broadcasts
on local radio. In May 2015, Gustave Roussy launched
a new ambitious campaign involving more active
interventions in the media. Press releases in the
mass-circulation written press were complemented
by television and radio publicity and further press
releases devoted solely to the subject of donations.
directed at solicitors. In 2015, Gustave Roussy became
still more involved with solicitors with a successful
stand at the May 2015 Solicitors’ Conference. This
summer, the Institute launched an information letter
“BEQUEATH/CURE” intended for those making their
wills and those helping them to do so.
All through the year, the fundraising team will continue to meet solicitors and advisers about handling
of wills.
DISTRIBUTION OF DONATIONS,
BEQUESTS AND OTHER GIFTS
DONATIONS
11.3 M€
DEVELOPING A CLOSE RELATIONSHIP WITH LAWYERS
The Institute has strengthened its contacts with the
lawyers who organise inheritance, draw up wills and
advise those of their clients who wish to give a purpose to their wealth by making a donation. In 2014,
solicitors’ offices were sent the Gustave Roussy
donors’ magazine as well as specific e-mailings.
Seven of the “No need to own a chateau…” advertisements have been published in the specialised press
BEQUESTS, DONATIONS,
LIFE INSURANCE AND
OTHER GIFTS
4.4 M€
“LA LIONNE OU L’AUTRUCHE”
A SHORT EDUCATIONAL FILM MADE ABOUT BREAST CANCER SCREENING
AT GUSTAVE ROUSSY
I
n 2014, Gustave Roussy hosted the filming of the
short film, “La Lionne ou l’Autruche” (The lioness
or the ostrich). This won 1st prize awarded by the
“Patients’ talents awards” jury 2014. It was produced
by Leem and directed by Isabelle Sebagh, a former
breast cancer patient at the Institute.
The movie presents the portraits of two women who
have to face the possibility of having breast cancer.
The lioness takes the initiative and the ostrich is
reluctant to face up to the problem. This fictional
7 minute film is homage to femininity. It was distributed
in the context of Pink October and delivers a message
on prevention and education about screening. This
was a way both of acknowledging Gustave Roussy
staff and, for the director, of transforming her experience into a work of art. “La Lionne ou l’Autruche”
was combined with a short publicity item appealing
for donations to Gustave Roussy. This 25 second clip
was widely screened free of charge by a number of
television channels.
47
16.2M€
16.15M€
FUNDRAISING IN 2014
+ 15.1 % COMPARED WITH 2013
POSTS IN 2014
GUSTAVE ROUSSY’S ACCOUNT OF USE OF FUNDS
DONORS, STILL MORE ACTIVE
GUSTAVE ROUSSY AS A PRIVATE HEALTH ESTABLISHMENT OF PUBLIC BENEFIT IS
AUTHORISED TO RECEIVE DONATIONS AND BEQUESTS WITH A VIEW TO FUNDING
ITS ANTI-CANCER MISSION.
F
unds raised from the public derive from national
canvassing and loyalty campaigns, specific initiatives, bequests and gifts. By holding events
the Institute’s profile is maintained vis-à-vis potential
donors, donations are encouraged and connections
strengthened.
DONORS REMAIN LOYAL AND NUMEROUS
Funds raised in 2014 totalled 11.3 M€. This marked
increase compared with 2013 (+ 37.1%) was mainly
explained by a single donation of 2.4 M€ from
Fondation Philanthropia. Donations to Gustave Roussy
in memory of a deceased loved one increased by 26%;
donors wish in this way to continue their fight by targeting their donations.
Gustave Roussy recorded more than 80,000 donations
(+ 2.5%) in 2014 and attracted more than 17,000 new
donors. The stable number of new donors and of
donations reflects Gustave Roussy’s attractions as a
charity and the loyalty of its donors despite a difficult
economic situation.
INCREASING SPONSORSHIP
Companies, foundations and charitable associations
are active supporters through their donations (which
increased by 5% in 2014) of innovative research programmes at Gustave Roussy. Sponsorship is a major
source of development funding for the next three years.
Donations from the big names in charitable giving such
as the Philanthropia Foundation, the Dassault Group,
Natixis, agnès b, Clear Channel, Crédit Mutuel, Dell and
Matmut are supplemented by those from the commitment of smaller companies who are striving loyally to
speed up advances in research. These include Cop
Copine, EBSCO, La Quincaillerie and PDRR Giacalone.
MAINTAINING CONTACT FOR BEQUESTS,
DONATIONS AND LIFE INSURANCE
In view of the difficult economic situation, which
explains the fall of 16.4% in bequests, Gustave
Roussy intends to communicate more with solicitors’
offices in France, where these bequests are, in fact,
organised.
USE OF FUNDS
Spending on its social missions totalled 6.7 M€, an
increase of 25.4%. This included direct intervention
by Gustave Roussy to a sum of 4.6 M€, and funded:
• basic research to a total of 1 M€;
• research programmes or investment (building, purchase of materials) to an amount of 2.2 M€. Half of these
amounts was directed to the “Push back the walls for the
children” programme;
• department specific projects, paid for out of funds
raised by themselves to a sum of 1.3 M€;
• 60,000 € for admissions and patient quality of life.
Otherwise, social missions included, to a sum of
2.13 M€, payments from other organisations such
as the Gustave Roussy Foundation and missions carried out abroad under the annual assignment covering coordination of the work of the Franco-African
Paediatric Oncology Group (GFAOP).
The expenses of research funds were down by 14%,
at a total of 2.37 M€.
Major projects were financed in 2014 thanks to the
generosity of donors:
• purchase of the latest generation da Vinci Xi surgical robot, a strategic investment made possible
by a one-off donation of 2.78 M€ spread over two
years from the Philanthropia Foundation to fund the
acquisition of equipment, related consumables and
maintenance;
• the acquisition of two tomo-radiotherapy machines
costing a total of 5.2 M€ overall for two years, funded
by donations and bequests;
• the “Push back the walls for the children” programme was a campaign initiated in 2012 appealing
for one-off donations. Thanks to our donors, this was
successful and has now closed.
Half of the 3.5 M€ required for construction work was
funded through donations and bequests.
m
FOR...
OPERATING
ON THE INTERNET
In 2014, funds raised through the
internet rose by 28%, while there was
an increase in amounts collected from
on-line personal fundraising pages
by 35% compared with 2013.
Gustave Roussy’s efforts to grow
fundraising via the internet have borne
fruit: 5% of funds raised now come in
this way; the aim is to increase this
to 10% within three years.
GUSTAVE ROUSSY
IS GRATEFUL
In 2014, The Institute decided
to display its gratitude to
its partners by erecting the
“Ambassadors’ Wall” in the
hospital entrance. In April, it also
invited its donors and their staff
to a one-off private evening event
at the Unesco building with
a recital by the famous Russian
pianist Denis Matsuev.
48
FOUNDATION’S ACCOUNT OF USE OF FUNDS
GUSTAVE ROUSSY FOUNDATION:
SUPPORTING CANCER RESEARCH
PERFORMED AT THE INSTITUTE
ESTABLISHED IN 2005, THE GUSTAVE ROUSSY RESEARCH FOUNDATION IS
RECOGNISED AS BEING OF PUBLIC BENEFIT. ITS MISSION IS TO USE FINANCIAL
MEANS TO FACILITATE RESEARCH WORK AT THE INSTITUTE.
4.4M€
OF DONATIONS AND GIFTS
1.4M€
OF DONATIONS TO THE ISF
CAMPAIGN, I.E. + 30%
I
n 2014, donations and gifts collected by the
Foundation reached a sum of more than 4 M€. The
ISF campaign had a very positive effect as donations
from this campaign totalled 1.4 M€, representing an
increase of 30%.
Events organised by the Foundation raised around
360,000 € in 2014. The 2nd “Cancer Revolution” open
golf competition at Saint-Cloud and the auction of
“street art” at the Molitor swimming pool succeeded
in stimulating the generosity of big donors. The latter
event marked the occasion of the closure of the Cancer
Revolution campaign 2010-2013, which raised more
than 11 M€ for personalised medicine, the initial target
having been 10 M€.
THE SPONSORS, VITAL SUPPORTERS
OF THE GUSTAVE ROUSSY FOUNDATION
In the setting of the sponsorship agreement with
Fondation Philanthropia signed in 2013, 1.6 M€
was handed over in 2014; this quadrennial contract
to a total sum of 5.45 M€, has the goal of providing
financial support for the personalised medicine programme, for a project to improve patient quality of
life and for the “Course of excellence in Oncology
– Fondation Philanthropia” (see page 33). The
Fondation Philanthropia is now the largest private
sponsor of the Institute.
Natixis is another supporter of research at Gustave
Roussy. This latter sponsor, made a commitment to
the Gustave Roussy Foundation in late 2011 to support three new research teams financially up to a
total sum of 1.5 M€ over five years.
EXPENDITURE
In conformity with its objectives, in 2014 the Foundation
supported research on cancer carried out at Gustave
Roussy: funding of teams, development of international research programmes, acquisition of apparatus
and the fitting out of laboratories. In this way, the
Foundation funds the production of molecular portraits
of tumours to the sum of 650,000 €.
The accounts of the Gustave Roussy Foundation,
audited by KPMG, are the subject of a publication of
Annual Expenditure Account of Funds Raised sent
to all donors and available for downloading from the
Gustave Roussy website.
appendices
49
50
GUSTAVE ROUSSY, SOCIALLY
RESPONSIBLE
T
ENVIRONMENTAL
INDICATORS AS OF
31/12/2014
906 tons
Domestic waste
265 tons
70 tons
489 kilos
180 kilos
123 kilos
Hospital waste
Rubble
Fluorescent tubes in containers
Batteries
Light bulbs
2,226 skips of cardboard
100,082
WATER CONSUMPTION
MWh
ELECTRICITY CONSUMPTION
5,816
MANAGING ENVIRONMENTAL EFFECTS
In order to mitigate its environmental effects,
Gustave Roussy applies all its efforts and its commitment to innovation to improve its management
of energy and waste disposal and to establish a
policy of sustainable development in the theatre suite. Since 2013, the Institute’s approach
to responsible purchasing has involved taking
account of “sustainable development” in evaluation of our suppliers’ tenders.
• Management of energy
Gustave Roussy is a consumer of energy on a
scale which has substantial environmental and
cost implications. The Directorate of Purchasing
and Logistics is aware of the problems of energy
management and is committed to regular, detailed
monitoring of energy consumption.
m3
30,352
he Corporate Social Responsibility (CSR) is
the concept which informs the ways in which
companies assimilate social and environmental factors into their activity. An organisation
on the scale of Gustave Roussy could not be in the
vanguard without adhering to the highest societal
standards. That is why the RSE is incorporated
into Gustave Roussy’s 2015-2020 hospital plan.
It has three principal elements, the first being
our aim to attract staff and retain them, so that
our organisation remains effective in the fields of
research, patient care and education. The second
is our responsibility in relation to the employment
needs of the locality in which we are situated and
the third is the preservation of the environment by
meeting exemplary standards in our use of energy
and the handling of waste.
• Management of waste disposal
Gustave Roussy has set targets of recycling
200 tonnes of paper per year between now and
2020 and of lowering its medical waste production by 5 to 6%, a reduction of 12 to 15 tonnes per
year. This year (2015), paper recycling is being
MWh
GAS CONSUMPTION
Living
38,000
FUEL CONSUMPTION
the future
today
litres
IN 2015, THE INSTITUTE WILL
EMBARK ON A BIODEGRADABLE
WASTE CYCLING PROJECT
TOTALLING 80 TONNES PER YEAR.
piloted in some departments. In the theatre suite,
an approach involving all the staff is aiming to
reduce deleterious environmental effects: waste
production, consumption of water and electricity,
pollution, etc. Metal (scalpel and laryngoscope
blades…) recycling is already in place.
SYMPATHY AND PROFESSIONAL EXCELLENCE
Motivating staff in a comprehensive approach to
achieve excellence at an individual and collective
level requires a dynamic human resources policy.
In particular, this incorporates micromanagement of teams, new technologies and e-learning.
Gustave Roussy, through the efforts of its Human
Resources Department, encourages its employees
to develop their skills by combining training with
personal and professional growth.
Through its training policy, Gustave Roussy aims
to improve the knowledge and technical skills
of its staff and also supports those with increa
sing leadership roles. These individuals will have
responsibilities for operational direction, in forming
teams to tackle new projects and in the motivation and development of skills in those with whom
they work.
A managerial development programme was
introduced in 2010. It comprises a wide range of
practical training modules tailored to the indivi
dual according to their level of responsibility within
the organisation. Time is also set aside for joint
consideration of current organisational problems.
51
GUSTAVE ROUSSY, THE AMBITION
TO SET STANDARDS
Communication, a good working environment,
equality of opportunity and safety are elements of
the first importance in making Gustave Roussy a
good employer. This desire to set high standards
came to the fore at the time of the merger with
Chevilly-Larue Hospital centre, which proceeded
not only without job losses but with support and
training for those who were being newly incorporated. Gustave Roussy also introduces practices
which make it a more attractive employer with
loyal, talented staff so that stable teams can contribute to research, patient care and teaching.
• Renewed commitment to employment
of the disabled
In March 2012, Gustave Roussy signed its first
enterprise agreement to foster employment and
integration of disabled individuals. The outcome
is very encouraging with 21 people being recruited
against a target of 20 and a total of 118 disabled
employees in 2014 compared with only 66 in 2011.
The measures adopted have been fruitful, since
Gustave Roussy met governmental guidelines,
which means that it is exempted from paying the
Agefiph levy. The Institute continued its commitment by signing, in late 2014, a renewal of the
agreement, to apply from 2015 to 2017.
• Work satisfaction under the microscope
A work psychologist carried out a work satisfaction
survey in the patient care departments. This was
initiated late in 2013 and also aimed to suggest
improvements and to help hospital management
to identify measures to increase satisfaction levels.
In total, 862 individuals participated in the survey.
The 65% level of participation reflected interest in
this approach and in the elements being examined:
a sense of fairness, the material and social environment, communication, recognition and psychological
stress.
The results of this first approach are positive in that
a number of good practices were found to be already
in place.
This survey might be performed twice or three times
a year and would thus become a barometer of satisfaction within the organisation.
• Equality of opportunity
Special attention continues to be paid to reinforcing the arrangements in favour of equal employment treatment of men and women, to avoid
age-discrimination and to facilitate cultural integration of new arrivals. In addition, there has been
a strengthening of the commitment to the working
age population in Gustave Roussy’s geographical
locality: welcoming young people seeking work
experience, improving local affordable housing
opportunities and increasing the number of places
available in the crèche.
63%
LEVEL OF SATISFACTION
IN STAFF QUESTIONED
SOCIAL INDICATORS AS OF 31/12/2014
Salaried staff (excluding Chevilly-Larue personnel employed from the 1st January 2015)
2,768
employees
3,212
8.8%
Rate of absenteeism
2,067
701
Mean salary
50
6
Collective
agreements signed
creation of posts in CDI
200
CDI
472
CDD
Total number of staff taken on in the patient
care and research departments
44,065
Hours of
training
2,678
Attachee
training
94 %
Rate of completion
of training programmes
118
Disabled
employees in
the workforce
52
GOVERNANCE
RALLYING OF THE WHOLE WORKFORCE AT GUSTAVE ROUSSY
AROUND COMMUNICATION AND QUALITY.
A
t Gustave Roussy, the pursuit of quality depends
both on high quality management and everybody’s desire that the Institute should be successful. Governance is based on a model which values
integration and delegation, involving ease of communication and individual and collective autonomy.
This form of governance gives departments, in colla
boration with the Board, a major role in the definition of
objectives and resources. The Committees are themselves directed in an integrated and decentralised
way; their role will be strengthened in future years.
The management delegation flowing from internal
decentralisation results in independence, flexibility
and effectiveness. It produces high quality work and
contributes to managerial innovation, a priority area
of the Institute’s strategy for 2015-2020.
The Board, the medical body, nursing and admi
nistrative staff: it is all of these at Gustave Roussy
whose efforts result in patient care which is welcoming
and effective.
COMPOSITION OF GUSTAVE ROUSSY BOARD
OF DIRECTORS IN JUNE 2015
EX-OFFICIO MEMBERS (18)
Mr. Jean-François Carenco
Chairman, Prefect of the Île-de-France Region,
Prefect of Paris
Mr. Pierre Garzon
Member of the Val-de-Marne Départemental Council
Mr. David Belliard
Member of the Paris Council
Professor François Sigaux
Representative of the National Cancer Institute
Mr. Thierry Damerval
Representative of the National
Scientific Institute for Medical
and Research Studies
Mr. Martin Hirsch
Professor Serge Bobin
Representative of Paris Public Hospitals
Mrs. Véronique Paquis
Member of the Economic and Social Council
Dean of the Faculty of Medicine
Mr. Jean-Pierre Burnier
Representative of the Ministry of Research
Mr. Jean-Claude Boucherat
Mr. Jean-Pierre Davant
Mrs. Annie Podeur
Members by virtue of their expertise
Mrs. Catherine Vergely
Mr. Jean-Pierre Escande
Representatives of Users
Doctor Dominique
Valteau-Couanet
Doctor Diane Goéré
Members of Medical Staff
Mrs. Christine Fontaine
Mrs. Nadia Aguini
Members of the Company Committee
MEMBERS WITH
CONSULTATIVE INPUT
Mr. Thierry Leleu
Prefect of the Val-de-Marne Department
Represented by Mr. Ivan Bouchier
Assistant prefect of L’Hay-les-Roses
INVITED MEMBERS
Mr. Éric Vechard
Local Authority Delegate from
the Val-de-Marne ARS (Regional Health Agency)
Professor Alexander Eggermont
GUSTAVE ROUSSY DIRECTION
AND ADMINISTRATION
Mr. Claude Evin
Deputy General Director
Gustave Roussy General Director
Director of the Regional Health Agency
Mrs. Lætitia Circosta
Assistant to the Management Board
Auditor (KPMG)
Mrs. Christine Lascombe
Communications Director
Mrs. Anne Montaron
Mr. Charles Guépratte
Care Management
Mrs. Sophie Beaupère
Director of Financial Affairs, Treasurer
Doctor Ellen Benhamou Borowski
Research Director
Mrs. Véronique Billaud
Director of Investments and Logistics
Mr. Philippe Bourassin
Clinical Research Director
Professor Michel Ducreux
Project Manager
Director of Activities and Finances
SECRETARIAT
Mr. Jean Gatinaud
Chair of the Medical Commission
Delegated Director
Director of Human Resources
Medical Coordinator
Mr. Robert Servat
Professor Éric Solary
Mr. Stéphane Stépanian
Professor Gilles Vassal
Mrs. Psylvia Dewas-Tasseau
53
GENERAL MANAGEMENT
General Director
A. Eggermont
International
Internal contractualization
assistance and
performance support
task team
V. Brière
Assistant General Director
C. Guépratte
Research Director
É. Solary
Director delegated
to the Director General
V. Billaud
ACTIVITY UNIT
Medical Coordinator
M. Ducreux
RESEARCH
AND TEACHING
Research Management
É. Solary
Clinical Research
Management
G. Vassal
Teaching Management
M. Schlumberger
HEAD OF STRATEGY
Quality and Management
of Risks Management
É. Minvielle
Communication Management
C. Lascombe
Legal Affairs Department
N. Vérotte
Radioprotection
N. Guilabert
HEAD OF PROJECTS
Care Sectors
M. Di Palma
Project Cancer Campus
G. Lenoir
COMMITIES
DEPARTMENTS
Cervico-facial Pathology
S. Temam
Medical Oncology
K. Fizazi
Thoracic Pathology
B. Besse
Child and Adolescent cancer
research department
D. Valteau-Couanet
Gastro-digestive
D. Malka
Breast
S. Delaloge
Gynecology
C. Lhommé
Early Trials
J.-C. Soria
Endocrine tumors
É. Baudin
Urology
B. Escudier
Dermatology
C. Robert
Soft Tissues – Bone
A. Le Cesne
Neurology
F. Dhermain
Haematology
V. Ribrag
Paediatric Pathology
J. Grill
Genetical oncologist
O. Caron
General surgery
D. Elias
Cervico-facial cancer research
F. Janot
Drug Development (DITEP)
J.‑C. Soria
Acute care
B. Gachot
Medical imaging
C. Dromain
Medical Pathology
and Biology
J.-Y. Scoazec
Pharmacy
F. Lemare
DISSPO*
S. Dauchy
HUMAN RESOURCES
AND FINANCE
Activity and finances
management
S. Beaupère
Medical information service
M. Mons
Financial/treasury affairs
R. Servat
Human resources
Ph. Bourassin
Care management
A. Montaron
Information systems
management
N. Mezaour
Investments and logistics
management
S. Stépanian
Fundraising and Partnerships
C. Amet-Hacker
Fondation Gustave Roussy
Ambulatory care
M. Di Palma
Operating rooms
J.‑L. Bourgain
Radiotherapy
É. Deutsch
Medical physics
D. Lefkopoulos
* DISSPO : Interdisciplinary Department of supportive care
for onco haematology patients.
Organization chart on July 1st 2015.
54
WORK ACTIVITY AND FINANCIAL RESULTS
IN 2014, GUSTAVE ROUSSY WAS CLOSE TO FINANCIAL BALANCE (- 1.3 M€) AS A RESULT
OF AN INCREASE IN ADMISSIONS AND ANCILLARY SOURCE INCOME AND TO GOOD
CONTROL OF EXPENSES. THESE FIGURES, THE RESULT OF A COLLECTIVE EFFORT,
SHOULD BE EMPHASISED STILL MORE BECAUSE THE FORECAST DEFICIT WAS 4.9 M€.
17.9M€
FINANCING CAPACITY
+3.1%
PATIENTS ADMITTED
G
ustave Roussy therefore remained close to
financial balance in 2014 (- 1,293 K€, i.e.
0.4% of overall revenue which now totals
313,845,713 €). This is after incorporating in the
accounts an overall profit-sharing figure of 800 K€
(not budgeted), which may be compared with the
budget forecast predicting a deficit of 4.9 M€.
This marked improvement in results was due to a
surplus of 7.6 M€ in revenue derived from both the
French Health Insurance system and “paying and
foreign patients”, as well as from other ancillary
sources.
In 2014, the number of new patients hospitalised was
3.1% higher at a total of 5,773 patients over the year.
The number of full hospital stays exceeded targets by
3.3% and the 2013 figures by 4.6%. This represented
an additional 848 hospital stays. Ambulatory activity
did not reach the target (- 0.5%), but was still greater
than in 2013 by 1.1%, i.e. 457 additional sessions
compared with 2013. Finally, activity in radiotherapy
met the target and increased by 4% compared with
2013 for outpatient sessions (i.e. + 2,177 sessions) and
by 8% for sessions carried out on patients
during a full hospital admission (i.e. + 439 sessions).
Thus, T2A activity, paid at 100%, exceeded target by
1.1% (and that of 2013 by 3.1%) essentially because
of the increased full-admission hospital load and a
price effect for admissions excluding radiotherapy,
where the PMCT (Mean Weighting per Case Treated)
increased by + 1.6%. In addition to the 100% payment
of T2A, there was a 432 K€ amount derived from
unfreezing of contingency funds, the level of which is
set by the authorities.
At the same time, work involving “paying foreign
patients” exceeded the budget by 5.7 M€, showing
very strong growth in treatment of foreign patients in
2014 (+ 25% for admissions and + 32% for outpatient
visits).
Finally, under the category of ancillary income, the
Drug Development Department (DITEP) and SORC
(operational clinical research department) generated
considerable revenue amounting to 1.6 M€ of additional income. This also demonstrated that Gustave
Roussy is succeeding in staking its claim to be the
leading European centre for clinical trials.
Conversely, annual subsidies from Inserm and the
CNRS (representing a budget of 2 M€) were not
received in 2014.
As for outgoings, the increase was controlled: salary
costs exactly matched their budgeted amount. The
boost of consolidating the profit-sharing budget of
800 K€, medical costs, logistic and structural costs
(apart from special provisions and exceptional items
related to the merger with CHSP) all varied by less
than 1% on the 2014 forecasts.
Monies set aside as contingency funds and other
endowments (2.5 M€), as well as exceptional provision of 0.8 M€ explain 3.3 M€ of budgetary overrun
out of a total of 4 M€ of additional outgoings in the
2014 hospital budget.
In addition, a number of projects were completed in 2014:
• work on the 2015-2020 hospital plan involved all
of the staff;
• preparation for the merger (effective from the
1st January 2015) with the Chevilly-Larue Hospital
centre specialising in lung disease which enabled
Gustave Roussy to increase its admissions;
• major purchases were made (acquisition of a second
tomo-radiotherapy machine for the Radiotherapy
Department, the effects of which will be felt in 2015,
acquisition of a surgical robot – the first of its type
in France – thanks to a dedicated donation from the
Fondation Philanthropia and completion of renovation
works in the Department of Childhood and Adolescent
Oncology, the cost of which was more than 3 M€ over
several years).
It was possible to make these purchases because of
the generosity of donors and bequests from wills on
the one hand and because of our virtually balanced
financial results on the other. The latter meant that
the auto-financing capacity (CAF) remained stable at
17.9 M€ (vs 18.3 M€ in 2013). The financial resources
for the year reached 29.3 M€ and their disbursement
29.5 M€ (including 6.4 M€ reimbursement of loans)
allowing working capital to remain almost unchanged
in 2014 (deduction from working capital of 0.1 M€
compared with – 2.1 M€ the previous year). At the
same time, the need for negative working capital fell
to 5.7 M€, entailing a 5.8 M€ diminution in funds.
As has been the case for several years now, the
financial balance ratios have improved further. It is
noteworthy that all of the 2014 ratios meet the target
ratios set by decree: the financial independence ratio
has fallen below the 50% (to 48.6%) limit, the debt/
asset ratio continued its fall below the 30% bar (to
26.9%) and the apparent duration of the debt stabilised at 4.7 years (vs the 10 years in the decree).
55
AUDITOR’S REPORT ON GUSTAVE ROUSSY
ANNUAL ACCOUNTS
FOR THE FINANCIAL YEAR ENDING 31ST DECEMBER 2014
Performing the function requested by the Board of Directors, we are delivering our report for the
financial year ending 31st December 2014 on:
• examination of the Gustave Roussy annual accounts as enclosed with this report;
• the justification of our assessments;
• the specific verification and information required by law.
The annual accounts were drawn up by the Gustave Roussy Board. On the basis of our audit it is
incumbent on us to express an opinion on these accounts.
OPINION ON THE ANNUAL ACCOUNTS
We conducted our audit according to normal professional practice applicable in France.
This requires the performance of due diligence to be reasonably assured that the annual
accounts do not contain any significant faults. An audit comprises checking by sampling or
other methods of selection of material to justify the sums and the information presented in
the annual accounts. It also involves an assessment of the accounting principles employed,
the significant estimates adopted and the overall presentation of the accounts. We consider
that the material we have collected, upon which we have founded our opinion, is sufficient
and appropriate in nature.
JUSTIFICATION OF OUR ASSESSMENTS
In application of the provisions of article L. 823-9 of the French Code of Commerce relative
to the justification of our assessments, we inform you that the assessments made by us
addressed whether the nature of the accounting principles applied was appropriate and
whether the nature of the significant estimates adopted was reasonable, in particular for
trapped capital, credits and provision for contingencies and liabilities.
These assessments apply to our audit treatment of the annual accounts in their entirety
and have, therefore, contributed to the formation of our opinion expressed in the 1 st part
of this report.
SPECIFIC VERIFICATION AND INFORMATION
We also proceeded according to normal professional practice applicable in France to
specific verifications required by law.
We have no observations to make on the accuracy and consistency with the annual accounts
of the information presented in the “Financial report and accounts 2014” and in the
documents sent to members of the Board of Directors relating to the financial situation
and the annual accounts.
Paris La Défense, 20 th May 2015
KPMG Audit
Department of KPMG S.A.
Jean Gatinaud
Associate
56
BALANCE SHEET 2014
FISCAL YEAR ENDING 31ST DECEMBER 2014
Assets
(in euros)
2014
Gross
Depreciations
and write-offs
2013
Net
Net
FIXED ASSETS
Intangible fixed assets
- start-up costs
- costs of studies and research and development
0.00
0.00
6,965,317.72
3,080,058.98
3,885,258.74
3,547,850.85
15,113,826.98
10,340,360.51
4,773,466.47
4,111,711.06
- other intangible fixed assets
0.00
0.00
- intangible fixed assets in progress
0.00
0.00
- c oncessions and similar rights. patents. licences.
trademarks & processes. similar rights and assets
Tangible fixed assets
- land
6,947,851.68
3,148,935.28
3,798,916.40
3,893,524.16
- buildings
287,533,143.75
133,014,301.68
154,518,842.07
157,619,926.99
- technical installations. plant and equipment
111,866,212.42
77,024,133.98
34,842,078.44
32,227,306.80
32,110,322.31
24,914,022.77
7,196,299.54
7,402,946.60
1,642,274.68
863,110.65
- assigned fixed assets
0.00
0.00
- allocated fixed assets
0.00
0.00
212,792.45
212,792.45
- other tangible fixed assets
- tangible fixed assets in progress
1,642,274.68
Financial fixed assets
- investments and receivables related to investments
- other fixed securities
- loans
- others
212,792.45
15,588.90
15,588.90
15,588.90
2,000,000.00
2,000,000.00
0.00
32,937.15
32,937.15
33,937.15
0.00
0.00
212,918,454.84
209,928,695.61
2,235,231.22
2,235,231.22
1,962,013.27
628,294.61
628,294.61
460,807.58
0.00
0.00
71,411.73
60,764.35
0.00
0.00
5,619,572.14
6,017,752.06
12,355,501.47
7,869,579.18
Investment linked account
TOTAL I
464,440,268.04
251,521,813.20
CURRENT ASSETS
Inventories and works in progresss
- pharmaceutical products
- small medical products
- other supplies
- products
71,411.73
- goods
- other inventories
5,619,572.14
Operating receivables
- patients and consultants
13,417,224.18
- pivot fund / Health Insurance
26,751,001.58
26,751,001.58
26,044,048.08
659,468.90
659,468.90
639,602.13
0.00
0.00
- other third-party payers
1,061,722.71
- others
Miscellaneous receivables
18,843,058.23
18,843,058.23
18,437,074.86
Investment securities
12,550,953.20
12,550,953.20
19,329,001.64
787,871.89
787,871.89
218,994.60
Liquid assets
Prepaid expenses
TOTAL II
TOTAL GENERAL
250,988.48
313,133.27
81,815,076.16
250,988.48
1,061,722.71
80,753,353.45
81,352,771.02
546,255,344.20
252,583,535.91
293,671,808.29
291,281,466.63
57
Liabilities
(in euros)
2014
2013
EQUITY
Contributions and association funds
Reserves
40,532,124.47
40,532,124.47
2,586,409.90
2,586,409.90
-30,367,015.97
-29,836,710.40
Retained earnings
Accumulated deficit
Fiscal year result (surplus or deficit)
-1,293,445.60
-530,305.57
Investment grants
61,726,129.07
58,48,386.12
0.00
2,393,202.53
73,184,201.87
73,634,107.05
11,671,426.10
10,093,721.05
2,820,103.60
0.00
14,491,529.70
10,093,721.05
85,685,517.79
87,171,750.91
9,637.00
6,647.00
101,481.89
362,503.52
0.00
0.00
- supplier payables and related accounts
24,097,805.75
24,397,034.98
- patient advances and down-payments
4,726,742.79
4,193,256.17
- pivot fund/health insurance advance
9,439,264.46
10,711,960.46
13,028,265.25
12,368,745.40
5,752,740.97
6,762,094.22
61,486,802.49
60,529,492.51
1,667,818.33
1,050,153.36
TOTAL III
205,996,076.72
207,553,638.53
TOTAL GENERAL
293,671,808.29
291,281,466.63
Regulated provisions (CET provisions allocated to provisions for expense in 2014)
TOTAL I
PROVISIONS FOR LIABILITIES AND CHARGES
Provisions for liabilities
Provisions for charges linked to the CET implementation
TOTAL II
LIABILITIES
Financial debts
- loans from credit institutions
- loans and miscellaneous financials debts
- credit lines
Accounts payable
- advances received
- tax and social debts
Miscellaneous liabilities
- liabilities in respect of fixed assets and related accounts
- other miscellaneous liabilities (pending donations and legacies,
accounts payable for research and teaching)
- deferred income
58
2014 PROFIT AND LOSS ACCOUNT BY NATURE
(in euros)
2014
2013
OPERATING REVENUE
Sales of medicines
Revenue from auxiliary activities
Revenue from hospital activity
Operating grants and investments
Reversals of write-offs, depreciations and provisions
Other everyday management revenue
5,477,314.85
6,474,285.11
16,271,957.34
13,671,143.29
235,877,471.64
222,333,091.16
33,531,635.99
38,093,403.05
356,944.95
1,415,006.57
8,985,668.40
10,695,997.52
300,500,993.17
292,682,926.70
52,252,633.23
48,916,134.82
-451,352.36
258,203.22
Cost of materials and supplies not held in inventory
20,248,313.38
20,451,294.81
External services and other external services
45,910,177.53
43,100,509.70
13,873,447.00
13,211,032.91
17,684.42
20,262.66
101,346,290.89
99,234,376.89
45,987,598.81
44,689,336.06
24,369,625.80
24,380,201.26
TOTAL I
OPERATING COSTS
Purchases held in inventory; other suppliess
- Inventory changes
Taxes, duties and assimilated payments
- on remunerations
- others
Personnel costs
- remunerations and other personnel-related costs
- social security costs
Depreciation charges and provisions
- on fixed assets: depreciation charges and amortisation
- on current assets: provision for impairment
- for liabilities and charges: depreciation charges and provisions
OTHER CHARGES OF EVERYDAY MANAGEMENT
TOTAL II
1 - OPERATING INCOME (I-II)
260,821.34
294,311.45
2,361,551.07
860,241.17
-476,415.12
1,531,341.42
305,700,375.99
296,947,246.37
-5,199,382.82
-4,264,319.67
59
(in euros)
2014
2013
FINANCIAL REVENUE
Investments and other financial fixed assets and other receivables
20,925.04
229,477.86
993.94
13,717.93
Reversals of provisions
0.00
0.00
Transfers of financial charges
0.00
0.00
3,009.47
0.00
Financial income from investments, discounts obtained and other financial revenue
Exchange gains
Net income from sales of marketable securities
0.00
0.00
24,928.45
243,195.79
0.00
0.00
3,312,181.02
3,492,977.25
568.95
0.00
0.00
0.00
3,312,749.97
3,492,977.25
2 - FINANCIAL INCOME ( III-IV)
-3,287,821.52
-3,249,781.46
3 - OPERATING INCOME BEFORE TAX AND EXCEPTIONAL ITEMS ( I-II+III-IV)
-8,487,204.34
-7,514,101.13
248,542.20
181,601.49
1,114,255.76
2,552,277.73
7,430,845.80
5,852,942.30
TOTAL III
FINANCIAL CHARGES
Depreciation, impairment and provisions
Interests and assimilated charges
Exchange losses
Net losses from disposals of marketable securities
TOTAL IV
EXTRAORDINARY INCOME
On management operations
- current financial year
- previous financial years
On capital operations
Reversals on provisions and depreciations
0.00
0.00
8,793,643.76
8,586,821.52
- current financial year
668,177.04
48,310.25
- previous financial years
926,746.35
1,036,643.35
458.39
8,633.00
TOTAL V
EXTRAORDINARY CHARGES
On management operations
On capital operations
Depreciation, impairment and provisions
- regulated provisions
- depreciation charges and extraordinary write-offs
133,856.53
4,503.24
375,582.83
TOTAL VI
1,599,885.02
1,603,025.96
4 - EXTRAORDINARY INCOME (V-VI)
7,193,758.74
6,983,795.56
0.00
0.00
5 - TOTAL REVENUES (I+III+V)
309,319,565.38
301,512,944.01
6 - TOTAL CHARGESS (II+IV+VI)
310,613,010.98
302,043,249.58
-1,293,445.60
-530,305.57
Company Tax
SURPLUS OR DEFICIT (5 - 6)
60
AUDITOR’S REPORT ON THE ANNUAL
EXPENDITURE ACCOUNT OF FUNDS RAISED
FROM THE PUBLIC
FOR THE FINANCIAL YEAR ENDING 31ST DECEMBER 2014
Acting as auditor and in application of the provisions of article 1 of the decree of 30th July 1993, we
proceeded to verify the information presented in the Gustave Roussy Institute annual expenditure
account of funds raised from the public for the financial year ending 31st December 2014, which
is attached to this report.
This annual expenditure account was drawn up under the direction of the President and the
Treasurer of the Gustave Roussy Institute. It is incumbent on us to offer our opinion on the accuracy and consistency with the accounting documents of the information presented in this annual
expenditure account of funds raised.
We performed the due diligence which we considered to be required according to the professional guidance issued by the “Compagnie nationale des commissaires aux comptes” (National
Association of Auditors). This diligence consisted of verification that the figures presented in the
annual expenditure account of funds raised are consistent with the accounting documents of the
organisation, and an assessment of their accuracy. These verifications do not constitute an audit
of these expenditure accounts and are not intended to pass judgement on the appropriateness of
the expenditure.
At the outset, we proceeded to examine the annual accounts for the financial year ending 31 st
December 2014 and we have presented our opinion without reservations in the report on the annual
accounts which we released on 20th May 2015.
We have no observations to make on the accuracy and consistency with the accounting documents
of the information presented in the Gustave Roussy Institute annual expenditure account.
Paris La Défense, 21st May 2015
KPMG Audit
Department of KPMG S.A.
Jean Gatinaud
Associate
61
OVERALL ANNUAL USE OF RESOURCES
ON 31 DECEMBER 2014
(in euros)
USES
Uses of N =
income
statement
Allocation by
use of
resources
raised by the
public on N
1 - SOCIAL MISSIONS
263,277,688.89
6,727,929.89
1.1. In France
- Activities carried out directly
263,247,688.89
260,679,933.77
6,697,929.89
4,567,929.89
56,672,629.74
4,510,198.58
198,643,989.04
57,731.31
5,363,314.99
0.00
2,567,755.12
2,130,000.00
2,130,000.00
437,755.12
0.00
30,000.00
0.00
30,000.00
2,130,000.00
0.00
0.00
30,000.00
0.00
30,000.00
of which basic and clinical research
of which patient care and quality of life
of which teaching
-P
ayments to other organisms
operating in France
of which Gustave Roussy Foundation
of which Gustave Roussy Transfer
of which other organisms
1.2. Abroad
of which activities carried out directly
of which payments to a central organ
or other organisms
2 - COST OF FUNDRAISING
2.1. Costs of fundraising from calls
to general public generosity
2.2. Costs of fundraising from private
funds
2.3. Charges due to researching grants
and public tenders publicss
3 - OPERATING COSTS
2,370,026.07
2,370,026.07
RESOURCES
Report on the resources raised from
the,public which have not been allocated or
used at the start of the fiscal year
1 - RESOURCES RAISED
BY THE PUBLIC
1.1. Donations and bequests received
of which individual donations
which have not been allocated
of which Individual donations
which have been allocated
of which bequests and other gifts
which have not been allocated
of which bequests and other gifts
which have been allocated
1.2. Other income linked to public
generosity
2,370,026.07 2 - OTHER PRIVATE FUNDS
2,370,026.07 of which Gustave Roussy Foundation
0.00
0.00 of which Gustave Roussy Transfer
0.00
0.00 of which other bodies
55,335,831.86
I. Total use of resources for the financial
year recorded on the profit and loss
account
II. Provisions expenses
III. Projected uses
of allocated funds
IV. Surplus in the financial
year’s resources
320,983,546.82
V. OVERALL TOTAL
VI. Share of the gross fixed asset
acquisitions for the financial year
financed by resources raised from
the public
VII. Neutralisation of depreciation
charges of fixed assets financed from
the date of the first application of the
Regulation by resources raised from the
public
VIII. Total cash outflows financed by
the resources raised form the public
328,683,353.30
2,622,372.41
5,077,434.07
676,131.86 3 - GRANTS AND PUBLIC TENDERS
4 - OTHER INCOME
9,774,087.82 I. Total resources for the financial year
recorded on the profit and loss account
II. Reversals of provisions
III. Report on the resources allocated but
not used from previous financial years
IV. Change in funds dedicated which have
been raised by the public
(cf. see table of dedicated funds)
V. Shortfall in the financial year’s
resources
VI. OVERALL TOTAL
6,396,233.53 VI. Total cash outflows financed by
the resources raised from the public
Remaining resources raised from the
public which were not allocated or used
by the end of the fiscal year
16,170,321.35
Monitoring
of resources
Resources
raised
collected
by the public
on N = income
and used
statement
on N
3,938,872.67
16,144,967.49 16,144,967.49
16,101,290.55 16,101,290.55
6,220,705.28 6,220,705.28
5,042,341.23
5,042,341.23
4,818,749.14
4,818,749.14
19,494.90
19,494.90
43,676.94
43,676.94
39,162,425.23
6,146,651.00
332,750.50
32,683,023.73
223,951,274.44
49,067,741.19
328,326,408.35 16,144,967.49
356,944.95
328,683,353.30 16,144,967.49
16,170,321.35
3,913,518.81
62
INTERNATIONAL PUBLICATIONS
GUSTAVE ROUSSY 2014
WITH A THOMSON REUTERS 2013 IMPACT FACTOR ABOVE 20 (51 PUBLICATIONS)
1. André F., Bachelot T., Commo F., Campone M., Arnedos M., Dieras V.,
Lacroix-Triki M., Lacroix L., Cohen P., Gentien D., Adélaide J., Dalenc F.,
Goncalves A., Levy C., Ferrero J.M., Bonneterre J., Lefeuvre C., Jimenez
M., Filleron T., and Bonnefoi H. Comparative genomic hybridisation array
and DNA sequencing to direct treatment of metastatic breast cancer :
A multicentre, prospective trial (SAFIR01/UNICANCER). [2014] Lancet
Oncology (15) 3 : 267-274. Impact factor : 24.725
2. André F., O’Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., Masuda
N., Wilks S., Arena F., Isaacs C., Yap Y.S., Papai Z., Lang I., Armstrong
A., Lerzo G., White M., Shen K., Litton J., Chen D., Zhang Y., Ali S., Taran
T., and Gianni L. Everolimus for women with trastuzumab-resistant,
HER2-positive, advanced breast cancer (BOLERO-3) : a randomised,
double-blind, placebo-controlled phase 3 trial. [2014] Lancet Oncology
(15) 6 : 580-591. Impact factor : 24.725
3. André F., Gianni L., and Investigators B.O.L.E. BOLERO-3 results :
pharmacological activity or pharmacokinetic effect? Reply. [2014] Lancet
Oncology (15) 8 : E304-E305. Impact factor : 24.725
4. Assie G., Letouze E., Fassnacht M., Jouinot A., Luscap W., Barreau O.,
Omeiri H., Rodriguez S., Perlemoine K., Rene-Corail F., Elarouci N.,
Sbiera S., Kroiss M., Allolio B., Waldmann J., Quinkler M., Mannelli M.,
Mantero F., Papathomas T., De Krijger R., Tabarin A., Kerlan V., Baudin
E., Tissier F., Dousset B., Groussin L., Amar L., Clauser E., Bertagna
X., Ragazzon B., Beuschlein F., Libe R., de Reynies A., and Bertherat J.
Integrated genomic characterization of adrenocortical carcinoma. [2014]
Nature Genetics (46) 6 : 607-612. Impact factor : 29.648
5. Beelen R., Raaschou-Nielsen O., Stafoggia M., Andersen Z.J., Weinmayr
G., Hoffmann B., Wolf K., Samoli E., Fischer P., Nieuwenhuijsen M.,
Vineis P., Xun W.W., Katsouyanni K., Dimakopoulou K., Oudin A., Forsberg
B., Modig L., Havulinna A.-S., Lanki T., Turunen A., Oftedal B., Nystad W.,
Nafstad P., De Faire U., Pedersen N.-L., Östenson C.-G., Fratiglioni L.,
Penell J., Korek M., Pershagen G., Eriksen K.T., Overvad K., Ellermann
T., Eeftens M., Peeters P.H., Meliefste K., Wang M., Bueno-de-Mesquita
B., Sugiri D., Krämer U., Heinrich J.a., De Hoogh K., Key T.a., Peters
A., Hampel R., Concin H.a., Nagel G., Ineichen A.a.a., Schaffner E.a.a.,
Probst-Hensch N.a.a., Künzli N.a.a., Schindler C.a.a., Schikowski T.a.a.,
Adam M.a.a., Phuleria H.a.a., Vilier A.a.a.a., Clavel-Chapelon F.a.a.a.,
Declercq C.a., Grioni S.a., Krogh V.a., Tsai M.Y., Ricceri F.a., Sacerdote
C.a., Galassi C.a., Migliore E.a., Ranzi A.a., Cesaroni G., Badaloni C.,
Forastiere F., Tamayo I., Amiano P., Dorronsoro M., Katsoulis M.a.,
Trichopoulou A.a., Brunekreef B., and Hoek G. Effects of long-term
exposure to air pollution on natural-cause mortality : An analysis of 22
European cohorts within the multicentre ESCAPE project. [2014] Lancet
(383) 9919 : 785-795. Impact factor : 39.207
6. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N.,
Higano C.S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., Davis
I.D., de Bono J.S., Evans C.P., Fizazi K., Joshua A.M., Kim C.S., Kimura
G., Mainwaring P., Mansbach H., Miller K., Noonberg S.B., Perabo F.,
Phung D., Saad F., Scher H.I., Taplin M.E., Venner P.M., and Tombal B.
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.
[2014] The New England journal of medicine (371) 5 : 424-433. Impact
factor : 54.420
7. Bidard F.C., Peeters D.J., Fehm T., Nolé F., Gisbert-Criado R., Mavroudis
D., Grisanti S., Generali D., Garcia-Saenz J.A., Stebbing J., Caldas C.,
Gazzaniga P., Manso L., Zamarchi R., de Lascoiti A.F., De Mattos-Arruda
L., Ignatiadis M., Lebofsky R., van Laere S.J., Meier-Stiegen F., Sandri
M.T., Vidal-Martinez J., Politaki E., Consoli F., Bottini A., Diaz-Rubio
E., Krell J., Dawson S.J., Raimondi C., Rutten A., Janni W., Munzone
E., Caranana V., Agelaki S., Almici C., Dirix L., Solomayer E.F., Zorzino
L., Johannes H., Reis-Filho J.S., Pantel K., Pierga J.Y., and Michiels S.
Clinical validity of circulating tumour cells in patients with metastatic
breast cancer : a pooled analysis of individual patient data. [2014] Lancet
8. Boussemart L., Malka-Mahieu H., Girault I., Allard D., Hemmingsson O.,
Tomasic G., Thomas M., Basmadjian C., Ribeiro N., Thuaud F., Mateus
C., Routier E., Kamsu-Kom N., Agoussi S., Eggermont A.M., Désaubry L.,
Robert C., and Vagner S. eIF4F is a nexus of resistance to anti-BRAF and
anti-MEK cancer therapies. [2014] Nature (513) 7516 : 105-105. Impact
factor : 42.351
9. Brose M.S., Nutting C.M., Jarzab B., Elisei R., Siena S., Bastholt L., De
La Fouchardiere C., Pacini F., Paschke R., Shong Y.K., Sherman S.I., Smit
J.W.A., Chung J., Kappeler C., Pena C., Molnar I., Schlumberger M.J., and
Investigators D.E.C.I. Sorafenib in radioactive iodine-refractory, locally
advanced or metastatic differentiated thyroid cancer : a randomised,
double-blind, phase 3 trial. [2014] Lancet (384) 9940 : 319-328. Impact
factor : 39.207
10. Burdett S., Rydzewska L.H.M., Tierney J.F., Auperin A., Pignon J.P.,
Le Pechoux C., Le Chevalier T., and Van Meerbeeck J. Preoperative
chemotherapy for non-small-cell lung cancer - Authors’ reply. [2014]
Lancet (384) 9939 : 233-233. Impact factor : 39.207
11. Burdett S., Rydzewska L.H.M., Tierney J.F., Auperin A., Le Pechoux C., Le
Chevalier T., Pignon J.P., and Grp N.M.-A.C. Preoperative chemotherapy
for non-small-cell lung cancer : a systematic review and meta-analysis
of individual participant data. [2014] Lancet (383) 9928 : 1561-1571.
Impact factor : 39.207
12. Caplin M.E., Pavel M., Cwikla J.B., Phan A.T., Raderer M., Sedlackova
E., Cadiot G., Wolin E.M., Capdevila J., Wall L., Rindi G., Langley A.,
Martinez S., Blumberg J., and Ruszniewski P. Lanreotide in metastatic
enteropancreatic neuroendocrine tumors. [2014] New England journal of
medicine (371) 3 : 224-233. Impact factor : 54.420
13. Conroy T., Galais M.P., Raoul J.L., Bouche O., Gourgou-Bourgade S.,
Douillard J.Y., Étienne P.L., Boige V., Martel-Lafay I., Michel P., LlacerMoscardo C., Francois E., Crehange G., Ben Abdelghani M., Juzyna B.,
Bedenne L., and Adenis A. Definitive chemoradiotherapy with FOLFOX
versus fluorouracil and cisplatin in patients with oesophageal cancer
(PRODIGE5/ACCORD17) : final results of a randomised, phase 2/3 trial.
[2014] Lancet Oncology (15) 3 : 305-314. Impact factor : 24.725
14. De Meerleer G., Khoo V., Escudier B., Joniau S., Bossi A., Ost P., Briganti
A., Fonteyne V., Van Vulpen M., Lumen N., Spahn M., and Mareel M.
Radiotherapy for renal-cell carcinoma. [2014] Lancet Oncology (15) 4 :
E170-E177. Impact factor : 24.725
15. De Ruysscher D., Faivre-Finn C., Le Pechoux C., Peeters S., and
Belderbos J. High-dose re-irradiation following radical radiotherapy for
non-small-cell lung cancer. [2014] Lancet Oncology (15) 13 : e620-e624.
16. Eggermont A.M.M., Spatz A., and Robert C. Cutaneous melanoma. [2014]
17. Fizazi K., Scher H.I., Miller K., Basch E., Sternberg C.N., Cella D., Forer
D., Hirmand M., and de Bono J.S. Effect of enzalutamide on time to first
skeletal-related event, pain, and quality of life in men with castrationresistant prostate cancer : results from the randomised, phase 3 AFFIRM
trial. [2014] Lancet Oncology (15) 10 : 1147-1156. Impact factor : 24.725
18. Fizazi K., Pagliaro L., Laplanche A., Fléchon A., Mardiak J., Geoffrois L.,
Kerbrat P., Chevreau C., Delva R., Rolland F., Theodore C., Roubaud G.,
Gravis G., Eymard J.C., Malhaire J.P., Linassier C., Habibian M., Martin
A.L., Journeau F., Reckova M., Logothetis C., and Culine S. Personalised
chemotherapy based on tumour marker decline in poor prognosis
germ-cell tumours (GETUG 13) : a phase 3, multicentre, randomised
trial. [2014] Lancet Oncology (15) 13 : 1442-1450. Impact factor : 24.725
63
19. Fizazi K., Massard C., Bono P., Jones R., Kataja V., James N., Garcia
J.A., Protheroe A., Tammela T.L., Elliott T., Mattila L., Aspegren J.,
Vuorela A., Langmuir P., Mustonen M., and Grp A.S. Activity and safety
of ODM-201 in patients with progressive metastatic castration-resistant
prostate cancer (ARADES) : an open-label phase 1 dose-escalation and
randomised phase 2 dose expansion trial. [2014] Lancet Oncology (15) 9 :
975-985. Impact factor : 24.725
20. Flaherty K.T., Hennig M., Lee S.J., Ascierto P.A., Dummer R., Eggermont
A.M.M., Hauschild A., Kefford R., Kirkwood J.M., Long G.V., Lorigan
P., Mackensen A., McArthur G., O’Day S., Patel P.M., Robert C., and
Schadendorf D. Surrogate endpoints for overall survival in metastatic
melanoma : a meta-analysis of randomised controlled trials. [2014]
Lancet Oncology (15) 3 : 297-304. Impact factor : 24.725
21. Galluzzi L., Pietrocola F., Levine B., and Kroemer G. Metabolic Control of
Autophagy. [2014] Cell (159) 6 : 1263-1276. Impact factor : 33.116
22. Galluzzi L., Pedro J.M.B.-S., and Kroemer G. Organelle-specific
initiation of cell death. [2014] Nature CELL BIOLOGY (16) 8 : 728-736.
23. Green D.R., Galluzzi L., and Kroemer G. Metabolic control of cell death.
[2014] Science (345) 6203 : 1250256-1250256. Impact factor : 31.477
24. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S.,
Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., Kohrt H.E.K.,
Horn L., Lawrence D.P., Rost S., Leabman M., Xiao Y., Mokatrin A., Koeppen
H., Hegde P.S., Mellman I., Chen D.S., and Hodi F.S. Predictive correlates
of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
[2014] Nature (515) 7528 : 563-567. Impact factor : 42.351
25. Hescot S., Vignaux O., and Goldwasser F. Pancreatic atrophy from
sorafenib. [2014] New England journal of medicine (370) 2 : 186-186.
26. Kool M., Jones D.T.W., Jaeger N., Northcott P.A., Pugh T.J., Hovestadt V., Piro
R.M., Esparza L.A., Markant S.L., Remke M., Milde T., Bourdeaut F., Ryzhova
M., Sturm D., Pfaff E., Stark S., Hutter S., Seker-Cin H., Johann P., Bender S.,
Schmidt C., Rausch T., Shih D., Reimand J., Sieber L., Wittmann A., Linke L.,
Witt H., Weber U.D., Zapatka M., Koenig R., Beroukhim R., Bergthold G., van
Sluis P., Volckmann R., Koster J., Versteeg R., Schmidt S., Wolf S., Lawerenz
C., Bartholomae C.C., von Kalle C., Unterberg A., Herold-Mende C., Hofer
S., Kulozik A.E., von Deimling A., Scheurlen W., Felsberg J., Reifenberger
G., Hasselblatt M., Crawford J.R., Grant G.A., Jabado N., Perry A., Cowdrey
C., Croul S., Zadeh G., Korbel J.O., Doz F., Delattre O., Bader G.D., McCabe
M.G., Collins V.P., Kieran M.W., Cho Y.J., Pomeroy S.L., Witt O., Brors B.,
Taylor M.D., Schueller U., Korshunov A., Eils R., Wechsler-Reya R.J., Lichter
P., and Pfister S.M. Genome Sequencing of SHH Medulloblastoma Predicts
Genotype-Related Response to Smoothened Inhibition. [2014] Cancer Cell
(25) 3 : 393-405. Impact factor : 23.893
27. Kwon E.D., Drake C.G., Scher H.I., Fizazi K., Bossi A., den Eertwegh
A.J.M., Krainer M., Houede N., Santos R., Mahammedi H., Ng S., Maio
M., Franke F.A., Sundar S., Agarwal N., Bergman A.M., Ciuleanu T.E.,
Korbenfeld E., Sengeløv L., Hansen S., Logothetis C., Beer T.M., McHenry
M.B., Gagnier P., Liu D., and Gerritsen W.R. Ipilimumab versus placebo
after radiotherapy in patients with metastatic castration-resistant
prostate cancer that had progressed after docetaxel chemotherapy
(CA184-043) : A multicentre, randomised, double-blind, phase 3 trial.
[2014] Lancet Oncology (15) 7 : 700-712. Impact factor : 24.725
28. Lane A.A., Chapuy B., Lin C.Y., Tivey T., Li H., Townsend E.C., van Bodegom
D., Day T.A., Wu S.C., Liu H., Yoda A., Alexe G., Schinzel A.C., Sullivan T.J.,
Malinge S.Ã., Taylor J.E., Stegmaier K., Jaffe J.D., Bustin M., te Kronnie
G., Izraeli S., Harris M.H., Stevenson K.E., Neuberg D., Silverman L.B.,
Sallan S.E., Bradner J.E., Hahn W.C., Crispino J.D., Pellman D., and
Weinstock D.M. Triplication of a 21q22 region contributes to B cell
transformation through HMGN1 overexpression and loss of histone H3
Lys27 trimethylation. [2014] Nature Genetics (46) 6 : 618-623. Impact
factor : 29.648
29. Lawler M., Le Chevalier T., Banks I., Conte P., De Lorenzo F., Meunier F.,
Pinedo H.M., Selby P., Murphy M.J., and Johnston P.G. A Bill of Rights for
patients with cancer in Europe. [2014] Lancet Oncology (15) 3 : 258-260.
30. Long G.V., Stroyakovskiy D., Gogas H.H., Levchenko E.E., De Braud F.F.,
Larkin J., Garbe C.C., Jouary T., Hauschild A., Grob J.J., Chiarion Sileni
V.V., Lebbe C.C., Mandala M., Millward M., Arance A.A., Bondarenko I.,
Haanen J.B.A.G., Hansson J.J., Utikal J.J., Ferraresi V., Kovalenko N.N.,
Mohr P., Probachai V., Schadendorf D.D., Nathan P.P., Robert C.C., Ribas
A., DeMarini D.J., Irani J.G., Casey M., Ouellet D., Martin A.M., Le N.,
Patel K., and Flaherty K. Combined BRAF and MEK inhibition versus
BRAF inhibition alone in melanoma. [2014] New England journal of
medicine (371) 20 : 1877-1888. Impact factor : 54.420
31. Madeo F., Pietrocola F., Eisenberg T., and Kroemer G. Caloric restriction
mimetics : towards a molecular definition. [2014] Nature reviews Drug
discovery (13) 10 : 727-740. Impact factor : 37.231
32. Malka D., Cervera P., Foulon S., Trarbach T., De La Fouchardière
C., Boucher E., Fartoux L., Faivre S., Blanc J.F., Viret F., Assenat E.,
Seufferlein T., Herrmann T., Grenier J., Hammel P., Dollinger M.,
Andre T., Hahn P., Heinemann V., Rousseau V., Ducreux M., Pignon J.P.,
Wendum D., Rosmorduc O., and Greten T.F. Gemcitabine and oxaliplatin
with or without cetuximab in advanced biliary-tract cancer (BINGO) : a
randomised, open-label, non-comparative phase 2 trial. [2014] Lancet
33. Marino G., Niso-Santano M., Baehrecke E.H., Kroemer G.G., and Marino G.
Self-consumption : the interplay of autophagy and apoptosis. [2014] Nature
Reviews Molecular Cell Biology (15) 2 : 81-94. Impact factor : 36.458
34. McArthur G.A., Chapman P.B., Robert C., Larkin J., Haanen J.B., Dummer
R., Ribas A., Hogg D., Hamid O., Ascierto P.A., Garbe C., Testori A., Maio
M., Lorigan P., Lebbé C., Jouary T., Schadendorf D., O’Day S.J., Kirkwood
J.M., Eggermont A.M., Dréno B., Sosman J.A., Flaherty K.T., Yin M., Caro I.,
Cheng S., Trunzer K., and Hauschild A.a. Safety and efficacy of vemurafenib
in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3) :
Extended follow-up of a phase 3, randomised, open-label study. [2014]
35. McGale P., Taylor C., Correa C., Cutter D., Duane F., Ewertz M., Gray
R., Mannu G., Peto R., Whelan T., Wang Y., Wang Z., and Darby S. Effect
of radiotherapy after mastectomy and axillary surgery on 10-year
recurrence and 20-year breast cancer mortality : meta-analysis of
individual patient data for 8135 women in 22 randomised trials. [2014]
36. Monk B.J., Poveda A., Vergote I., Raspagliesi F., Fujiwara K., Bae D.S.,
Oaknin A., Ray-Coquard I., Provencher D.M., Karlan B.Y., Lhomme C.,
Richardson G., Rincon D.G., Coleman R.L., Herzog T.J., Marth C., Brize A.,
Fabbro M., Redondo A., Bamias A., Tassoudji M., Navale L., Warner D.J.,
and Oza A.M. Anti-angiopoietin therapy with trebananib for recurrent
ovarian cancer (TRINOVA-1) : a randomised, multicentre, double-blind,
placebo-controlled phase 3 trial. [2014] Lancet Oncology (15) 8 : 799-808.
37. Motzer R.J., Porta C., Vogelzang N.J., Sternberg C.N., Szczylik C.,
Zolnierek J., Kollmannsberger C., Rha S.Y., Bjarnason G.A., Melichar B.,
De Giorgi U., Grunwald V., Davis I.D., Lee J.L., Esteban E., Urbanowitz G.,
Cai C., Squires M., Marker M., Shi M.M., and Escudier B. Dovitinib versus
sorafenib for third-line targeted treatment of patients with metastatic
renal cell carcinoma : An open-label, randomised phase 3 trial. [2014]
64
38. Palomero T., Couronné L., Khiabanian H., Kim M.Y., Ambesi-Impiombato A.,
Perez-Garcia A., Carpenter Z., Abate F., Allegretta M., Haydu J.E., Jiang X.,
Lossos I.S., Nicolas C., Balbin M., Bastard C., Bhagat G., Piris M.A., Campo
E., Bernard O.A., Rabadan R., and Ferrando A.A. Recurrent mutations
in epigenetic regulators, RHOA and FYN kinase in peripheral T cell
lymphomas. [2014] Nature Genetics (46) 2 : 166-170. Impact factor : 29.648
39. Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt
J., Burris H.A., Petrylak D.P., Teng S.l., Shen X., Boyd Z., Hegde P.S.,
Chen D.S., and Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment
leads to clinical activity in metastatic bladder cancer. [2014] Nature (515)
7528 : 558-562. Impact factor : 42.351
40. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel
J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., Savage K.J.,
Hernberg M.M., Lebbé C., Charles J., Mihalcioiu C., Chiarion-Sileni V.,
Mauch C., Cognetti F., Arance A., Schmidt H., Schadendorf D., Gogas
H., Lundgren-Eriksson L., Horak C., Sharkey B., Waxman I.M., Atkinson
V., and Ascierto P. Nivolumab in Previously Untreated Melanoma
without BRAF Mutation. [2014] New England journal of medicine :
141116004513004-141116004513004. Impact factor : 54.420
41. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber
J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R.,
Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow
M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus
S.W., Kang S.P., and Daud A. Anti-programmed-death-receptor-1
treatment with pembrolizumab in ipilimumab-refractory advanced
melanoma : a randomised dose-comparison cohort of a phase 1 trial.
[2014] Lancet (384) 9948 : 1109-1117. Impact factor : 39.207
42. Shi J., Yang X.R., Ballew B., Rotunno M., Calista D., Fargnoli M.C.,
Ghiorzo P., Bressac-de Paillerets B., Nagore E., Avril M.F., Caporaso
N.E., McMaster M.L., Cullen M., Wang Z., Zhang X., Bruno W., Pastorino
L., Queirolo P., Banuls-Roca J., Garcia-Casado Z., Vaysse A., Mohamdi
H., Riazalhosseini Y., Foglio M., Jouenne F., Hua X., Hyland P.L., Yin J.,
Vallabhaneni H., Chai W., Minghetti P., Pellegrini C., Ravichandran S.,
Eggermont A., Lathrop M., Peris K., Scarra G.B., Landi G., Savage S.A.,
Sampson J.N., He J., Yeager M., Goldin L.R., Demenais F., Chanock
S.J., Tucker M.A., Goldstein A.M., Liu Y., and Landi M.T. Rare missense
variants in POT1 predispose to familial cutaneous malignant melanoma.
[2014] Nature Genetics (46) 5 : 482-486. Impact factor : 29.648
43. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale
I., Goubar A., Baracco E.E., Remédios C., Fend L., Hannani D., Aymeric
L., Ma Y., Niso-Santano M., Kepp O., Schultze J.L., Tüting T., Belardelli
F., Bracci L., La Sorsa V., Ziccheddu G., Sestili P., Urbani F., Delorenzi M.,
Lacroix-Triki M., Quidville V., Conforti R., Spano J.P., Pusztai L., PoirierColame V., Delaloge S., Penault-Llorca F., Ladoire S., Arnould L., Cyrta
J., Dessoliers M.C., Eggermont A., Bianchi M.E., Pittet M., Engblom C.,
Pfirschke C., Préville X., Uzè G., Schreiber R.D., Chow M.T., Smyth M.J.,
Proietti E., André F., Kroemer G., and Zitvogel L. Cancer cell-autonomous
contribution of type I interferon signaling to the efficacy of chemotherapy.
[2014] Nature medicine (20) 11 : 1301-1309. Impact factor : 28.054
44. Sturm D., Bender S., Jones D.T.W., Lichter P., Grill J., Becher O., Hawkins
C., Majewski J., Jones C., Costello J.F., Iavarone A., Aldape K., Brennan
C.W., Jabado N., and Pfister S.M. Paediatric and adult glioblastoma :
Multiform (epi)genomic culprits emerge. [2014] Nature Reviews Cancer
(14) 2 : 92-107. Impact factor : 37.912
45. Sun C., Wang L., Huang S., Heynen G.J.J.E., Prahallad A., Robert C.,
Haanen J., Blank C., Wesseling J., Willems S.M., Zecchin D., Hobor
S., Bajpe P.K., Lieftink C., Mateus C., Vagner S., Grernrum W., Hofland
I., Schlicker A., Wessels L.F.A., Beijersbergen R.L., Bardelli A., Di
Nicolantonio F., Eggermont A.M.M., and Bernards R. Reversible and
adaptive resistance to BRAF(V600E) inhibition in melanoma. [2014]
Nature (508) 1 : 118-122. Impact factor : 42.351
46. Taieb J., Tabernero J., Mini E., Subtil F., Folprecht G., van Laethem
J.L., Thaler J., Bridgewater J., Petersen L.N., Blons H., Collette L., Van
Cutsem E., Rougier P., Salazar R., Bedenne L., Emile J.F., LaurentPuig P., and Lepage C. Oxaliplatin, fluorouracil, and leucovorin with
or without cetuximab in patients with resected stage III colon cancer
(PETACC-8) : an open-label, randomised phase 3 trial. [2014] Lancet
47. Taylor K.R., Mackay A., Truffaux N., Butterfield Y.S., Morozova O.,
Philippe C., Castel D., Grasso C.S., Vinci M., Carvalho D., Carcaboso
A.M., de Torres C., Cruz O., Mora J., Entz-Werle N., Ingram W.J., Monje
M., Hargrave D., Bullock A.N., Puget S., Yip S., Jones C., and Grill J.
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine
glioma. [2014] Nature Genetics (46) 5 : 457-461. Impact factor : 29.648
48. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J.M.,
Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., West A.N.,
Carmona M., Kivork C., Seja E., Cherry G., Gutierrez A.J., Grogan T.R.,
Mateus C., Tomasic G., Glaspy J.A., Emerson R.O., Robins H., Pierce R.H.,
Elashoff D.A., Robert C., and Ribas A. PD-1 blockade induces responses
by inhibiting adaptive immune resistance. [2014] Nature (515) 7528 : 568571. Impact factor : 42.351
49. Wang Y., McKay J.D., Rafnar T., Wang Z., Timofeeva M.N., Broderick P.,
Zong X., Laplana M., Wei Y., Han Y., Lloyd A., Delahaye-Sourdeix M., Chubb
D., Gaborieau V., Wheeler W., Chatterjee N., Thorleifsson G., Sulem P.,
Liu G., Kaaks R., Henrion M., Kinnersley B., Vallée M., Lecalvez-Kelm F.,
Stevens V.L., Gapstur S.M., Chen W.V., Zaridze D., Szeszenia-Dabrowska
N., Lissowska J., Rudnai P., Fabianova E., Mates D., Bencko V., Foretova L.,
Janout V., Krokan H.E., Gabrielsen M.E., Skorpen F., Vatten L., Njolstad I.,
Chen C., Goodman G., Benhamou S., Vooder T., Välk K., Nelis M., Metspalu
A., Lener M., Lubinski J., Johansson M., Vineis P., Agudo A., Clavel-Chapelon
F., Bueno-de-Mesquita H.B., Trichopoulos D., Khaw K.T., Johansson M.,
Weiderpass E., Tjonneland A., Riboli E., Lathrop M., Scelo G., Albanes D.,
Caporaso N.E., Ye Y., Gu J., Wu X., Spitz M.R., Dienemann H., Rosenberger
A., Su L., Matakidou A., Eisen T., Stefansson K., Risch A., Chanock S.J.,
Christiani D.C., Hung R.J., Brennan P., Landi M.T., Houlston R.S., and Amos
C.I. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung
cancer. [2014] Nature Genetics (46) 7 : 736-741. Impact factor : 29.648
50. Wolpin B.M., Rizzato C., Kraft P., Kooperberg C., Petersen G.M., Wang Z.,
Arslan A.A., Beane-Freeman L., Bracci P.M., Buring J., Canzian F., Duell
E.J., Gallinger S., Giles G.G., Goodman G.E., Goodman P.J., Jacobs E.J.,
Kamineni A., Klein A.P., Kolonel L.N., Kulke M.H., Li D., Malats N., Olson
S.H., Risch H.A., Sesso H.D., Visvanathan K., White E., Zheng W., Abnet
C.C., Albanes D., Andreotti G., Austin M.A., Barfield R., Basso D., Berndt
S.I., Boutron-Ruault M.C., Brotzman M., Büchler M.W., Bueno-de-Mesquita
H.B., Bugert P., Burdette L., Campa D., Caporaso N.E., Capurso G., Chung
C., Cotterchio M., Costello E., Elena J., Funel N., Gaziano J.M., Giese
N.A., Giovannucci E.L., Goggins M., Gorman M.J., Gross M., Haiman C.A.,
Hassan M., Helzlsouer K.J., Henderson B.E., Holly E.A., Hu N., Hunter D.J.,
Innocenti F., Jenab M., Kaaks R., Key T.J., Khaw K.T., Klein E.A., Kogevinas
M., Krogh V., Kupcinskas J., Kurtz R.C., LaCroix A., Landi M.T., Landi S.,
Le Marchand L., Mambrini A., Mannisto S., Milne R.L., Nakamura Y., Oberg
A.L., Owzar K., Patel A.V., Peeters P.H.M., Peters U., Pezzilli R., Piepoli A.,
Porta M., Real F.X., Riboli E., Rothman N., Scarpa A., Shu X.O., Silverman
D.T., Soucek P., Sund M., Talar-Wojnarowska R., Taylor P.R., Theodoropoulos
G.E., Thornquist M., Tjonneland A., Tobias G.S., Trichopoulos D., Vodicka
P., Wactawski-Wende J., Wentzensen N., Wu C., Yu H., Yu K., ZeleniuchJacquotte A., Hoover R., Hartge P., Fuchs C., Chanock S.J., StolzenbergSolomon R.S., and Amundadottir L.T. Genome-wide association study
identifies multiple susceptibility loci for pancreatic cancer. [2014] Nature
Genetics (46) 9 : 994-1000. Impact factor : 29.648
51. Zitvogel L. and Kroemer G. CD103+ Dendritic Cells Producing
Interleukin-12 in Anticancer Immunosurveillance. [2014] Cancer Cell
(26) 5 : 591-593. Impact factor : 23.893
65
GUSTAVE ROUSSY 2014
WITH A THOMSON REUTERS 2013 IMPACT FACTOR BETWEEN 10 AND 20 (102 PUBLICATIONS)
1. Aleksandrova K., Boeing H., Nöthlings U., Jenab M., Fedirko V., Kaaks
R., Lukanova A., Trichopoulou A., Trichopoulos D., Boffetta P., Trepo E.,
Westhpal S., Duarte-Salles T., Stepien M., Overvad K., Tjonneland A.,
Halkjaer J., Boutron-Ruault M.C., Dossus L., Racine A., Lagiou P., Bamia
C., Benetou V., Agnoli C., Palli D., Panico S., Tumino R., Vineis P., Buenode-Mesquita B., Peeters P.H., Gram I.T., Lund E., Weiderpass E., Quiros J.R.,
Agudo A., Sanchez M.J., Gavrila D., Barricarte A., Dorronsoro M., Ohlsson
B., Lindkvist B., Johansson A., Sund M., Khaw K.T., Wareham N., Travis R.C.,
Riboli E., and Pischon T. Inflammatory and metabolic biomarkers and risk
of liver and biliary tract cancer. [2014] Hepatology (60) 3 : 858-871. Impact
factor : 11.190
2. Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A.,
Le Moulec S., Gravis G., Beuzeboc P., Massard C., Rouge T.d.L.M., Delanoy
N., Elaidi R.T., and Oudard S. Duration of response to androgen-deprivation
therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D),
and cabazitaxel (C) in metastatic castration-resistant prostate cancer
(mCRPC). [2014] Journal of Clinical Oncology (32) 4 Suppl.. Impact factor :
17.879
3. Barthelemy P., Escudier B., Joly F., Geoffrois L., Laguerre B., Houede N.,
Gross-Goupil M., Yann-Alexandre V., Lucidarme O., Bidault F., Kelkouli N.,
and Oudard S. Long-term responders to everolimus: A subgroup analysis
of the sector study. [2014] Journal of Clinical Oncology (32) 4 Suppl.. Impact
factor : 17.879
4. Beer T.M., Logothetis C., Gerritsen W.R., Kwon E.D., Scher H.I., Bossi A.,
van den Eertwegh A.J.M., Drake C.G., McHenry B., Liu D., and Fizazi K.
Characterization of immune-related adverse events (irAEs) in a phase 3
trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC.
[2014] Journal of Clinical Oncology (32) 4 Suppl.. Impact factor : 17.879
5. Beer T.M., Hotte S.J., De Bono J.S., Beuzeboc P., Gabrail N.Y., Cain D.,
Jacobs C., and Fizazi K. Pain palliation as an oncology label indication:
Lessons learned in custirsen phase III development. [2014] Journal of
Clinical Oncology (32) 4 Suppl.. Impact factor : 17.879
6. Beer T.M., Armstrong A.J., Sternberg C.N., Higano C.S., Iversen P., Loriot
Y., Rathkopf D.E., Bhattacharya S., Carles J., de Bono J.S., Evans C.P.,
Joshua A.M., Kim C.S., Kimura G., Mainwaring P.N., Mansbach H.H., Miller
K., Noonberg S.B., Venner P.M., and Tombal B. Enzalutamide in men with
chemotherapy-naive metastatic prostate cancer (mCRPC): Results of
phase III PREVAIL study. [2014] Journal of Clinical Oncology (32) 4 Suppl..
7. Berruti A., Fassnacht M., Haak H., Else T., Baudin E., Sperone P., Kroiss M.,
Kerkhofs T., Williams A.R., Ardito A., Leboulleux S., Volante M., Deutschbein
T., Feelders R., Ronchi C., Grisanti S., Gelderblom H., Porpiglia F., Papotti
M., Hammer G.D., Allolio B., and Terzolo M. Prognostic role of overt
hypercortisolism in completely operated patients with adrenocortical
cancer. [2014] European Urology (65) 4 : 832-838. Impact factor : 12.480
8. Bex A., Fournier L., Lassau N., Mulders P., Nathan P., Oyen W.J.G., and
Powles T. Assessing the response to targeted therapies in renal cell
carcinoma: Technical insights and practical considerations. [2014] European
Urology (65) 4 : 766-777. Impact factor : 12.480
9. Blanchard P., Pignon J.P., and Bourhis J. Reply to D. Tural et al.
Journal of Clinical Oncology (32) 3 : 259-260. Impact factor : 17.879
[2014]
10. Blanchard P., Bourhis J., and Pignon J.P. Is Taxane-Cisplatin-Fluorouracil
Superior to Cisplatin-Fluorouracil As Induction Chemotherapy in Outcome
in Locally Advanced Head and Neck Cancers? Reply. [2014] Journal of
Clinical Oncology (32) 3 : 259-260. Impact factor : 17.879
11. Bluteau D., Balduini A., Balayn N., Currao M., Nurden P., Deswarte C.,
Leverger G., Noris P., Perrotta S., Solary E., Vainchenker W., Debili N.,
Favier R., and Raslova H. Thrombocytopenia-associated mutations in the
ANKRD26 regulatory region induce MAPK hyperactivation. [2014] Journal of
Clinical Investigation (124) 2 : 580-591. Impact factor : 13.765
12. Bonastre J., Marguet S., Lueza B., Michiels S., Delaloge S., and Saghatchian
M. Cost effectiveness of molecular profiling for adjuvant decision making
in patients with node-negative breast cancer. [2014] Journal of Clinical
13. Brasme J.F., Chalumeau M., Oberlin O., Valteau-Couanet D., and Gaspar
N. Time to diagnosis of ewing tumors in children and adolescents is not
associated with metastasis or survival: A prospective multicenter study of
436 patients. [2014] Journal of Clinical Oncology (32) 18 : 1935-1940. Impact
factor : 17.879
14. Brasme J.F., Chalumeau M., Oberlin O., Valteau-Couanet D., and Gaspar N.
Reply to L. Alonso et al. [2014] Journal of Clinical Oncology (32) 35 : 40204021. Impact factor : 17.879
15. Chouaid C., Borget I., and Vergnenegre A. Targeted therapies in non-smallcell lung cancer management: no cost-effective strategies? [2014] Journal
of Clinical Oncology (32) 31 : 3577-3577. Impact factor : 17.879
16. Damm F., Mylonas E., Cosson A., Yoshida K., Della Valle V., Mouly E., Diop
M., Scourzic L., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Kikushige
Y., Davi F., Lambert J., Gautheret D., Merle-Béral H., Sutton L., Dessen
P., Solary E., Akashi K., Vainchenker W., Mercher T., Droin N., Ogawa S.,
Nguyen-Khac F., and Bernard O.A. Acquired initiating mutations in early
hematopoietic cells of CLL patients. [2014] Cancer Discovery (4) 9 : 10881101. Impact factor : 15.929
17. Denkert C., von Minckwitz G., Brase J.C., Sinn B.V., Gade S., Kronenwett
R., Pfitzner B.M., Salat C., Loi S., Schmitt W.D., Schem C., Fisch K., DarbEsfahani S., Mehta K., Sotiriou C., Wienert S., Klare P., Andre F., Klauschen
F., Blohmer J.U., Krappmann K., Schmidt M., Tesch H., Kummel S.,
Sinn P., Jackisch C., Dietel M., Reimer T., Untch M., and Loibl S. TumorInfiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy
With or Without Carboplatin in Human Epidermal Growth Factor Receptor
2-Positive and Triple-Negative Primary Breast Cancers. [2014] Journal of
Clinical Oncology. Impact factor : 17.879
18. Dimakopoulou K., Samoli E., Beelen R., Stafoggia M., Andersen Z.J.,
Hoffmann B., Fischer P., Nieuwenhuijsen M., Vineis P., Xun W., Hoek G.,
Raaschou-Nielsen O., Oudin A., Forsberg B., Modig L., Jousilahti P., Lanki
T., Turunen A., Oftedal B., Nafstad P., Schwarze P.E., Penell J., Fratiglioni L.,
Andersson N., Pedersen N., Korek M., De Faire U., Eriksen K.T., Tjonneland
A., Becker T., Wang M., Bueno-de-Mesquita B., Tsai M.Y., Eeftens M., Peeters
P.H., Meliefste K., Marcon A., Kramer U., Kuhlbusch T.A.J., Vossoughi M.,
Key T., de Hoogh K., Hampel R., Peters A., Heinrich J., Weinmayr G., Concin
H., Nagel G., Ineichen A., Jacquemin B., Stempfelet M., Vilier A., Ricceri F.,
Sacerdote C., Pedeli X., Katsoulis M., Trichopoulou A., Brunekreef B., and
Katsouyanni K. Air Pollution and Nonmalignant Respiratory Mortality in 16
Cohorts within the ESCAPE Project. [2014] American Journal of Respiratory
and Critical Care Medicine (189) 6 : 684-696. Impact factor : 11.986
19. Drake C.G., Kwon E.D., Fizazi K., Bossi A., van den Eertwegh A.J.M.,
Logothetis C., Scher H.I., Beer T.M., McHenry B., Liu D., and Gerritsen W.R.
Results of subset analyses on overall survival (OS) from study CA184043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic
castration-resistant prostate cancer (mCRPC). [2014] Journal of Clinical
Oncology (32) 4 S2. Impact factor : 17.879
66
20. Dreicer R., Jones R., Oudard S., Efstathiou E., Saad F., De Wit R., De Bono
J.S., Shi Y., Tejura B., Agus D.B., Borgstein N.G., Bellmunt J., and Fizazi K.
Results from a phase 3, randomized, double-blind, multicenter, placebocontrolled trial of orteronel (TAK-700) plus prednisone in patients with
metastatic castration-resistant prostate cancer (mCRPC) that has
progressed during or following docetaxel-based. [2014] Journal of Clinical
Oncology (32) 4 S2. Impact factor : 17.879
Lund E., Brustad M., Olsen K.S., Weiderpass E., Zamora-Ros R., Sanchez
M.J., Ardanaz E., Amiano P., Navarro C., Ramon Quiros J., Werner M., Sund
M., Lindkvist B., Malm J., Travis R.C., Khaw K.T., Stepien M., Scalbert A.,
Romieu I., Lagiou P., Riboli E., and Jenab M. Prediagnostic Circulating
Vitamin D Levels and Risk of Hepatocellular Carcinoma in European
Populations: A Nested Case-Control Study. [2014] Hepatology (60) 4 : 12221230. Impact factor : 11.190
21. Eggermont A.M.M. and Robert C. MELANOMA Smart therapeutic strategies
in immuno-oncology. [2014] Nature Reviews Clinical Oncology (11) 4 : 181182. Impact factor : 17.879
30. Ferté C., Koscielny S., Albiges L., Rocher L., Soria J.C., Iacovelli R., Loriot Y.,
Fizazi K., and Escudier B. Tumor Growth Rate Provides Useful Information
to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell
Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD
Phase 3 Trial Data. [2014] European Urology (65) 4 : 713-720. Impact factor :
12.480
22. Eisenberg T., Schroeder S., Buttner S., Carmona-Gutierrez D., Pendl T.,
Andryushkova A., Marino G., Pietrocola F., Harger A., Zimmermann A.,
Magnes C., Sinner F., Sedej S., Pieber T.R., Dengjel J., Sigrist S., Kroemer
G., and Madeo F. A histone point mutation that switches on autophagy.
[2014] Autophagy (10) 6 : 1143-1145. Impact factor : 11.423
23. Eisenberg T., Schroeder S., Andryushkova A., Pendl T., Kuttner V., Bhukel
A., Marino G., Pietrocola F., Harger A., Zimmermann A., Moustafa T.,
Sprenger A., Jany E., Buttner S., Carmona-Gutierrez D., Ruckenstuhl C.,
Ring J., Reichelt W., Schimmel K., Leeb T., Moser C., Schatz S., Kamolz
L.P., Magnes C., Sinner F., Sedej S., Fröhlich K.U., uhasz G., ieber T.R.,
engjel J., igrist S.J., roemer G., and adeo F. Nucleocytosolic depletion
of the energy metabolite acetyl-coenzyme A stimulates autophagy and
prolongs lifespan. [2014] Cell Metabolism (19) 3 : 431-444. Impact factor :
16.747
24. Escudier B., Porta C., Bono P., Powles T., Eisen T., Sternberg C.N., Gschwend
J.E., De Giorgi U., Parikh O., Hawkins R., Sevin E., Négrier S., Khan S., Diaz
J., Redhu S., Mehmud F., and Cella D. Randomized, controlled, doubleblind, cross-over trial assessing treatment preference for pazopanib
versus sunitinib in patients with metastatic renal cell carcinoma: PISCES
study. [2014] Journal of Clinical Oncology (32) 14 : 1412-1418. Impact
factor : 17.879
25. Escudier B., Porta C., Powles T., Eisen T., Sternberg C.N., Mehmud F., and
Cella D. Reply to S. Barni et Al and M. Sun et Al. [2014] Journal of Clinical
26. Escudier B.J., Porta C., Squires M., Szczylik C., Kollmannsberger C.K.,
Melichar B., Rha S.Y., Esteban E., Bjarnason G.A., Vogelzang N.J., Sternberg
C.N., Shi M., Marker M., and Motzer R.J. Biomarker analysis from a phase
III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with
metastatic renal cell carcinoma after one prior VEGF pathway-targeted
therapy and one prior mTOR inhibitor therapy. [2014] Journal of Clinical
Oncology (32) 4 Suppl.. Impact factor : 17.879
27. Escudier B.J., Bracarda S., Rey J.P.M., Szczylik C., Nathan P.D., Negrier
S., Cattaneo A., Weiss C., Porta C., and Gruenwald V. Open-label, phase
II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1
and type 2 histology. [2014] Journal of Clinical Oncology (32) 4 S2. Impact
factor : 17.879
28. Favaudon V., Caplier L., Monceau V., Pouzoulet F., Sayarath M., Fouillade C.,
Poupon M.F., Brito I., Hupe P., Bourhis J., Hall J., Fontaine J.J., and Vozenin
M.C. Ultrahigh dose-rate FLASH irradiation increases the differential
response between normal and tumor tissue in mice. [2014] Science
Translational Medicine (6) 245 : 245ra93-245ra93. Impact factor : 14.414
29. Fedirko V., Duarte-Salles T., Bamia C., Trichopoulou A., Aleksandrova K.,
Trichopoulos D., Trepo E., Tjonneland A., Olsen A., Overvad K., BoutronRuault M.C., Clavel-Chapelon F., Kvaskoff M., Kuehn T., Lukanova A., Boeing
H., Buijsse B., Klinaki E., Tsimakidi C., Naccarati A., Tagliabue G., Panico S.,
Tumino R., Palli D., Bueno-de-Mesquita H.B., Siersema P.D., Peters P.H.,
31. Fizazi K., Delva R., Caty A., Chevreau C., Kerbrat P., Rolland F., Priou F.,
Geoffrois L., Rixe O., Beuzeboc P., Malhaire J.P., Culine S., Aubelle M.S.,
and Laplanche A. A risk-adapted study of cisplatin and etoposide, with or
without ifosfamide, in patients with metastatic seminoma: Results of the
GETUG S99 multicenter prospective study. [2014] European Urology (65) 2 :
381-386. Impact factor : 12.480
32. Fizazi K., Flaig T.W., Ohlmann C.H., Scher H.I., De Bono J.S., Rathkopf D.E.,
Ryan C.J., Kheoh T.S., Li J., Todd M.B., Griffin T.W., Molina A., and Stoeckle
M. Does Gleason score (GS) predict efficacy of abiraterone acetate (AA)
therapy in patients (pts) with metastatic castration-resistant prostate
cancer (mCRPC)? An analysis of AA phase 3 trials. [2014] Journal of Clinical
33. Galluzzi L., Kepp O., and Kroemer G. MLKL regulates necrotic plasma
membrane permeabilization. [2014] Cell research (24) 2 : 139-140. Impact
factor : 11.981
34. Gandhi L., Bahleda R., Tolaney S.M., Kwak E.L., Cleary J.M., Pandya S.S.,
Hollebecque A., Abbas R., Ananthakrishnan R., Berkenblit A., Krygowski
M., Liang Y., Turnbull K.W., Shapiro G.I., and Soria J.C. Phase I Study of
Neratinib in Combination With Temsirolimus in Patients With Human
Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors.
[2014] Journal of Clinical Oncology (32) 2 : 68-+. Impact factor : 17.879
35. Garcia J.A., Kataja V.V., James N.D., Jones R.H., Protheroe A., Massard C.,
Mattila L., Mustonen M.V.J., Aspegren J., and Fizazi K. Bone and soft tissue
response from a phase I/II study with ODM-201 in metastatic castrationresistant prostate cancer (mCRPC). [2014] Journal of Clinical Oncology (32)
S4. Impact factor : 17.879
36. Garlipp B., De Baere T., Damm R., Irmscher R., van Buskirk M., Stübs P.,
Deschamps F., Meyer F., Seidensticker R., Mohnike K., Pech M., Amthauer
H., Lippert H., Ricke J., and Seidensticker M. Left-liver hypertrophy after
therapeutic right-liver radioembolization is substantial but less than
after portal vein embolization. [2014] Hepatology (59) 5 : 1864-1873. Impact
factor : 11.190
37. Gartrell B.A., Coleman R.E., Fizazi K., Miller K., Saad F., Sternberg C.N.,
and Galsky M.D. Toxicities Following Treatment with Bisphosphonates and
Receptor Activator of Nuclear Factor-kappa B Ligand Inhibitors in Patients
with Advanced Prostate Cancer. [2014] European Urology (65) 2 : 278-286.
38. Gibert B., Delloye-Bourgeois C., Gattolliat C.H., Meurette O., Le Guernevel
S., Fombonne J., Ducarouge B., Lavial F., Bouhallier F., Creveaux M.,
Negulescu A.M., Bénard J., Janoueix-Lerosey I., Harel-Bellan A., Delattre
O., and Mehlen P. Regulation by miR181 family of the dependence receptor
CDON tumor suppressive activity in neuroblastoma. [2014] Jnci-Journal of
the National Cancer Institute (106) 11. Impact factor : 15.161
67
39. Gravis G., Boher J.M., Fizazi K., Joly F., Priou F., Marino P., Latorzeff
I., Delva R., Krakowski I., Laguerre B., Walz J., Rolland F., Théodore
C., Deplanque G., Ferrero J.M., Pouessel D., Mourey L., Beuzeboc P.,
Zanetta S., Habibian M., Berdah J.F., Dauba J., Baciuchka M., Platini
C., Linassier C., Labourey J.L., Machiels J.P., Kouri C.E., Ravaud A.,
Suc E., Eymard J.C., Hasbini A., Bousquet G., Soulie M., and Oudard
S. Prognostic Factors for Survival in Noncastrate Metastatic Prostate
Cancer: Validation of the Glass Model and Development of a Novel
Simplified Prognostic Model. [2014] European Urology. Impact factor :
12.480
40. Grill J. and Dufour C. Neuro-oncology : Stability of medulloblastoma
subgroups at tumour recurrence. [2014] Nature Reviews Neurology (10) 1 :
5-6. Impact factor : 14.103
41. Guinney J., Dienstmann R., Ferté C., Friend S., and McCormick F. Social
interactomes for enabling research communities. [2014] Cancer Discovery
(4) 11 : 1265-1268. Impact factor : 15.929
42. Halabi S., Lin C.Y., Kelly W.K., Fizazi K.S., Moul J.W., Kaplan E.B., Morris
M.J., and Small E.J. Updated Prognostic Model for Predicting Overall
Survival in First-Line Chemotherapy for Patients With Metastatic
Castration-Resistant Prostate Cancer. [2014] Journal of Clinical Oncology
(32) 7 : 671-+. Impact factor : 17.879
43. Hoster E., Klapper W., Hermine O., Kluin-Nelemans H.C., Walewski J., Van
Hoof A., Trneny M., Geisler C.H., Raimondo F.D., Szymczyk M., Stilgenbauer
S., Thieblemont C., Hallek M., Forstpointner R., Pott C., Ribrag V., Doorduijn
J., Hiddemann W., Dreyling M.H., and Unterhalt M. Confirmation of the
mantle-cell lymphoma International Prognostic Index in randomized
trials of the European Mantle-Cell Lymphoma Network. [2014] Journal of
44. Hutson T.E., Escudier B., Esteban E., Bjarnason G.A., Lim H.Y., Pittman
K.B., Senico P., Niethammer A., Lu D.R., Hariharan S., and Motzer R.J.
Randomized phase III trial of temsirolimus versus sorafenib as secondline therapy after sunitinib in patients with metastatic renal cell carcinoma.
[2014] Journal of Clinical Oncology (32) 8 : 760-767. Impact factor : 17.879
45. Iacovelli R., Massari F., Albiges L., Loriot Y., Massard C., Fizazi K., and
Escudier B. Evidence and Clinical Relevance of Tumor Flare in Patients
Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic
Renal Cell Carcinoma. [2014] European Urology. Impact factor : 12.480
46. Iacovelli R., Massari F., Albiges L., and Escudier B. Prognostic value of
flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib
(PA) in metastatic renal cell carcinoma (mRCC). [2014] Journal of Clinical
47. Jaafoura S., de Goër de Herve M.G., Hernandez-Vargas E.A., Hendel-Chavez
H., Abdoh M., Mateo M.C., Krzysiek R., Merad M., Seng R., Tardieu M.,
Delfraissy J.F., Goujard C., and Taoufik Y. Progressive contraction of the
latent HIV reservoir around a core of less-differentiated CD4+ memory T
Cells. [2014] Nature communications (5) : 5407-5407. Impact factor : 10.742
48. Janin M., Mylonas E., Saada V., Micol J.B., Renneville A., Quivoron C.,
Koscielny S., Scourzic L., Forget S., Pautas C., Caillot D., Preudhomme
C., Dombret H., Berthon C., Barouki R., Rabier D., Auger N., Griscelli F.,
Chachaty E., Leclercq E., Courtier M.H., Bennaceur-Griscelli A., Solary E.,
Bernard O.A., Penard-Lacronique V., Ottolenghi C., and De Botton S. Serum
2-hydroxyglutarate production in IDH1- And IDH2-mutated de novo acute
myeloid leukemia: A study by the acute leukemia french association
group. [2014] Journal of Clinical Oncology (32) 4 : 297-305. Impact factor :
17.879
49. Kroemer G. and Perfettini J.L. Entosis, a key player in cancer cell
competition. [2014] Cell research (24) 11 : 1280-1281. Impact factor : 11.981
50. Kvaskoff M., Bijon A., Mesrine S., Vilier A., Baglietto L., Fournier A., ClavelChapelon F., Dossus L., and Boutron-Ruault M.C. Association between
Melanocytic Nevi and Risk of Breast Diseases: The French E3N Prospective
Cohort. [2014] PLOS MEDICINE (11) 6 : e1001660-e1001660. Impact factor :
14.000
51. Kyro C., Olsen A., Landberg R., Skeie G., Loft S., Aman P., Leenders M.,
Dik V.K., Siersema P.D., Pischon T., Christensen J., Overvad K., BoutronRuault M.C., Fagherazzi G., Cottet V., Kuehn T., Chang-Claude J., Boeing
H., Trichopoulou A., Bamia C., Trichopoulos D., Palli D., Krogh V., Tumino
R., Vineis P., Panico S., Peeters P.H., Weiderpass E., Bakken T., Asli L.A.,
Argueelles M., Jakszyn P., Sanchez M.J., Amiano P., Huerta J.M., Barricarte
A., Ljuslinder I., Palmqvist R., Khaw K.T., Wareham N., Key T.J., Travis
R.C., Ferrari P., Freisling H., Jenab M., Gunter M.J., Murphy N., Riboli E.,
Tjonneland A., and Bueno-de-Mesquita H.B. Plasma Alkylresorcinols,
Biomarkers of Whole-Grain Wheat and Rye Intake, and Incidence of
Colorectal Cancer. [2014] Jnci-Journal of the National Cancer Institute (106)
1 : djt352-djt352. Impact factor : 15.161
52. Langenberg C., Sharp S.J., Franks P.W., Scott R.A., Deloukas P., Forouhi
N.G., Froguel P., Groop L.C., Hansen T., Palla L., Pedersen O., Schulze
M.B., Tormo M.J., Wheeler E., Agnoli C., Arriola L., Barricarte A., Boeing
H., Clarke G.M., Clavel-Chapelon F., Duell E.J., Fagherazzi G., Kaaks R.,
Kerrison N.D., Key T.J., Khaw K.T., Kroger J., Lajous M., Morris A.P., Navarro
C., Nilsson P.M., Overvad K., Palli D., Panico S., Quiros J.R., Rolandsson O.,
Sacerdote C., Sanchez M.J., Slimani N., Spijkerman A.M.W., Tumino R., van
d.A., van der Schouw Y.T., Barroso I., McCarthy M.I., Riboli E., and Wareham
N.J. Gene-lifestyle interaction and type 2 diabetes: the EPIC interact casecohort study. [2014] PLOS MEDICINE (11) 5 : e1001647-e1001647. Impact
factor : 14.000
53. Lassau N., Koscielny S., Taieb S., Lacroix J., Aziza R., Joly F., Chevreau C.,
Negrier S., Gravis G., and Escudier B.J. Validation of imaging biomarker in
a multicentric study to predict PFS in mRCC treated with TKI. [2014] Journal
of Clinical Oncology (32) 4 Suppl.. Impact factor : 17.879
54. Le Deley M.C., Paulussen M., Lewis I., Brennan B., Ranft A., Whelan J., Le
Teuff G., Michon J., Ladenstein R., Marec-Bérard P., van den Berg H., Hjorth
L., Wheatley K., Judson I., Juergens H., Craft A., Oberlin O., and Dirksen U.
Cyclophosphamide compared with ifosfamide in consolidation treatment
of standard-risk Ewing sarcoma: results of the randomized noninferiority
Euro-EWING99-R1 trial. [2014] Journal of Clinical Oncology (32) 23 : 24402448. Impact factor : 17.879
55. Levy A., Rivera S., del Campo E.R., Chargari C., and Arriagada R.
Individualizing Adjuvant Radiotherapy in Patients With Breast Cancer:
Let’s Not Get Ahead of Ourselves. [2014] Journal of Clinical Oncology (32)
29 : 3339-3339. Impact factor : 17.879
56. Lhommé C., Leary A., Uzan C., Pautier P., Gouy S., and Morice P. Adjuvant
chemotherapy in stage I ovarian germ cell tumors: should indications and
treatment modalities be different in young girls and adults? [2014] Journal
of Clinical Oncology (32) 25 : 2815-2816. Impact factor : 17.879
57. Loibl S., von Minckwitz G., Schneeweiss A., Paepke S., Lehmann A., Rezai
M., Zahm D.M., Sinn P., Khandan F., Eidtmann H., Dohnal K., Heinrichs C.,
Huober J., Pfitzner B., Fasching P.A., Andre F., Lindner J.L., Sotiriou C.,
Dykgers A., Guo S., Gade S., Nekljudova V., Loi S., Untch M., and Denkert C.
PIK3CA mutations are associated with lower rates of pathologic complete
response to anti-human epidermal growth factor receptor 2 (her2)
therapy in primary HER2-overexpressing breast cancer. [2014] Journal of
68
58. Loriot Y., Pagliaro L.C., Flechon A., Mardiak J., Geoffrois L., Kerbrat P.,
Chevreau C., Delva R., Rolland F., Theodore C., Bui B., Gravis G., Eymard
J.C., Malhaire J.P., Linassier C., Habibian M., Logothetis C., Culine S.,
Laplanche A., and Fizazi K. Patterns of relapse in poor-prognosis germ
cell tumors in the GETUG 13 trial: Implications for assessment of brain
progression. [2014] Journal of Clinical Oncology (32) S4. Impact factor :
17.879
59. Loriot Y., Massard C., and Fizazi K. One Size Does Not Fit All: Can We
Choose the Best Sequence of Treatment in Asymptomatic Castrationresistant Prostate Cancer Patients? [2014] European Urology (66) 4 : 653654. Impact factor : 12.480
60. Loriot Y. and Fizazi K. Towards random sequencing or precision medicine
in castration-resistant prostate cancer? [2014] European Urology (65) 1 :
37-38. Impact factor : 12.480
61. Malouf G.G., Job S., Paradis V., Fabre M., Brugieres L., Saintigny P., Vescovo
L., Belghiti J., Branchereau S., Faivre S., De Reyniès A., and Raymond E.
Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma
reveals an endocrine signature. [2014] Hepatology (59) 6 : 2228-2237.
62. Mariño G., Pietrocola F., Eisenberg T., Kong Y., Malik S.A., Andryushkova A.,
Schroeder S., Pendl T., Harger A., Niso-Santano M., Zamzami N., Scoazec
M., Durand S.r., Enot D.P., Fernández ÁF., Martins I., Kepp O., Senovilla L.,
Bauvy C., Morselli E., Vacchelli E., Bennetzen M., Magnes C., Sinner F.,
Pieber T., López-Otín C., Maiuri M.C., Codogno P., Andersen J.S., Hill J.A.,
Madeo F., and Kroemer G. Regulation of autophagy by cytosolic acetylcoenzyme A. [2014] Molecular cell (53) 5 : 710-725. Impact factor : 14.464
63. Mariette C., Dahan L., Mornex F.o., Maillard E., Thomas P.A., Meunier
B., Boige V.r., Pezet D., Robb W.B., Le Brun-Ly V.r., Bosset J.F.o., Mabrut
J.Y., Triboulet J.P., Bedenne L., and Seitz J.F.o. Surgery alone versus
chemoradiotherapy followed by surgery for stage I and II esophageal
cancer: final analysis of randomized controlled phase III trial FFCD 9901.
[2014] Journal of Clinical Oncology (32) 23 : 2416-2422. Impact factor :
17.879
64. Marino G., Pietrocola F., Kong Y., Eisenberg T., Hill J.A., Madeo F., and
Kroemer G. Dimethyl alpha-ketoglutarate inhibits maladaptive autophagy
in pressure overload-induced cardiomyopathy. [2014] Autophagy (10) 5 :
930-932. Impact factor : 11.423
65. Massard C., Tammela T.L.J., Vjaters E., Lietuvietis V., Bono P., Penttinen
H., Nykanen P., Snapir A., Mattila L., and Fizazi K. A study of two ODM201 formulations with a safety and tolerability extension phase in patients
with metastatic chemotherapy-naive castration-resistant prostate cancer
(CRPC). [2014] Journal of Clinical Oncology (32) 4 Suppl.. Impact factor :
17.879
66. Miller K.D., Diéras V., Harbeck N., Andre F., Mahtani R.L., Gianni L., Albain
K.S., Crivellari D., Fang L., Michelson G., De Haas S.L., and Burris H.A.
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients
with human epidermal growth factor receptor 2-positive, locally advanced,
or metastatic breast cancer. [2014] Journal of Clinical Oncology (32) 14 :
1437-1444. Impact factor : 17.879
67. Molina T.J., Canioni D., Copie-Bergman C., Recher C., Brière J., Haioun C.,
Berger F., Fermé C., Copin M.C., Casasnovas O., Thieblemont C., Petrella
T., Leroy K., Salles G., Fabiani B., Morschauser F., Mounier N., Coiffier
B., Jardin F., Gaulard P., Jais J.P., and Tilly H. Young patients with nongerminal center B-cell-like diffuse large B-cell lymphoma benefit from
intensified chemotherapy with ACVBP plus rituximab compared with
CHOP plus rituximab: analysis of data from the Groupe d’Etudes des
Lymphomes de l’Adulte/lympho. [2014] Journal of Clinical Oncology (32)
35 : 3996-4003. Impact factor : 17.879
68. Morice P., Gouy S., Querleu D., and Leblanc E. Using Positron Emission
Tomography Imaging for Maximum Benefit in Locally Advanced Cervical
Cancer Reply. [2014] Journal of Clinical Oncology (32) 4 : 358-359. Impact
factor : 17.879
69. Morice P., Gouy S., Querleu D., and Leblanc E. Reply to m.s. Rajagopalan et
Al and p.g. Rose. [2014] Journal of Clinical Oncology (32) 4 : 358-359. Impact
factor : 17.879
70. Mulders P.F.A., Molina A., Marberger M., Saad F., Higano C.S., Chi K.N., Li
J., Kheoh T., Haqq C.M., and Fizazi K. Efficacy and Safety of Abiraterone
Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with
Metastatic Castration-resistant Prostate Cancer After Docetaxel-based
Chemotherapy. [2014] European Urology (65) 5 : 875-883. Impact factor :
12.480
71. Nassif M., Valenzuela V., Rojas-Rivera D., Vidal R., Matus S., Castillo K.,
Fuentealba Y., Kroemer G., Levine B., and Hetz C. Pathogenic role of
BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis. [2014]
Autophagy (10) 7 : 1256-1271. Impact factor : 11.423
72. Naudin C., Sirvent A., Leroy C., Larive R., Simon V., Pannequin J., Bourgaux
J.F., Pierre J., Robert B., Hollande F., and Roche S. SLAP displays tumour
suppressor functions in colorectal cancer via destabilization of the SRC
substrate EPHA2. [2014] Nature communications (5) : 3159-3159. Impact
factor : 10.742
73. Nguyen T.V., Riou L., Aoufouchi S., and Rosselli F. Fanca deficiency
reduces A/T transitions in somatic hypermutation and alters class switch
recombination junctions in mouse B cells. [2014] Journal of Experimental
Medicine (211) 6 : 1011-1018. Impact factor : 13.912
74. Noman M.Z., Desantis G., Janji B., Hasmim M., Karray S., Dessen P.,
Bronte V., and Chouaib S. PD-L1 is a novel direct target of HIF-1&, and its
blockade under hypoxia enhanced MDSC-mediated T cell activation. [2014]
Journal of Experimental Medicine (211) 5 : 781-790. Impact factor : 13.912
75. Oudard S., Joly F., Geoffrois L., Laguerre B., Houede N., Barthelemy P.,
Gross-Goupil M., Yann-Alexandre V., Lucidarme O., Bidault F., Kelkouli N.,
and Escudier B. Retrospective evaluation of tyrosine kinase inhibitor (TKI)everolimus (eve) and/or TKI-eve-TKI sequences in metastatic renal cell
carcinoma (mRCC): A French survey-The sector study. [2014] Journal of
Clinical Oncology (32) 4 Suppl.. Impact factor : 17.879
76. Oudard S., Kheoh T.S., Yu M.K., Smith M.R., Small E.J., Mulders P.F.A.,
Fizazi K., Rathkopf D.E., Saad F., Scher H.I., Bellmunt J., Taplin M.E., Davis
I.D., Schrijvers D.L., Protheroe A., Molina A., Griffin T.W., De Bono J.S., and
Ryan C.J. Impact of prior endocrine therapy on radiographic progressionfree survival (rPFS) in patients (pts) with chemotherapy-naive metastatic
castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.
77. Peeters M., Oliner K.S., Price T.J., Cervantes A., Sobrero A.F., Ducreux M.,
Hotko Y., Andre T., Chan E., Lordick F., Punt C.J.A., Strickland A., Wilson
G., Ciuleanu T.E., Roman L., Van Cutsem E., Tian Y., Jung A.S., Sidhu R.,
and Patterson S.D. Analysis of KRAS/NRAS mutations in phase 3 study
20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for
second-line treatment (tx) of metastatic colorectal cancer (mCRC). [2014]
Journal of Clinical Oncology (32) 3 Suppl.. Impact factor : 17.879
69
78. Pinton P. and Kroemer G. Cancer therapy: Altering mitochondrial
properties. [2014] Nature chemical biology (10) 2 : 89-90. Impact factor :
13.217
79. Raemaekers J.M.M., André M.P.E., Federico M., Girinsky T., Oumedaly
R., Brusamolino E., Brice P., Fermé C., Van Der Maazen R., Gotti
M., Bouabdallah R., Sebban C.J., Lievens Y., Re A., Stamatoullas A.,
Morschhauser F., Lugtenburg P.J., Abruzzese E., Olivier P., Casasnovas
R.O., Van Imhoff G., Raveloarivahy T., Bellei M., Van Der Borght T., Bardet
S., Versari A., Hutchings M., Meignan M., and Fortpied C. Omitting
Radiotherapy in early positron emission tomography-negative stage I/II
Hodgkin lymphoma is associated with an increased risk of early relapse:
Clinical results of the preplanned interim analysis of the randomized
EORTC/LYSA/FIL H10 trial. [2014] Journal of Clinical Oncology (32) 12 :
1188-1194. Impact factor : 17.879
80. Rao S., Tortola L., Perlot T., Wirnsberger G., Novatchkova M., Nitsch R.,
Sykacek P., Frank L., Schramek D., Komnenovic V., Sigl V., Aumayr K.,
Schmauss G., Fellner N., Handschuh S., Glösmann M., Pasierbek P.,
Schlederer M., Resch G.P., Ma Y., Yang H., Popper H., Kenner L., Kroemer
G., and Penninger J.M. A dual role for autophagy in a murine model of lung
cancer. [2014] Nature communications (5). Impact factor : 10.742
81. Rao S., Yang H., Penninger J.M., and Kroemer G. Autophagy in non- small
cell lung carcinogenesis. [2014] Autophagy (10) 3 : 529-531. Impact factor :
11.423
82. Rathkopf D.E., Smith M.R., de Bono J.S., Logothetis C.J., Shore N.D., de
Souza P., Fizazi K., Mulders P.F.A., Mainwaring P., Hainsworth J.D., Beer
T.M., North S., Fradet Y., Van Poppel H., Carles J., Flaig T.W., Efstathiou E.,
Yu E.Y., Higano C.S., Taplin M.E., Griffin T.W., Todd M.B., Yu M.K., Park Y.C.,
Kheoh T., Small E.J., Scher H.I., Molina A., Ryan C.J., and Saad F. Updated
Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in
Metastatic Castration-resistant Prostate Cancer Patients Without Prior
Chemotherapy (COU-AA-302). [2014] European Urology (66) 5 : 815-825.
83. Rebouissou S., Bernard-Pierrot I., De Reyniès A., Lepage M.L., Krucker C.,
Chapeaublanc E., Hérault A., Kamoun A., Caillault A., Letouzé E., Elarouci
N., Neuzillet Y., Denoux Y., Molinié V., Vordos D., Laplanche A., Maillé P.,
Soyeux P., Ofualuka K., Reyal F., Biton A., Sibony M., Paoletti X., Southgate
J., Benhamou S., Lebret T., Allory Y., and Radvanyi F. EGFR as a potential
therapeutic target for a subset of muscle-invasive bladder cancers
presenting a basal-like phenotype. [2014] Science Translational Medicine
(6) 244 : 244ra91-244ra91. Impact factor : 14.414
84. Rinaldi S., Plummer M., Biessy C., Tsilidis K.K., Ostergaard J.N., Overvad
K., Tjonneland A., Halkjaer J., Boutron-Ruault M.C., Clavel-Chapelon F.,
Dossus L., Kaaks R., Lukanova A., Boeing H., Trichopoulou A., Lagiou P.,
Trichopoulos D., Palli D., Agnoli C., Tumino R., Vineis P., Panico S., DeMesquita H.B.B., Peeters P.H., Weiderpass E., Lund E., Quiros J.R., Agudo
A., Molina E., Larranaga N., Navarro C., Ardanaz E., Manjer J., Almquist
M., Sandström M., Hennings J., Khaw K.T., Schmidt J., Travis R.C., Byrnes
G., Scalbert A., Romieu I., Gunter M., Riboli E., and Franceschi S. Thyroidstimulating hormone, thyroglobulin, and thyroid hormones and risk of
differentiated thyroid carcinoma: The EPIC study. [2014] Jnci-Journal of the
National Cancer Institute (106) 6 : dju097-dju097. Impact factor : 15.161
85. Rini B.I., Bellmunt J., Clancy J., Wang K., Niethammer A.G., Hariharan
S., and Escudier B. Randomized phase III trial of temsirolimus and
bevacizumab versus interferon alfa and bevacizumab in metastatic renal
cell carcinoma: INTORACT trial. [2014] Journal of Clinical Oncology (32) 8 :
752-759. Impact factor : 17.879
86. Rosmarin D., Palles C., Church D., Domingo E., Jones A., Johnstone E.,
Wang H., Love S., Julier P., Scudder C., Nicholson G., Gonzalez-Neira A.,
Martin M., Sargent D., Green E., McLeod H., Zanger U.M., Schwab M.,
Braun M., Seymour M., Thompson L., Lacas B., Boige V., Ribelles N.,
Afzal S., Enghusen H., Jensen S.A., Etienne-Grimaldi M.C., Milano G.,
Wadelius M., Glimelius B., Garmo H., Gusella M., Lecomte T., LaurentPuig P., Martinez-Balibrea E., Sharma R., Garcia-Foncillas J., Kleibl
Z., Morel A., Pignon J.P., Midgley R., Kerr D., and Tomlinson I. Genetic
markers of toxicity from capecitabine and other fluorouracil-based
regimens: Investigation in the QUASAR2 study, systematic review, and
meta-analysis. [2014] Journal of Clinical Oncology (32) 10 : 1031-1039.
87. Saad F., de Bono J., Shore N., Fizazi K., Loriot Y., Hirmand M., Franks B.,
Haas G.P., and Scher H.I. Efficacy Outcomes by Baseline Prostate-specific
Antigen Quartile in the AFFIRM Trial. [2014] European Urology. Impact
factor : 12.480
88. Schroeder S., Pendl T., Zimmermann A., Eisenberg T., Carmona-Gutierrez
D., Ruckenstuhl C., Marino G., Pietrocola F., Harger A., Magnes C., Sinner
F., Pieber T.R., Dengjel J., Sigrist S.J., Kroemer G., and Madeo F. Acetylcoenzyme A: A metabolic master regulator of autophagy and longevity.
[2014] Autophagy (10) 7 : 1335-1337. Impact factor : 11.423
89. Shore N.D., Bono P., Massard C., Snapir A., Sarapohja T., and Fizazi K. ODM201 and the CNS: A clinical perspective. [2014] Journal of Clinical Oncology
(32) 4 Suppl.. Impact factor : 17.879
90. Sieri S., Chiodini P., Agnoli C., Pala V., Berrino F., Trichopoulou A., Benetou
V., Vasilopoulou E., Sanchez M.J., Chirlaque M.D., Amiano P., Ramon Quiros
J., Ardanaz E., Buckland G., Masala G., Panico S., Grioni S., Sacerdote C.,
Tumino R., Boutron-Ruault M.C., Clavel-Chapelon F., Fagherazzi G., Peeters
P.H.M., van Gils C.H., Bueno-de-Mesquita H.B., van Kranen H.J., Key T.J.,
Travis R.C., Khaw K.T., Wareham N.J., Kaaks R., Lukanova A., Boeing H.,
Schuetze M., Sonestedt E., Wirfaelt E., Sund M., Andersson A., Chajes
V., Rinaldi S., Romieu I., Weiderpass E., Skeie G., Dagrun E., Tjonneland
A., Halkjaer J., Overvard K., Merritt M.A., Cox D., Riboli E., and Krogh V.
Dietary Fat Intake and Development of Specific Breast Cancer Subtypes.
[2014] Jnci-Journal of the National Cancer Institute (106) 5 : dju068-dju068.
91. Smith M.R., Coleman R.E., Klotz L., Pittman K.B., Milecki P., Wei R.,
Balakumaran A., and Fizazi K. Denosumab for the prevention of
symptomatic skeletal events in patients with castration-resistant
advanced prostate cancer: A comparison with skeletal-related events.
92. Smith M.R., Matheny S., Saad F., Rathkopf D.E., Mulders P.F.A., De Bono
J.S., Small E.J., Shore N.D., Fizazi K., Kheoh T.S., Li J., Todd M.B., Griffin
T.W., Yu M.K., and Ryan C.J. Response to androgen signaling (AS)-directed
therapy after treatment with abiraterone acetate (AA) in patients (pts)
with metastatic castration-resistant prostate cancer (mCRPC): Post hoc
analysis of study COU-AA-302. [2014] Journal of Clinical Oncology (32) 4
Suppl.. Impact factor : 17.879
93. Sonpavde G., Sudarshan S., and Escudier B. Do the sites of metastases
provide additional information regarding prognosis and biology in renal
cell carcinoma? [2014] European Urology (65) 3 : 585-586. Impact factor :
12.480
70
94. Veccia A., Ortega C., Di Lorenzo G., La Russa F., Burgio S.L., Facchini G.,
Messina C., Sacco C., Spizzo G., Aieta M., Lodde M., Mansueto G., Zucali
P.A., D’Angelo A., Iacovelli R., Massari F., Morelli F., Procopio G., Ruatta F.,
and Caffo O. Clinical outcomes of patients (pts) age 60 or younger treated
with docetaxel (DOC) for castration-resistant prostate cancer (CRPC):
Results of an Italian multicenter retrospective study (CYCLOP study). [2014]
Journal of Clinical Oncology (32) S4. Impact factor : 17.879
95. Viprey V.F., Gregory W.M., Corrias M.V., Tchirkov A., Swerts K., Vicha A.,
Dallorso S., Brock P., Luksch R., Valteau-Couanet D., Papadakis V., Laureys
G., Pearson A.D., Ladenstein R., and Burchill S.A. Neuroblastoma mRNAs
predict outcome in children with stage 4 neuroblastoma: A European
HR-NBL1/SIOPEN study. [2014] Journal of Clinical Oncology (32) 10 : 10741083. Impact factor : 17.879
96. Viry E., Baginska J., Berchem G., Noman M.Z., Medves S., Chouaib S., and
Janji B. Autophagic degradation of GZMB/granzyme B : a new mechanism
of hypoxic tumor cell escape from natural killer cell-mediated lysis. [2014]
Autophagy (10) 1 : 173-175. Impact factor : 11.423
97. Wislez M., Barlesi F., Besse B., Mazieres J., Merle P., Cadranel J., AudigierValette C., Moro-Sibilot D., Gautier-Felizot L., Goupil F., Renault A., Quoix E.,
Souquet P.J., Madroszyck A., Corre R., Perol D., Morin F., Zalcman G., and
Soria J.C. Customized adjuvant phase II trial in patients with non-smallcell lung cancer: IFCT-0801 TASTE. [2014] Journal of Clinical Oncology (32)
12 : 1256-1261. Impact factor : 17.879
99. Yamada O., Mahfoudhi E., Plo I., Ozaki K., Nakatake M., Akiyama M.,
Yamada H., Kawauchi K., and Vainchenker W. Emergence of a BCR-ABL
Translocation in a Patient With the JAK2V617F Mutation: Evidence for
Secondary Acquisition of BCR-ABL in the JAK2V617F Clone. [2014] Journal
of Clinical Oncology (32) 21 : E76-E79. Impact factor : 17.879
100. Yu E.Y., Saad F., Londhe A., Shore N.D., Van Poppel H., Rathkopf D.E., Smith
M.R., Logothetis C., De Souza P.L., Fizazi K., Mulders P.F.A., Mainwaring
P.N., Hainsworth J.D., Beer T.M., North S.A., Small E.J., Scher H.I., Griffin
T.W., Yu M.K., and Ryan C.J. Association of alkaline phosphatase (ALP) with
clinical outcomes in chemotherapy-naive patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.
101. Zitvogel L. and Kroemer G. Cytokines reinstate NK cell-mediated cancer
immunosurveillance. [2014] Journal of Clinical Investigation (124) 11 :
4687-4689. Impact factor : 13.765
102. Zitvogel L. and Kroemer G. Targeting foxp1 for reinstating anticancer
immunosurveillance. [2014] Immunity (41) 3 : 345-347. Impact factor :
19.748
98. Wu C., Kraft P., Stolzenberg-Solomon R., Steplowski E., Brotzman M., Xu M.,
Mudgal P., Amundadottir 5., Arslan A.A., Bueno-de-Mesquita H.B., Gross
M., Helzlsouer K., Jacobs E.J., Kooperberg C., Petersen G.M., Zheng W.,
Albanes D., Boutron-Ruault M.C., Buring J.E., Canzian F., Cao G., Duell
E.J., Elena J.W., Gaziano J.M., Giovannucci E.L., Hallmans G., Hutchinson
A., Hunter D.J., Jenab M., Jiang G., Khaw K.T., LaCroix A., Li Z., Mendelsohn
J.B., Panico S., Patel A.V., Qian Z.R., Riboli E., Sesso H., Shen H., Shu Z.O.,
Tjonneland A., Tobias G.S., Trichopoulos D., Virtamo J., Visvanathan K.,
Wactawski-Wende J., Wang C., Yu K., Zeleniuch-Jacquotte A., Chanock S.,
Hoover R., Hartge P., Fuchs C.S., Lin D., and Wolpin B.M. Genome-wide
association study of survival in patients with pancreatic adenocarcinoma.
[2014] Gut. Impact factor : 13.319
GUSTAVE ROUSSY 2014
WITH A THOMSON REUTERS 2013 IMPACT FACTOR BETWEEN 5 AND 10 (324 PUBLICATIONS)
Find the list of publications of Institute teams with an Impact Factor
between 5 and 10 on the Gustave Roussy website.
gustaveroussy.fr
GUSTAVE ROUSSY TODAY
Compassion, commitment, creativity, dynamism and
the sharing of expertise are the values that define
Gustave Roussy and lead it to place innovation at the
heart of its humanitarian, scientific, technological
and service activities. Its advances in these areas
are of direct benefit to the patient. Gustave Roussy
represents a beacon of advanced medicine and
personalised care. It is recognised internationally as a
model of innovation and a place where major progress
in the fight against cancer is being made.
3,000 300 2,800 47,600 369
SALARIED STAFF
RESEARCHERS
STUDENTS
AND TRAINED
PROFESSIONALS
PATIENTS TREATED
CLINICAL
STUDIES
Figures up to 1st January 2015
Refer to our annual report for 2014
and its appendices online:
• Publications with an Impact Factor between 5 and 10
• Details of the research teams at
gustaveroussy.fr
heading: annual reports
Gustave Roussy is a member of UNICANCER.
UNICANCER is a group of Comprehensive Cancer Centres and is
devoted exclusively to the fight against cancer. It promotes a treatment
model based on a multidisciplinary approach, personalisation of
treatment and support for the research / patient-care continuum.
www.unicancer.fr
www.gustaveroussy.fr
Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Tél. : 01 42 11 42 11
Fax : 01 42 11 53 00
Follow us :
ANNUAL REPORT 2014 - Living the futuretoday
Photo credits: Stéphanie Têtu, DHSimon, SADEV94, ASCO / Rodney White, Gustave Roussy - Communications Department Gustave Roussy - Design and Production:
Living
the future
ANNUAL REPORT
2014
today
- Printed by Grillet Impressions

Publication - Gustave Roussy

Transcription

Similar documents

Serrurier-Bovy, from a collection ll

scientific directory 2015 - 2019

Foreword - touchONCOLOGY

See the document

CvSSS

Gérard DEPARDIEU Benoît POELVOORDE Vincent LACOSTE

TRICENTENARI Presentació ICO - Portal e

Gustave Serrurier-Bovy A Protagonist Rediscovered

Big data Web sites: 40 billion indexed web pages Youtube: 100 hrs

The Grand Budapest Hotel

2015 JUNE LINK VOL 32 ISSUE 2 - ccons

Press kit